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ABSTRACT 
Purpose: Breast cancer represents a heterogeneous group of neoplastic diseases with 
distinctive histopathological subtypes, genomic alterations, metastases to distant sites and 
patient therapeutic responses.   Globally, breast cancer is the most common cancer affecting 
women and it is estimated that in 2030 more than 747,802 women will die from the disease.  
Genetic risk factors, including race and ethnicity, account for about 5-10% of all breast 
cancer occurrences.  Breast cancer initiation and progression are multifaceted processes 
encompassing complex molecular alterations.  The epidermal growth factor receptor (EGFR) 
is abnormally activated in many cancers and its signal transduction pathways play an 
important role in regulating cell proliferation and survival.  In breast cancer, the altered 
expression of EGFR and HER-2 receptors (gain-of-function mutations and increased gene 
copy number/gene amplification) parallels an aggressive clinical course and the development 
of resistance to anticancer and adjuvant endocrine therapies.  EGFR inhibitors that 
specifically target the intracellular and extracellular domains of EGFR include monoclonal 
antibodies (e.g., cetuximab and trastuzamab) and tyrosine kinase inhibitors (e.g., gefitinib 
and erlotinib) and are amongst the most effective agents that are currently used in clinical 
practice.  In this study we examined the effects of doxorubicin (DOX), cisplatin (CPL) and 
three investigational tyrosine kinase inhibitors (TKIs): EGFR inhibitor I, EGFR Inhibitor 
II/BIBX1382 and EGFR/ErbB-2/ErbB-4 Inhibitor, individually and in combination, on 
human MCF-7 breast carcinoma cells.  
Methods: Analyses of MCF-7 breast carcinoma cells exposed to doxorubicin, cisplatin and 
EGFR inhibitors (TKIs), alone and in combination, included growth and dose-response 
curves (cytotoxicity assays), drug synergy analysis, morphological staining of apoptotic cells 
with haematoxylin and eosin, Annexin V-FITC, and quantitative Real-Time PCR (qPCR) of 
EGFR gene expression.  Combination drug effect analysis was used to study the efficacy of 
EGFR inhibitor combinations on MCF-7 cells.  The Loewe additivity, Bliss independence 
and median effect analysis models were used for data analysis using appropriate software.  
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Results: This study investigated the effects of TKIs on the growth and proliferation of MCF-
7 breast carcinoma cells in culture.  MCF-7 cells were exposed to different concentrations of 
TKIs alone and in combination with each other.  Inhibition of cell growth by TKIs used 
individually occurred in a dose- and time-dependent manner.  When EGFR Inhibitor I, EGFR 
Inhibitor II/BIBX1382 and the multi-specific EGFR/ErbB-2/ErB-4 Inhibitor were used in 
combination with each other at equimolar log dose concentrations, the combined effects on 
cell growth was significantly different to inhibitors used individually as reflected in a 
decreased EC50 (IC50) during combination treatments.  Generally, for the combinations with 
DOX, CPL and the TKIs, synergistic as well as antagonistic effects were observed at 
isoeffective concentrations with resultant decreases in dose reduction indices (DRIs) 
implying greater efficacies with the respective combinations.  In this study, conventional 
PCR was used to detect and illustrate the presence of the EGFR gene in the samples, while 
RT-qPCR was used to determine the mRNA expression levels of this gene in MCF-7 breast 
carcinoma cells. 
Conclusion: This study demonstrated a significant growth inhibition of MCF-7 cells upon 
exposure to TKI combinations.  The drug combination indices suggested that when TKIs are 
used in combination, their efficacy is enhanced through synergistic interactions at higher 
fraction affected (Fa, cell-kill) levels, consistent with both the Loewe additivity and Bliss 
independence models.  The present study is consistent with previous assertions that 
concurrent blocking of the ErbB family of RTKs and other drug targets (e.g., topoisomerase 
II targeted by DOX and induction of apoptosis by CPL in a manner analogous to blocking the 
anti-apoptotic Bcl-2) in cancer cells may be of particular benefit to breast cancer patients.  
Elucidation of the mechanisms involved in the combined cytotoxicity of DOX, CPL and 
TKIs and optimizing their synergistic concentrations (multi-targeted cancer therapy) to 
enhance efficacy would be a major breakthrough in cancer drug discovery and 
development—targeting specific populations of cancer cells and reducing TKI-induced 
toxicity to normal cells and vital organs. 
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
1.1 Introduction and Background to the Study
The objective of this chapter is to briefly set forth our current understanding of the functional 
anatomy, physiology and pathology of the female breast.  It also covers breast cancer with 
regard to its epidemiology, incidence and mortality statistics, molecular taxonomy, 
pathogenesis, initiation, progression, metastatic spread, expression of drug resistance and 
recurrence, and the global research efforts directed towards its prevention and the 
development of targeted molecular and personalized therapies.  In addition, it includes a 
review of pertinent literature to introduce and contextualize the specialized areas of breast 
cancer research, the hypothesis to be tested, and a discussion of the rationale for the choice of 
methods to investigate the research problem and analyze the results to achieve the set 
objectives. 
1.2 Functional Anatomy and Physiology of the Female Breast 
A number of complex anatomical alterations and molecular events are linked to breast cancer 
initiation and progression.  The current status of knowledge regarding the normal macro- and 
micro-anatomy of the human mammary gland and the well-defined development and 
differentiation transformations it undergoes from embryogenesis through to post-menopausal 
age has been aptly reviewed recently.  Contemporary descriptions of breast anatomy are 
based mainly on Sir Astley Paston Cooper’s (1768-1841) accounts in 1840 (Figure 1.1) of 
dissections of mammalian breasts (http://jdc.jefferson.edu/cooper/).  An in-depth 
understanding of the anatomy of the breast is imperative to accurate clinical breast 
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examination, inspection and palpation.  Skillful clinical breast examination enables clinicians 
to promote breast cancer education (early detection, risk factors, symptoms) and awareness 
among patients.  Furthermore, clinical proficiency in breast anatomy and examination can aid 
in the detection of cancers not easily discerned by diagnostic mammography, as well as 
enable physicians to manage patients on breast treatments such as breast augmentation (e.g., 
saline or silicone implants), breast reduction surgery and reconstruction, breast lifts, breast 
lump removal (lumpectomy), mastectomy and axillary lymph node dissection. 
  
Figure 1.1: On the anatomy of the breast, by Sir Astley Paston Cooper, 1840,1 a rare historical copy accessible 
online (http://www.jefferson.edu/) from Thomas Jefferson University, shared under the auspices of Jefferson 
Digital Commons.  “... let us save what remains: not by vaults and locks which fence them from the public eye 
and use in consigning them to the waste of time, but by such a multiplication of copies, as shall place them 
beyond the reach of accident.” —Thomas Jefferson to Ebenezer Hazard, Philadelphia, February 18, 1791.  In: 
Thomas Jefferson: Writings: Autobiography, Notes on the State of Virginia, Public and Private Papers, 
Addresses, Letters, edited by Merrill D. Peterson, New York: Library of America. 
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Breasts or mammae are composed of fat and breast tissue, nerves, veins, arteries, lymphatic 
vessels and connective tissue and Cooper’s ligaments that support the breast and give it its 
shape.2  Figure 1.2 depicts the different parts of the lactating female breast.  The breast 
overlies the 2nd to 6th ribs.  The main chest muscle, the pectoralis major, is located between 
the breast and the ribs.  The basic parts of a mature mammary gland are the alveoli lined with 
milk-secreting cuboidal cells and surrounded by myoepithelial cells (MEPs or MECs).  The 
alveoli (glandular tissue) are contained in lobules.  Each lobule has a lactiferous duct that 
drains into the nipple.  Contractions of the MECs are synchronized by oxytocin and results in 
milk secretion by alveolar units into the lobule lumen toward the nipple.  The complex 
interconnections of lobules (minute oval sacs that produce milk) and ducts (that transport 
milk from the lobules to the nipple openings during lactation) form a structure that resembles 
bunches of grapes, referred to as lobes (Figure 1.3).  The dark area of skin surrounding the 
nipple is called the areola.  Nerves, in turn, impart sensation to the breast. 
 Mosby items and derived items © 2010, 2007, 2003 by Mosby, Inc., an affiliate of Elsevier, Inc. 
 
Figure 1.2: Micro-anatomical structure of the lactating female breast. A: Saggital section showing how 
glandular structures are anchored to the overlying skin and to the pectoral muscles by the suspensory 
ligaments of Cooper.  Each lobule of glandular tissue is drained by a lactiferous duct that opens through the 
nipple.  B: Anterior view showing overlying skin and connective tissue removed from the medial side to 
reveal the internal structure of the breast and underlying skeletal muscle.  In the non-lactating breast, the 
glandular tissue is much less prominent with adipose tissue constituting most of the breast.  Source: Patton & 
Thibodeau: Anatomy & Physiology, 7th edition.3 
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 ©2013, WebMD, LLC. All rights reserved, http://www.webmd.com. 
 
Figure 1.3: Structure of the female breast showing areola, nipple, arteries and veins, lymph nodes and 
lymphatic vessels, ducts and fatty tissue.  Source: http://women.webmd.com/picture-of-the-breasts. 
Breast development occurs during foetal growth, infancy (prepuberty), puberty, pregnancy 
and lactation-associated remodelling, and post-lactational and post-menopausal involution 
(shrinking).  Mammary differentiation and specialization surge during the pregnancy and 
lactation cycle (PLC) when the mammary gland transforms into a mature and functional 
milk-secretory organ.  The PLC cycle can recur in multiparous females and therefore 
childbearing and breastfeeding offer some protection against the development of breast 
cancer in the long term.4-7  However, in humans, crosstalk occurs between the signalling 
pathways that drive normal mammary morphogenesis during PLC and those oncogenic 
(aberrantly activated or suppressed) signals associated with breast cancer initiation, 
progression and metastasis.  In particular, self-renewal transcription factors are shared 
between normal human breastmilk stem cells (hBSCs) and various types of aggressive breast 
tumours, implying that generalizations about the protective effects of PLC should be made 
with prudence.8,9  The onset of post-menopausal involution is paralleled by a decreased 
ovarian function and blood levels of oestrogen and progesterone which cause regression and 
atrophy of the glandular tissue of the breast and a concomitant buildup of adipose tissue and 
correlated sequalae such as dysregulated mammary cell transformation and the development 
of breast cancer.9   
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1.3 Pathological Changes in Breast Tissue
The pathological lesions that occur in breast tissue, their specific clinical laboratory analyses 
and new paradigms of diagnoses are amply documented by an expansive literature.10-24  The 
implementation of mammography screening and clinicopathological diagnostics worldwide 
has not only seen an increased detection of precancerous lesions, but also a plethora of 
multidisciplinary approaches to promote novel individualized treatments in breast cancer 
patients.22,25,26  This dissertation will focus mainly on the pathological manifestations of 
breast cancer which are covered under the heading “Molecular Pathogenesis and 
Taxonomy of Breast Cancer.”  In this section, however, a surface glance at the most 
common non-malignant and pre-malignant pathological alterations in breast tissue is 
presented in Table 1.1.   
1.4 The Global Breast Cancer Landscape
 
1.4.1 Breast Cancer: Clarification of the Concept
Breast cancer is a heterogeneous group of diseases in terms of their distinctive 
histopathological types, dissemination patterns to distant sites, therapeutic responses and 
patient outcomes.27,28  Breast tumours exhibit diverse genetic mutations that involve complex 
signalling pathways and can thus be categorized into different subgroups according to their 
molecular expression profiles.29  Whether specific molecular pathways determine the subtype 
of breast cancer or whether diverse cell types undergo genetic and epigenetic transformations 
to establish each tumour subtype is currently awaiting clarification.22  Nonetheless, it is 
widely acknowledged that breast cancer patients would benefit from customized therapeutic 
rationales designed to treat their particular clinicopathological tumour type.  Recently, 
genomic profiling have suggested five breast cancer intrinsic subtypes (luminal A; luminal B; 
Her2-enriched; claudin-low—which appears enriched for mesenchymal and stem cell traits; 
basal-like) and a normal breast-like group. 27,30-33   
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Table 1.1: Summary of the most common breast lesions 
Lesion Description  References 
Breast cancer Breast cancer, like any other cancer, is generally defined as the uncontrolled growth and proliferation of cells of a type different from the 
normal complement of cells – in this case mammary cells.  As the cancer cells multiply abnormally in the breast, they can spread to other 
organs or sites of the body, if untreated.  Breast cancer occurs almost predominantly in females, but males are also affected.  Breast cancer 
is a heterogeneous disease with distinctive morphologies, molecular profiles, clinical behaviours and responses to therapy.  Common signs 
of breast cancer include a lump, bloody nipple discharge, or skin changes. 
34,35 
Ductal carcinoma in situ 
(DCIS) 
DCIS is initially confined to the duct cells.  DCIS is typically asymptomatic and presents as abnormal microcalcifications that can be 
discerned on a mammogram.  DCIS is thought to be a precursor of invasive ductal carcinoma based on molecular, epidemiological and 
pathological evidence.  Risk factors for DCIS include older age and family history.  Women diagnosed with DCIS have a high likelihood 
of being cured after breast-conserving surgery (BCS) followed by radiotherapy (RT). 
35-41 
Lobular carcinoma in situ 
(LCIS) 
First described as a rare premalignant lesion, LCIS is now considered to be a risk factor for future breast cancer development.  Current 
guidelines do not recommend mastectomy as an approach to risk reduction for most patients with LCIS.  Despite these recommendations, 
risk-reduction surgery is increasingly practised in the United States for women with LCIS.  LCIS can have associated imaging 
abnormalities, most commonly grouped as amorphous calcifications on mammography, a shadowing, avascular, irregular, hypoechoic mass 
on ultrasound (US), or heterogeneous non-mass-like enhancement with persistent enhancement kinetics on magnetic resonance imaging 
(MRI). 
42-45 
Pleomorphic lobular 
carcinoma in situ  
(PLCIS) 
PLCIS is a pathological variant of LCIS with distinct morphological features.  PLCIS correlates with invasive disease and its immuno-
histochemical profile suggests it is less likely to be ER- and PR-positive with higher positivity of HER2, Ki-67and p53.  It has been 
recommended that PLCIS should be treated more aggressively than LCIS and surgically excised in a similar fashion to DCIS. 
46,47 
Invasive ductal carcinoma 
(IDC) 
Current models of human breast cancer conceptualize disease progression as a linear multi-step sequence.  Cells originate as flat epithelial 
atypia (FEA), advance to atypical ductal hyperplasia (ADH), evolve into DCIS and culminate in the potentially lethal stage of IDC.  
Downregulated or loss of FOXC1 and claudin gene expression in both DCIS and IDC is an early event during breast cancer progression. 
40,48,49 
Invasive lobular carcinoma 
(ILC) 
ILC covers approximately 5-15% of breast cancers and appears to have a distinct biology.  It is less common than IDC.  ILC is likely to be 
more multifocal, ER-positive and HER-2 negative with a lower proliferative index compared to IDC.  When treated with conservative 
surgery, ILC has been shown to require frequent re-excision and/or mastectomy because of positive resection margins.  ILC may remain 
dormant for many years.  ILC in accessory breast tissue is unusual, but a high index of suspicion may prevent late diagnosis. 
50-54 
Continued/… 
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Table 1.1: Summary of the most common breast lesions (continued) 
Lesion Description  References 
Mucinous breast cancer 
(MBC) 
MBC is primarily a disease of postmenopausal women.  Pure MBC is rare with a good prognosis.  However, MBC mixed with other 
histological subtypes of invasive disease fails the more favourable prognosis.  Because of the relative rarity of pure MBC, little is known 
about its cell and tumour biology and relationship to invasive disease of other subtypes. 
55 
Simple benign breast cyst Benign simple breast cysts are a common sonographic result seen mainly in female breasts and present as palpable masses in women aged 
30-40, but also occurs in men.  Breast cysts may cause tenderness but do not necessitate further diagnostic evaluation.  In contrast, atypical 
breast cysts do carry a risk of malignancy.  Triple assessment of suspicious breast lesions may not always provide a definite diagnosis, e.g., 
epidermoid cysts of the breast pose a diagnostic dilemma as they are often deep-seated and minic carcinoma.   
56-60 
Mammary hydatidosis 
(Hydatid cyst of the breast) 
Also referred to as mammary echinococcosis.  The breast is a rare primary site of hydatid disease which develops from the larval stage of 
the dog tapeworm, Echinococcus granulosis.  Mammary hydatidosis generally occurs in females, which accounts for only 0.27% of cases, 
but has been reported in males.  Mammary hydatidosis may present as a non-tender and immobile mass in the upper lateral quadrant of the 
breast with normal overlying skin and nipple.  It is challenging to differentiate the breast's malignant and benign lesions from hydatid cysts 
by imaging methods. 
61-63 
Breast fibroadenoma 
(BFA) 
BFA is a common breast lesion affecting 25% of asymptomatic women.  BFA is considered a risk factor for breast cancer.  BFA is the 
most common benign breast tumour in adolescent girls and young women with a peak incidence in the second and third decades of life.  
Epithelial hyperplasia developing within a fibroadenoma is a general histopathological feature. 
10,64-66 
Fibrocystic breast disease 
(FBD) 
FBD is a benign condition that afflicts at least 50% of women of childbearing age.  Because of the occurrence rate, the condition is 
sometimes referred to as a nondisease.  The pathophysiology of FBD is linked to oestrogen predominance and progesterone deficiency that 
result in hyperproliferation of connective tissue (fibrosis), which is followed by facultative epithelial proliferation; the risk of breast cancer 
is increased two-fold to four-fold in such patients.  Replacement of E-cadherin by N-cadherin in the mammary gland results in the 
formation of fibrosis and cysts in the mammary gland.  Downregulation of E-cadherin—a cell-cell adhesion glycoprotein—correlates with 
tumorigenic progression.67  The clinical correlate of fibrocystic disease is reflected by breast and axillary pain or tenderness in response to 
development of fibrocystic plaques, nodularity, macrocysts, and fibrocystic lumps.  The disease progresses with advancing premenopausal 
age and is most pronounced in women during their 40s.  Fibrocystic changes regress during the postmenopausal period.  FBD is recognized 
to cause breast pain, lumpiness or cysts. 
68-71 
Adenosis of the breast Adenomyoepithelial adenosis of the breast is an extremely rare type of adenosis.  Complete resection of the tumour and coexisting 
malignant disease is recommended due to the predisposition to develop breast cancer or malignant adenomyoepithelioma, or recurrence. 
72 
Continued/… 
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Table 1.1: Summary of the most common breast lesions (continued) 
Lesion Description  References 
Usual ductal hyperplasia 
of the breast 
(UDH) 
UDH is considered to be a very early premalignant epithelial abnormality as currently classified by histologic features, but does not usually 
progress to invasive cancer.  UDH is a committed stem (progenitor) cell lesion distinctive from ADH and DCIS, but there is a likelihood 
that UDH is a precursor of ADH.  Women with UDH have a relative risk of 1.6-1.9 of subsequent breast cancer development.  Solid 
papillary ductal carcinoma in situ (SP-DCIS) shares many morphological features with UDH, and therefore SP-DCIS should not be 
misinterpreted as UDH.  Breast cancer risk in UDH is defined by ERα and Ki-67 expression. 
73-78 
Atypical ductal 
hyperplasia of the breast  
(ADH) 
ADH describes small atypical ductal lesions with insufficient criteria for a definite diagnosis of DCIS.  Currently no consensus exists on 
diagnostic criteria that discriminate ADH from low-grade DCIS.  Abnormal-appearing cells multiply either in the breast ducts or lobules 
and may be detected by a breast biopsy.  The risk of DCIS after a diagnosis of ADH is well-documented.  Even though the ADH is non-
cancerous, afflicted females are predisposed to developing breast cancer.   
25,41,79 
Intraductal papilloma  
(IDP) 
Cases of IDP in an axillary lymph node (ALN) are reported occasionally.  Histologically, IDP presents as proliferative epithelial lesions 
comprised of papillary and tubular structures lined by luminal cuboidal cells and a distinct outer layer of myoepithelial cells in the cystic 
space of the lymph node.  Since metastasis of breast cancer occurs most frequently in ALN, the presence of ectopic breast tissue (EBT) in 
ALN is a benign condition that must be differentiated from primary or metastatic carcinoma in order to prevent overtreatment of patients. 
10,80-84 
Phyllodes tumours  
(PTs) 
PTs are infrequent biphasic fibroepithelial neoplasms that account for <1% of all breast tumours.  Most PTs are benign with a risk of local 
recurrence whereas malignant PTs have a 13% risk of haematogenous metastasis. 
85 
Traumatic fatty necrosis Fat necrosis of the breast is a common benign inflammatory progression resulting from injury to breast fat, ranging from benign to 
malignant.  The mammographic manifestation of fat necrosis ranges from a lipid cyst to foci suspicious for malignancy such as massed 
microcalcifications or a spiculated area of increased density.  The changes of fat necrosis may be seen following blunt trauma, cyst 
aspiration, biopsy, lumpectomy, radiation therapy, reduction mammoplasty, breast reconstruction with a transverse rectus abdominis 
myocutaneous (TRAM) flap, implant removal, and anticoagulant therapy, as well as in patients without a related history.  Fat necrosis may 
also be discerned in benign lipomas.  It is important to identify the mammographic spectra of fat necrosis to circumvent unnecessary biopsy 
and to avoid overlooking breast cancer. 
86-89 
Gynaecomastia Gynaecomastia is the enlargement of male breast tissue.  Male breast disease includes a variety of benign and malignant conditions, many 
of which are hormonally influenced.  Gynaecomastia and skin lesions account for the majority of conditions in symptomatic men with a 
palpable abnormality. 
90 
Continued/… 
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Table 1.1: Summary of the most common breast lesions (continued) 
Lesion Description  References 
Mastitis The concept of mastitis in empirical studies remains inconsistent and awaits clarification of its aetiology and symptoms.  Mastitis is a 
common infectious disease during lactation, and the main aetiological agents are staphylococci, streptococci, and/or corynebacteria.  
Idiopathic granulomatous mastitis (IGM) is an unusual chronic inflammatory lesion of the breast, the clinicopathologic characteristics of 
which may be confused with breast carcinoma.  Ultrasonography (USG), biopsy, mammography (MMG) and magnetic resonance imaging 
(MRI) are used to distinguish idiopathic lobular granulomatous mastitis (ILGM) from tuberculous mastitis (non-idiopathic GM) in patients.  
Mastitis is associated with increased levels of milk HIV-1 and risk of mother-to-child transmission through breastfeeding.  HIV-1 
replication in breast milk intensifies with inflammation, causing higher milk viral loads during mastitis.  Tuberculous mastitis is a rare 
clinical finding and normally affects women from the Indian sub-continent and Africa.  It often mimics breast carcinoma and pyogenic 
breast abscess clinically and radiologically may both co-exist.  Routine laboratory investigations are not effective in its diagnosis.  Fine 
needle aspiration cytology (FNAC) / biopsy are indispensable for diagnosis and tuberculosis culture, when positive, may be very useful to 
direct antimicrobial therapy.  Antitubercular drugs in combination with aspiration or surgical drainage are usually associated with good 
prognosis.  However, periductal mastitis associated with epithelial hyperplasia, presenting as a subaerolar swelling in a male breast, may be 
misinterpreted as lobular carcinoma on FNAC.  Primary breast lymphoma may clinically mimic acute mastitis whereas lupus mastitis 
(disease associated with systemic lupus erythematosus) may present as breast carcinoma.  Inflammatory breast carcinoma (IBC) is rare; 
nonetheless, it is the most aggressive form of breast cancer with a very poor outcome.  Locally advanced breast cancer and acute mastitis 
have a presentation analogous to that of IBC.  Hence, the diagnosis of IBC continues to be a challenge in breast imaging.  MRI can play a 
crucial role in the differential diagnosis by providing criteria indicative of IBC.  
91-108 
Calcifications Malignant-appearing microcalcifications (MAMCs) represent one of the first MMG findings of non-palpable breast carcinomas (NPBCs).  
Calcifications of the breast are usually observed in patients following trauma (haematoma) in fat necrosis, with breast prosthesis, and after 
surgery and radiotherapy.  In patients with end-stage renal disease, calcium deposits in the soft tissues are also an acknowledged feature.  
Elevated serum calcium-phosphate (due to hyperparathyroidism), uraemia, increased parathyroid hormone levels, vitamin D overload and 
local tissue injury are predisposing factors for calcium deposits in soft tissues.  Most common sites of deposition are the vasculature, 
cornea, peri-articular tissues, skin and visceral organs.  Extensive calcifications in the breasts are rare.  Osteopontin (OPN) protein 
expression levels in breast carcinomas may play a role in the formation of calcifications that often are associated with breast cancer.  
Complete aspiration of microcalcifications may result in low rates of underestimation of malignancy.  Several studies have associated the 
presence of breast arterial calcifications (BACs) with an increased risk of diabetes, hypertension, coronary artery disease (CAD), and 
cardiovascular mortality. 
109-113 
 
 
 
 
10 
1.4.2 Breast Cancer Epidemiology: Incidence and Mortality Statistics 
According to the World Health Organization (WHO) and its cancer research agency, the 
International Agency for Research on Cancer (IARC), an estimated 12.7 million new cancer 
cases were diagnosed worldwide in 2008 and cancer caused more than 7.6 million deaths in 
that year (http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900; accessed 14 
October 2013).  The most frequently diagnosed cancers which exceeded 40% of all cases 
were lung, female breast, colorectal and stomach cancers.  Globally, breast cancer is the most 
common cancer affecting women—approximately 1.38 million new cases of this neoplasm 
were diagnosed in 2008, representing roughly 11% of new cases and 23% of all female 
cancers (http://www.wcrf.org/cancer_statistics/data_specific_cancers/breast_cancer_statistics.php).   
Figure 1.4 depicts the world incidence and mortality rates for breast cancer by region.  
Recent estimates have corroborated that breast cancer persists to be the most prevalent cancer 
in the vast majority of countries globally, i.e., by world region, country and human 
development index (HDI).114  The incidence of breast cancer is higher in developed countries 
than in developing countries, but this difference may be due, in part, to lifestyle, screening 
and incidence reporting practices.115,116  A recent systematic analysis of the Global Burden of 
Disease reported 438,000 breast cancer deaths globally in 2010.117   
Estimates for Europe in 2012 were 3.45 million new cases of cancer and 1.75 million deaths 
from cancer—most notably female breast cancer (464,000 cases), colorectal (447,000), 
prostate (417,000) and lung (410,000).  Together, these four cancers represented almost half 
of the overall burden of cancer in Europe.  The most common causes of death from cancer 
were cancers of the lung (353,000 deaths), colorectal (215,000), breast (131,000) and 
stomach (107,000).118  In the United States alone, it is estimated that 232,340 new cases of 
invasive breast cancer and 39,620 breast cancer deaths will occur among women in 2013.119 
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Figure 1.4: World incidence and mortality rates for breast cancer by region.  The estimates for 2008 
presented here were taken from the International Agency for Research on Cancer GLOBOCAN database 
which presents cancer statistics for all cancers combined and for specific types of cancer for most countries or 
territories of the world. (Source: Cancer Research UK: http://www.cancerresearchuk.org/cancer-
info/cancerstats/world/cancer-worldwide-the-global-picture, Accessed 13 October 2013; See also Ferlay J, 
Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and 
Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research 
on Cancer; 2010. Available from: http://globocan.iarc.fr, Accessed 13 October 2013).  
Breast cancer persists to be the most prevalent female cancer in the vast majority of countries 
worldwide (Figure 1.5).114  An appraisal of current trends approximate that in 2030 more than 
747,802 women will die from breast cancer worldwide if surveillance, i.e., detection of life-
threatening familial or sporadic disease at an earlier or more curable stage using diagnostic 
mammography (MMG) and clinical breast examination, prevention and treatment 
programmes are not implemented or improved.120,121 
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Figure 1.5: Most prevalent female cancers by country.  Data for 2008 presented here were taken from the 
International Agency for Research on Cancer GLOBOCAN database which presents cancer statistics for all 
cancers combined and for specific types of cancer for most countries or territories of the world.  (Source: 
Cancer Research UK: http://www.cancerresearchuk.org/cancer-info/cancerstats/world/cancer-worldwide-the-
global-picture, Accessed 13 October 2013; See also: http://globocan.iarc.fr, Accessed 13 October 2013).  
The intensification of breast cancer MMG (an X-ray of the breast) and frequency reporting in 
the United States and the rest of the world since 1980 has seen an increase in incidence 
registration of ductal carcinoma in situ (DCIS).121  The abnormal DCIS cells are mostly 
confined to the milk ducts and do not transform into invasive cancer cells.  Presently, it is 
difficult to discriminate DCIS that will develop into aggressive malignant cancer from the 
benign type, and thus many women are exposed to redundant therapeutic regimens that may 
lead to short- and long-term morbidities.  However, a recent study has shown, using 
univariate and multivariate analyses, that basal-like DCIS correlates with a higher risk of 
invasive- or general recurrence compared with non basal-like DCIS.122  Therefore, DCIS 
does necessitate therapy with breast-conserving surgery (BCS) and radiation to block 
development of invasive breast cancer.  It should be noted though that women do not only 
die of tumours limited to the breast or draining lymph nodes, but that the majority of breast 
cancer deaths may be caused by metastasis to vital organs such as bone, lung, liver, and 
brain, and consequential failure of these organ systems. 
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It is currently estimated that triple-negative breast cancers (TNBC), i.e., tumours that tested 
negative for oestrogen receptor (ER), progesterone receptor (PR) and human epidermal 
growth factor receptor 2 (HER2), contribute to 10-17% of all breast carcinomas, with higher 
incidence rates and poor survival outcomes observed for certain ethnic patient populations 
(such as African Americans) and young age groups,123-126 and women who are obese, 
premenopausal or of low socioeconomic background.127  A recent study has demonstrated 
that guideline-adherent adjuvant treatment significantly improves survival of TNBC patients 
<50 and ≥65 years old.128   
Several histochemical distinct subtypes of TNBC have been identified that express varying 
responses to chemo- and radiation therapy,129,130 but basaloid triple-negative breast cancer (B-
TNBC) probably represents one of the most invasive and therapy-resistant metastatic 
tumours of this type.34,131  TNBC has defective DNA repair pathways, including BRCA1 
mutations, which correlate with increased genomic instability, aggressive tumour behaviour 
and worst clinical history, even in the face of initial, yet short-term, extreme 
chemosensitivity.132  Current classifications based on histologic and immunohistochemical 
profiles may contribute to a substantial advance in predicting the outcome in TNBC 
patients.133 
1.4.3 Aetiology of Breast Cancer
Breast cancer is the most common cause of cancer deaths among females worldwide (Figure 
1.5).  Several excellent articles have documented the significant risk factors for breast cancer 
development.5,7,64,134-137  This section will describe briefly some of the aetiological factors that 
underpin breast cancer.  Gender is undoubtedly a major risk factor for developing breast 
cancer as the disease is about 100-fold more common among women than men.  A plausible 
explanation for this is simply because women have higher levels of oestrogen and 
progesterone—the female hormones that promote breast cancer cell growth.  This is also the 
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reason why many prospective studies link oestrogens or high concentrations of endogenous 
oestradiol to other established risk factors for breast cancer.  In women, the risk of 
developing breast cancer also increases with age since 1 out of 8 invasive breast cancers are 
found in women younger than 45, while 2 of 3 invasive breast cancers are found in women 
aged 55 or older.  Increased risk is associated with early menarche, late menopause and 
obesity in postmenopausal women.  Childbearing decreases risk and a more pronounced 
protection occurs in multiparous females and women with early first births.5,7  Prolonged 
breastfeeding has also been indicated as providing a protective effect against the 
development of breast cancer.7  The use of oral contraceptives and hormonal therapy for 
menopause slightly raises breast cancer risk, but the risk diminishes upon termination of 
usage.4,138   
Genetic risk factors, including race and ethnicity, account for about 5-10% of all breast 
cancer occurrences, with germline BRCA1/BRCA2 mutations detected in 28-40% of families 
with a history of the disease.139  BRCA1 and BRCA2 are tumour suppressor genes involved in 
homologous recombination repair (HRR) of DNA double-strand breaks, cell-cycle 
checkpoints, transcriptional regulation and chromatin remodelling.140  Germline mutations in 
either BRCA1 or BRCA2 predispose affected women to hereditary breast and ovarian cancer 
(HBOC) syndrome, which is inherited as an autosomal dominant trait.  HBOC syndrome is 
associated with not only early-onset breast cancer, but also an increased risk of ovarian, 
pancreatic, stomach, laryngeal, fallopian tube and prostate cancer.   
HBOC syndrome is linked to 5–7% of all cases of breast cancer, and females with HBOC 
syndrome have a lifetime 50–80% risk for developing breast cancer and 30–50% for ovarian 
cancer.141  Breastfeeding offers some protection against BRCA1-, but not BRCA2-associated 
breast cancer.6  A range of other genes conferring increased breast cancer risk have been 
described, including CHEK2, PTEN,TP53, ATM, STK11/LKB1, CDH1, NBS1, RAD50, 
BRIP1, PALB2 and IRF1.140,142-146  Generally, female breast cancers associated with germline 
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BRCA1 mutations are oestrogen receptor-negative (ER-) and predictably also deficient in 
progesterone receptor (PR) and HER2 overexpression.147,148 
Obesity is a recognized risk factor for breast cancer.  The molecular basis of a causal 
relationship between obesity and breast cancer risk, and essentially the influences of 
metabolic syndrome and insulin resistance, peripheral oestrogen aromatization in adipose 
tissue and direct effects of adipokines have been described by several authors.134,137  Other 
lifestyle and environmental risk factors for breast cancer include alcohol consumption, oral 
contraceptive pills (OCP), hormone replacement therapy (HRT), breastfeeding, diet, physical 
activity, smoking, reproductive factors, adverse life events, chemicals and radiation.149  
Certain premalignant or benign breast lesions may also predispose women to the risk of 
developing breast cancer (Table 1.1).  
1.4.4 Molecular Pathogenesis and Taxonomy of Breast Cancer  
Breast cancer progression is a multifaceted process encompassing complex molecular 
alterations which have baffled diagnostic oncologists for many years.  In recent years, 
integrated genomic and proteomic profiling of the signal transduction pathways associated 
with the different stages of breast cancer progression have improved our understanding of the 
heterogeneity of breast cancers with regard to their clinicopathologic expression patterns and 
pharmacotherapeutic responses.33,40,150-154  The current overarching model of human breast 
cancer progression conceptualizes a linear multistep process which starts as flat epithelial 
atypia (FEA), advances to atypical ductal hyperplasia (ADH), evolves into ductal carcinoma 
in situ (DCIS) and expands to the aggressive (malignant) stage of invasive ductal carcinoma 
(IDC).35,40   
Normal breast stem cells (nBSCs) are tissue-resident cells with a long-lifespan, self-renewal 
competence and pluripotent differentiation potential that enable them to constantly remodel 
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the breast tubulo-lobular/tubulo-alveolar architecture made up of luminal and myoepithelial 
cells.40  The nBSCs are characterized by low expression levels of heat-stable antigen (CD24), 
upregulated expression of the hyaluronic acid receptor (CD44) and aldehyde dehydrogenase 
(ALDH1), and lack of expression of epithelial cell adhesion molecule (EpCAM), 
haematopoietic and endothelial markers as well as the oestrogen and progesterone receptors.  
Since nBSCs have a long residence time in breast tissue, they are thought to accumulate and 
undergo genetic and epigenetic modifications that result in deregulation of their normal self-
renewal potential and the development of cancer stem cells (CSCs) that initiate different 
breast cancer subtypes.155,156   
Various factors circumscribe the “stemness” of CSCs, including quiescence, induced 
Notch/Wnt/Hh signalling, intensified DNA repair mechanisms, ALDH1 (a drug-metabolizing 
or detoxifying enzyme), upregulated ATP-binding cassette (ABC) transporters (such as 
ABCG1 (MDR1/P-glycoprotein, ABCG2, and breast cancer resistance protein (BCRP), 
induction of epithelial-to-mesenchymal transition (EMT) and modulated miRNAs that confer 
an aggressive malignant phenotype and both acquired and de novo drug resistance which, in 
turn, result in disease recurrence and poor prognosis.31,157,158  As the epidermal growth factor 
receptor (EGFR) and Notch signaling pathways have been linked to self-renewal of nBSCs, it 
is likely that the gain of enhanced EGFR/HER2 signalling and endocrine resistance may 
similarly arise from the selection of more breast cancer stem cells (BCSCs).159,160 
Insofar as the origin of breast cancer is concerned, the two most significant models for breast 
carcinogenesis are the sporadic clonal evolution model and the CSC, i.e., the BCSC 
model.33,40  The sporadic clonal evolution or EMT hypothesis relates to random mutations 
that target breast epithelial cells and confer on them selective genetic and epigenetic 
advantages that over time promote tumour progression.35  By contrast, the CSC model 
proposes that stem and progenitor cells that occupy only a fraction of a tumour have 
constitutive and unrestrictive self-renewal capacities to initiate and sustain tumour 
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progression, and express radio-, chemo- and endocrine-resistance which enable them to 
survive and trigger tumour recurrence.155,161,162  Nonetheless, these hypotheses are not 
mutually exclusive as stem cells can also undergo clonal evolution or EMT, suggesting a 
dynamic link between the two models which not only opens up opportunities for further 
delineation of the molecular origins of breast cancer, but also holds promise for the 
development of breast cancer treatment strategies that target such mechanisms.8,155,156,161,163-
167  Recent genomic classifications of breast cancers distinguish five breast cancer intrinsic 
subtypes (luminal A, luminal B, HER2-enriched, claudin-low, basal-like) and a normal 
breast-like group.27  As shown in Figure 1.6, these groups incorporate critical variances in 
incidence, survival and therapeutic responses relative to classical clinicopathological markers 
(ER, PR and HER2) for patients with breast cancer.168   
 
Figure 1.6: Distribution of clinicopathological categories relative to the intrinsic subtypes of breast cancer. 
A: Intrinsic subtype distribution within the triple-negative tumour category shown with and without claudin-
low tumours.  B: Distribution of ERD/HER2D, ERL/HER2D, ERL/HER2L clinical groups in the claudin-low, 
basal-like, HER2-enriched, luminal B, and luminal A within each subtype.27  Reproduced with permission 
from Elsevier B.V. via RightsLink® Copyright Clearance Center (Annexure 1). 
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Pathogenic germline mutations in BRCA1 or BRCA2 are detected in less than 33% of families 
with a history of breast cancer.  A recent study provided overwhelming evidence that BRCA1 
and BRCA2 tumours are not evenly distributed among molecular subtypes and sporadic 
breast cancer samples (Figure 1.7).139  Tumours that develop in patients with germline 
heterozygous mutations in BRCA1 or BRCA2 typically have defects in homologous 
recombination (HR)‐mediated repair of replication-associated DNA doublestrand breaks 
(DSBs).141   
Figure 1.7: Association between hereditary breast cancers and molecular subtypes.  Distribution of molecular 
subtypes among BRCA1, BRCA2 and sporadic breast cancer samples.  Tumours were classified into 
molecular subtypes using the PAM50 classifier. Numbers in brackets refer to the number of samples in each 
group.139  Reproduced in terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
Late onset cancer susceptibility patterns, such as HBOC syndrome, are inherited in an 
autosomal dominant manner.  A hallmark of HBOC syndrome is that BRCA1‐associated 
breast cancer is more likely to be oestrogen-receptor (ER) negative (ER-) compared to 
BRCA2-associated breast cancers which display similar distribution patterns to sporadic 
breast cancer subtypes.  In addition, genetic alterations in the DNA damage response (DDR) 
kinases, CHK2 or ataxia-telangiectasia mutated (ATM), might account for the predisposition 
associated with hereditary breast cancers that lack BRCA1 or BRCA2 mutations.  Common 
genetic alterations linked to heterozygous BRCA1 or BRCA2 mutations include loss of the 
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wild-type BRCA1 or BRCA2 allele (loss of heterozygosity, LOH), loss of TP53 (which 
encodes p53), and loss of ATM or CHK2 function.  Such mutations enable transformed cells 
to escape cell-cycle checkpoint controls and apoptosis, and thus to commence tumorigenesis.  
The fact that both BRCA1 and BRCA2 mutation carriers express these somatic alterations 
further corroborates their role in HR‐mediated repair and tumour suppression.   
However, loss of the wild-type BRCA allele is not essential for tumorigenesis as borne out by 
a study on tissue specimens derived from women with germline deletion mutations in BRCA1 
or BRCA2.169  This view has further been bolstered by a recent report that two principal 
evolutionary tumorigenic pathways in BRCA1 tumours are demarcated by the presence or 
absence of PTEN.170  Loss of PTEN was the most plausible first event, followed by mutations 
in either TP53 or BRCA1 LOH.  Mutations in TP53 was the second most commonly detected 
first event and it was mostly accompanied by BRCA1 LOH.  BRCA1 LOH was the least 
common first event.  Significantly, the predicted evolutionary paths to tumorigenesis 
correlated strongly with the tumour subtype as triple negative, i.e., ER−/PR−/HER2− tumours 
had PTEN loss as the first event (path 1), whereas luminal tumors showed mutant TP53 or 
BRCA1 LOH as the first event (path 2).170  This conceptualization of the temporal order of 
tumour-driving somatic events may be key for early detection, risk stratification, and the 
design of targeted therapies for high-risk breast cancer patients. 
Clearly, the rapid advances made in integrated genomic and transcriptomic analysis have 
played a pivotal role in delineating the variation in molecular and clinical characteristics of 
breast cancer.33,171-173  It is therefore not surprising that such developments have guided 
strong justification for a novel genome-driven integrated taxonomy of breast cancer which 
significantly enhances existing classification systems.  This novel classification combines 
molecular evidence on the genomic and transcriptomic landscapes of breast cancer into 10 
integrative clusters, each correlated with well-defined pathobiological causes and 
clinicopathological outcomes which may profoundly impact therapeutic ideals of targeted 
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and individualized management of breast cancer patients.171,174-176   
Growth factors and their transmembrane receptor tyrosine kinases (RTKs) play pivotal roles 
in cellular proliferation, survival, adhesion, migration and differentiation.177  In this 
dissertation the importance of epidermal growth factor receptor (EGFR/erbB) signalling in 
the pathogenesis of breast cancer is emphasized.  The EGFR/erbB family includes four 
homologous members, viz., EGFR (HER1/erbB-1), HER2 (erbB-2/neu), HER3 (erbB-3) and 
HER4 (erbB-4).178  Structurally, the EGFR is a 170-kDa protein with three major integrated 
and functional domains—an extracellular ligand-binding domain, a hydrophobic 
transmembrane domain and a cytoplasmic tyrosine kinase domain.  The respective ligands 
and their complex signal transduction pathways controlled by the activation of the EGFR 
family are summarized in Figures 1.8 to 1.10.177,179,180  
The oncologic relevance of ligand-mediated activation of the EGFR family and associated 
downstream effects, including the promotion of tumour growth and proliferation, tumour 
progression, angiogenesis, invasion, metastasis, and inhibition of apoptosis is widely 
acknowlegded.177,179-182  In breast cancer, the altered expression of EGFR and HER-2 
receptors (gain-of-function mutations and increased gene copy number/gene amplification) 
parallels an aggressive clinical course and the development of resistance to anticancer and 
adjuvant endocrine therapies.181,183-185  Since the EGFR/ErbB family form independent as 
well as multipartite transduction systems involving a diversity of adaptor and effector 
molecules in order to enhance signalling efficacy, the magnitude and consequences of their 
individual and combined expression profiles in invasive and in situ breast carcinomas is the 
subject of intense translational research to identify targets for breast cancer 
treatment.180,182,186-188   
The EGFR/erbB family members are also variously expressed in different types of breast 
cancer, e.g., the “gold standard” for basal-like subtype of invasive breast cancer (BLBC) 
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diagnosis is ER-/HER-2-/cytokeratin 5/6 (CK5/6)+/EGFR+.33,189  EGFR is also one of the 
growth factor receptor genes frequently (i.e., 45–70%) overexpressed in TNBC.34,190  Quite 
strikingly, the breast cancer phenotype induced by loss of BRCA1 approximates identifiable 
attributes of BLBC, including lymphocyte infiltration,191 ER-, EGFR overexpression and c-
MYC amplification.34  Expression analysis of EGFR along with BCRA1 has been applied as a 
molecular marker for predicting relapse-free survival (RFS) in TNBC patients.33,192  
Likewise, exploitation of the GRB-7 protein’s interaction with RTKs and EGFR has been 
useful as a biomarker for resistance to chemotherapy in TNBC patients.191   
 
Figure 1.8: Signal transduction pathways controlled by the activation of the EGFR. Three steps can be 
schematically defined in the activation of EGFR-dependent intracellular signalling. First, the binding of a 
receptor-specific ligand occurs in the extracellular portion of the EGFR or of one of the EGFR-related 
receptors (HER2, HER3, or HER4). Second, the formation of a functionally active EGFR-EGFR dimer 
(homodimer) or of an EGFR-HER2, EGFR-HER3, or EGFR-HER4 dimer (heterodimer) causes the ATP-
dependent phosphorylation of specific tyrosine residues in the EGFR intracellular domain. Third, this 
phosphorylation triggers a complex program of intracellular signals to the cytoplasm and then to the nucleus. 
The two major intracellular pathways activated by EGFR are the RAS–RAF–MEK–MAPK pathway, which 
controls gene transcription, cell-cycle progression from the G1 phase to the S phase, and cell proliferation, and 
the PI3K–Akt pathway, which activates a cascade of anti-apoptotic and prosurvival signals. bFGF: basic 
fibroblast growth factor; HB-EGF: heparin-binding EGF: MAPK: mitogen-activated protein kinase; P: 
phosphate; PI3K: phosphatidylinositol 3,4,5-kinase; TGFα: transforming growth factor α; VEGF: vascular 
endothelial growth factor. Reproduced with permission from Ciardiello and Tortora,179 Copyright 
Massachusetts Medical Society (http://www.nejm.org/page/about-nejm/permissions; Annexure 2). 
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Figure 1.9: ErbB receptors and ligands. Schematic presentation of ErbB receptors and their cognate ligands. It 
is of note that HER-2 and HER-3 cannot signal alone, but both receptors are capable of enhancing signalling 
through dimerization with EGFR (HER-1) and HER-4. AR, amphiregulin; BC, betacellulin; EGF, epidermal 
growth factor; EGFR, EGF receptor; EPR, epiregulin; HB-EGF, heparin-binding EGF-like ligand; HRG, 
heregulin; TGF-α, transforming growth factor-ß; TK, tyrosine kinase. Reproduced with permission from 
Karamouzis et al.180 (Annexure 3). 
Mammary tumours that lack immunohistochemical (IHC) expression of ER, PR, or HER2—
the so-called triple negative phenotype (TNP) tumours or TNBC—are generally assumed to 
be of basal-like subtype.  A limitation of this assumption is that some TNP tumours do not 
express cytokeratins (CKs) and thus expression of either CK5/6 or EGFR signify basal-like 
tumours.  These markers are used to subclassify TNP tumours into a core basal subgroup 
(CBP), which is consistent with basal-like subtype systematized on expression profiling, and 
the five negative phenotype (5NP), which lacks ER, PR, HER2, CK5/6, and EGFR.189,193  
Moreover, the expanded surrogate immunopanel of ER-, PR-, HER2-, CK5/6-, and EGFR- 
sustains a distinctive classification of basal-like breast cancer with improved prediction of 
breast cancer survival.194  This notion is congruent with the accepted tenet that EGFR is an 
essential regulator of mammary gland development and that mutations of the EGFR gene 
may interfere with normal breast function such as lactation and precipitate breast cancer 
progression.178,195  Studies have shown that even though the EGFR gene is upregulated in 
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only 2.7% of breast tumours derived from patients with poor prognosis, it is overexpressed in 
54% basal-like breast carcinomas, 50% of glioblastomas and 33% of human 
carcinomas.178,189,196  This heterogeneous expression of members of the HER family in breast 
cancers makes them attractive targets for the development of multipanel anticancer drugs 
and, specifically, refinement of existing breast cancer therapeutic regimens. 
 
Figure 1.10:. The ErbB receptors and signalling modules. Ligand-bound ErbB homo-and/or heterodimers 
signal from the cell surface to the nucleus through a multipartite transduction system comprising a variety of 
adaptor and effector molecules. Ten possible dimers can be formed by ErbB receptors, but they do not all 
share the same efficacy. This richly layered network consists of mutually interacting protein cascades that 
ultimately convey their signal to TFs, which positively or negatively affect the transcription of target genes. 
Among these, signalling cascades are the stress-activated protein kinases pathway such as PLC–PKC and 
JAK–STAT, the RAS–RAF–MEK–MAPK pathway and the PI-3K–AKT pathway. The Cbl non-receptor TK 
is activated by ligand-stimulated EGFR/HER-3 dimers and regulates EGFR endocytosis. One exclusive HER-
2 feature is its activity dependence on Hsp90 protein. ErbB receptors “transactions” differ based on the 
binding ligand, the dimer formed, the activated downstream signalling cascade and the cross-talk interactions 
with other intracellular pathways. This specificity is also reflected at the transcriptional control level and the 
eventual output signal, which may affect proliferation, differentiation, apoptosis, angiogenesis and metastasis. 
Hsp90, heat shock protein 90; JAK, janus kinase; MAPK, mitogen-activated protein kinase; MEK, 
MAPK/extracellular signal-regulated kinase (Erk) kinase; PAK, p21-activated kinase; PI-3K, 
phosphatidylinositol-3 kinase; PKB, protein kinase B; PKC, protein kinase C; PLC, phospholipase C; STAT, 
signal transducer and activator of transcription; TFs, transcription factors; TK, tyrosine kinase.  Reproduced 
with permission from Karamouzis et al.180 (Annexure 3). 
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1.4.5 Conventional and Targeted Breast Cancer Therapies
According to the WHO (http://www.who.int/mediacentre/factsheets/fs297/en; reviewed 
January 1, 2013), breast cancer (BC) continues to be the most commonly diagnosed 
malignancy and cause of mortality among women globally.116,118,121,197,198  During the last two 
decades, BC mortality rates in many industrialized countries have decreased owing to 
comprehensive screening programmes, early diagnosis, neoadjuvant therapy and a drastic 
drop in the use of hormone replacement therapy (HRT).  Various types of treatments are 
currently used in the management of BC, including surgery, chemotherapy, hormone therapy, 
radiation therapy and targeted therapy.199-202   
Surgery is not considered to be very effective in the treatment of metastatic breast cancer 
(MBC) due to dissemination of the disease to other organs and sites.  Also, the surgery 
decision-making provisions are likely to be inluenced by MBC prognostic factors such as 
clinically undetectable or small tumour size, negligible lymph node invasion, few metastatic 
sites (1 vs many), metastases in bones and soft tissues rather than visceral, fewer liver 
metastases, tumour grade, presence of ERs, HER2 overexpression, and the optimal choice of 
chemotherapy as first-line treatment.  However, breast-conserving surgery (BCS) indicated in 
BC has as its primary objective the removal of the tumour bulk and a perimeter of adjacent 
normal tissue while retaining the contour and shape of the breast.   
Current opinions guiding the use of chemo- and/or radiation therapy are very similar for most 
BCs, including early-stage TNBC and non-TNBC.  Despite variability among patients, 
BCSCs are resistant to conventional chemo- and radiation-therapies and have been linked to 
BC relapse and metastasis, as well as complications in clinical responses.199,203,204  Recently, 
its has been shown that low doses of doxorubicin produced minimum toxicity in T47D and 
SKBR3 BC cells, particularly when combined with ionizing radiation.  This combined 
therapeutic modality may prove advantageous if extended to patients with localized BC, and 
principally to overcome the side effects caused by doxorubicin such as cardiomyopathy, 
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acute arrhythmia, irreversible congestive heart failure, radiation recall dermatitis (an acute 
inflammatory reaction or focal lesion at previously irradiated areas triggered by the 
administration of precipitating systemic anticancer agents after radiation treatment),205 
decreased full blood counts and associated risks of infection and haemorrhage, loss of 
appetite, stomatitis, alopecia, nausea and vomiting, mouth sores, birth defects and 
hepatotoxicity.206   
Chemotherapy administered before surgery is known as neoadjuvant chemotherapy and after 
surgery it is referred to as adjuvant chemotherapy.  Several classes of conventional cytotoxic 
agents with distinct and overlapping mechanisms of action and with moderate adverse (toxic) 
effects have proved to be efficacious as mono- or combination therapies in patients with 
MBC.  The most active antineoplastics agents against MBC include the anthracyclines 
(doxorubicin, epirubicin and liposomal formulations of doxorubicin),207 alkylating agents 
(cyclophosphamide, melphalan, thiotepa and cisplatin), the anthraquinones (mitoxantrone), 
antimetabolites (methotrexate, 5-fluorouracil, capecitabine and gemcitabine), the vinca 
alkaloids (vinorelbine, vinblastine and vincristine), epothilone-derivatives (ixabepilone) and 
the taxanes (paclitaxel, nab-paclitaxel and docetaxel).208    
Anticancer drugs used in locally advanced primary or recurrent BC in various combinations 
produce dose-limiting toxicities, however, several drug-delivery systems and combination 
regimens have been shown to enhance antitumour efficacy with reduced systemic toxicity 
over standard drugs, even at lower doses.209,210  These include nanocarrier-conjugated 
doxorubicin, paclitaxel and cisplatin,211,212 neoadjuvant pegylated liposomal doxorubicin in 
combination with cisplatin and infusional fluoruracil,213 neoadjuvant treatment with NOV-
002 (a preparation containing disodium glutathione disulfide that modulates tumour cell 
proliferation and metastasis signalling pathways and enhances antitumour immune responses in 
cancer models when combined with doxorubicin and cyclophosphamide followed by docetaxel).  
Table 1.2 summarizes single agent and combination regimens recommended for MBC.  
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Table 1.2: The NCCN and ESMO list of single agents and combination regimens recommended or preferred in the management of MBC 
 2013 NCCN GUIDELINES ESMO GUIDELINES 
Single Agents 
Taxanes Paclitaxel Paclitaxel 
 Docetaxel Docetaxel 
 Albumin-bound paclitaxel Nab-paclitaxel 
   
Anthracyclines Doxorubicin Doxorubicin 
 Pegylated liposomal doxorubicin Pegylated liposomal doxorubicin 
 Epirubicin Epirubicin 
   
Antimetabolites Capecitabine Capecitabine 
 Gemcitabine Gemcitabine 
   
Microtubule inhibitors Vinorelbine Vinorelbine 
 Eribulin Eribulin 
   
Others Cyclophosphamide Ixabepilone (not approved by EMA) 
 Carboplatin Cyclophosphamide 
 Cisplatin  
 Ixabepilone  
Continued/... 
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Table 1.2: The NCCN and ESMO list of single agents and frequent combination regimens recommended or preferred in the management of MBC (continued) 
 2013 NCCN Guidelines ESMO Guidelines 
Combination Regimens 
 CAF/FAC (cyclophosphamide/doxorubicin/fluorouracil) CAF/FAC 
 FEC (fluorouracil/epirubicin/cyclophosphamide) FEC 
 AC (doxorubicin/cyclophosphamide) AC 
 EC (epirubicin/cyclophosphamide) EC 
 CMF (cyclophosphamide/methotrexate/fluorouracil) CMF 
 Docetaxel/capecitabine Docetaxel/capecitabine 
 GT (gemcitabine/paclitaxel) GT 
 Gemcitabine/carboplatin Liposomal doxorubicin/cyclophosphamide 
 Paclitaxel/bevacizumab Doxorubicin/paclitaxel 
  Doxorubicin/docetaxel 
  Epirubicin/paclitaxel 
  Epirubicin/docetaxel 
  Paclitaxel/vinorelbine 
  Paclitaxel/carboplatin 
  Capecitabine/vinorelbine 
  Vinorelbine/gemcitabine 
Adapted from Kaufman PA, Seidman AD, Vahdat LT. The role of non-taxane, microtubule dynamics inhibitors in the management of patients with metastatic breast cancer. Elsevier Office of Continuing Medical 
Education and Accreditation Council for Continuing Medical Education (ACCME), Release date of activity: July 1, 2013; http://www.elseviercme.com/bca/502, Accesssed 4 January 2014. Copyright © 2014 Elsevier 
Inc. NCCN, National Comprehensive Cancer Network; ESMO, European Society for Medical Oncology; Nab, albumin-bound paclitaxel (trade name Abraxane, also called nab-paclitaxel) is an alternative formulation 
in which paclitaxel is bound to albumin nano-particles; Pegylated liposomal doxorubicin, (Doxil, Caelyx) is a formulation of doxorubicin in poly(ethylene glycol)-coated (stealth) liposomes with prolonged 
bioavailability and efficacy;212 EMA, European Medicines Agency (http://www.ema.europa.eu/ema/).  
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BC is a heterogeneous disease, but family history represents the strongest risk factor as 
evidenced by genetic linkage analysis implicating high-penetrance genes, BRCA1, BRCA2, 
PTEN and TP53, in inherited BC syndromes.  Other genes involved in DNA repair, such as 
CHEK2, ATM, BRIP and PALB2, correlate with moderate risk.  Genome-wide association 
studies (GWAS) in BC point to single nucleotide polymorphisms (SNPs) in five novel genes, 
TNRC9, FGFR2, MAP3K1, H19 and lymphocyte-specific protein 1 (LSP1), all linked to 
susceptibility, whereas allelic variants associated with BC risk were recently recognized to 
include potential causative genes involved in cell cycle regulation, apoptosis, metabolism and 
mitochondrial functions.214  Accordingly, DNA repair is a central axis in BC cellular 
sensitivity to therapy and BC repair status will almost certainly influence personalized patient 
therapy, e.g., poly-ADP-ribose polymerase (PARP) inhibitors currently used as anticancer 
agents that target TNBC (ER-/PR-/HER2-), which accounts for about 9-21 % of all BCs, 
including patients with stage I-IV breast cancer, and known to exhibit BRCA1 deficiency, 
higher DNA copy alterations and LOH.126,132  As the developmental signalling pathways 
Wnt/beta-catenin, Notch and Hedgehog play a prominent part in the pathogenesis and 
progression of TNBC, novel therapeutic prospects are being explored to inhibit these 
pathways.200    
A high proportion of BCs are sporadic and risk factors are predominantly associated with 
oestrogen exposure and age.  Steroid hormones have been linked to the development of BC, 
and its increased risk is coupled to duration of exposure to and accrual of endogenous and 
exogenous oestrogens accompanying early menarche and late menopause, extreme numbers 
of menstrual cycles, nulliparity and the use of estro-progesterons.215  Present endocrine-
targeted approaches to BC prevention are essentially directed at the oestrogen receptor alpha 
(ERα) and is based on decreasing oestrogen levels by ovarian ablation or suppression in 
premenopausal women or aromatase inhibition in postmenopausal women, or by impeding 
ligand binding of oestrogen to ERα by selective ER modulators (SERMs) such as tamoxifen, 
lasofoxifen and raloxifene.181,215  SERMs antagonize oestrogens in certain target tissues and 
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mimic their actions in others.  Aromatase is a significant source of oestradiol in 
postmenopausal women with BC.136,216  At present, aromatase inhibitors (AIs) are being 
evaluated for their BC prophylactic potential, and it is anticipated that AIs (anastrozole, 
letrozole, and exemestane) with their efficacy and safety profiles, along with pure ER 
antagonists (fulvestrant), may eclipse SERMS in the chemoprevention setting.217-221 
Various single-agent and combination chemotherapy courses have been indicated to be 
effective against MBC, including monoclonal antibodies to HER2 (pertuzumab plus 
trastuzumab), IGF-1R–targeted therapies (cixutumumab, AMG 479), EGFR-targeted 
therapies (erlotinib plus docetaxel), EGFR/HER2 inhibitors (afatinib, neratinib), VEGF 
inhibitors (aflibercept), multitargeted TKIs (sunitinib plus paclitaxel; sorafenib, axitinib plus 
docetaxel; vandetanib; pazopanib), PI3K/AKT/mTOR pathway inhibitors (temsirolimus, 
everolimus plus exemestane,222 ridaforolimus), Src inhibitors (dasatinib), proteasome 
inhibitors (bortezomib), Hsp90 inhibitors (tanespimycin combined with trastuzumab), histone 
deacetylase (HDAC) inhibitors (vorinostat), PARP1 inhibitors (iniparib, olaparib),223 
microtubule dynamics inhibitors (eribulin),224 hedgehog inhibitors (cyclopamine),225 
autophagy modulators226 and inhibitors against several other pathways.130,181   These 
regimens underscore the complexity associated with BC management such as adjustments in 
drug schedules, initiation of supportive care due to acute and late onset adverse events and 
drug toxicities, interpatient variability in clinical responses and comorbidities.   
Lessons learned from preclinical and phase II clinical trials with these targeted rationales 
include improvements in our understanding of the signalling pathways involved in BC 
intiation, progression and metastases, the need to optimize single agent and multidrug 
combinations that would minimize toxic side effects in patients, but yield greater efficacy in 
terms of quality of life and disease-free survival.199  Moreover, further research into 
mammary oncogenesis and its malignant phenotype, and the exploitation of emerging high-
throughput technologies and imaging techniques (i.e., digital mammography, tomosynthesis, 
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ultrasonography, magnetic resonance imaging, nuclear medicine, and genomic techniques, 
such as real-time RT-PCR and microarrays) to identify prognostic and predictive biomarkers 
(e.g., cancer antigen 15-3; CA 15-3; a serum biomarker that is clinically useful in some 
patients with MBC, but has a sensitivity of only 60 to 70%, and circulating tumour DNA; 
ctDNA)227 may be of inestimable value in the discovery of individualized BC therapies 
conformable to genetic expression profiles and clinical responses (tumour heterogeneity, 
drug resistance, recurrence and survival outcomes).181,201,223,228-236   
Another important aspect in any consideration of targeted therapies for BC is that of the 
pivotal niche occupied by microRNAs (miRNAs or miRs) in various stages of BC 
development, including the expression profile of oncogenic miRNAs (oncomiRs) or tumour 
suppressor miRNAs and the tumorigenic potential of TNBC.  In this regard, miR-221 is 
radically overexpressed in TNBC and the oncosuppressor, p27Kip1, a proven miR-221 target, 
is downregulated in aggressive cancer cell lines.  In addition, the transcription factor, Slug, 
which is upregulated in BC cells, binds to the miR-221/miR-222 promoter to trigger the 
elevated expression of the miR-221/miR-222 cluster in BC cells.237  Since miRNAs can 
promote not just tumour suppressor mRNAs, but also oncogenic miRNAs (oncomiRs) and 
have been linked to cancer metastasis (metastamiRs) – the so-called opposing roles of 
miRNAs in tumorigenesis, depending on the cellular context238—miRNA silencing has 
become an attractive targeted approach to BC therapy.157,237,239,240 
Targeted therapy of MBC is exemplified by systemic treatment of tumour-bearing mice with 
miR-10b antagomirs which significantly suppressed breast cancer metastasis.241  It has been 
found that miR-10b is highly expressed in primary metastatic breast tumours, but can also 
initiate vigorous invasion and cell migration or metastasis (hallmarks of EMT), if 
overexpressed in otherwise non-metastatic breast tumours.242  Evidence suggests that miR-
10b blocks translation of the mRNA encoding the homeobox D10 (HOXD10) protein, 
intensifying the expression of the pro-metastatic gene, RHOC.  Furthermore, expression of 
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the BRMS1 (breast cancer metastasis suppressor-1) gene, a negative regulator of Twist (a key 
controller of EMT), perturbs the expression of miR-10b and RHOC, and enhances the 
expression of HOXD10 in MBC cells.243  Remarkably, BRMS1 suppresses metastasis of 
several tumours by complexing with SIN3, HDACs and a number of transcription factors that 
influence metastasis-associated gene expression (e.g., EGFR, OPN, PI4P5K1A, PLAU).  
BRMS1 expression in human MBC cells also downregulates EGFR expression and 
downstream (AKT) signaling.244   
A milestone in the treatment of recurrent BC has been the observation that miRNAs sensitize 
tumour cells to tamoxifen, one of the most extensively used SERMs.  Tamoxifen may be 
efficacious in many BC patients, but has been associated with resistance and recurrence due 
to truncations of ERα or loss of its expression, which is a major clinical obstacle in 
eradicating tumours that overexpress the receptor tyrosine kinase ERBB2.  Survival of BC 
cells stimulated by ERBB2 occurs via blockade of the tumour suppressive miR-15 and miR-
16 which, in turn, reinstate anti-apoptotic BCL‑2 expression.238,245  Other notable miRNAs in 
BC include miR-182-5p (mediates disruption of the homologous recombination, HR, 
pathway),239,240 various miRNAs that influence breast tumour resistance and recurrence,157,238 
miRNAs with altered expression in CD44+CD24−/low lineage breast CSCs,203 and the loss of 
several tumour suppressor miRNAs and overexpression of oncogenic miRNAs that induce 
loss of regulation of several cellular functional pathways involved in BC pathogenesis.246-248   
The preceeding paragraphs indicate that efficacious BC management demands the 
collaborative energies of a multidisciplinary oncology team and prudent attention to the 
patient’s individual tumour profile, i.e., the molecular and clinical characteristics.  A dire 
need thus exists to integrate systemic/chemotherapy, surgery, radiation therapy, and to 
develop personalized/targeted therapies for BC patients.  These therapeutic reflections also 
provide a rationale for experimental targeting of the multiplex components of the EGFR 
signaling pathways in BC and forms the basis for the study undertaken herein (section 1.5). 
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1.4.6 Breast Cancer Cell Lines
Cancer cell cultures grown in vitro have been fundamental in delineating the complexities of 
tumour biology and the robust pursuit of identifying novel drug targets to develop a wide 
spectrum of context-specific (proof-of-concept) anticancer drugs.  Many cancer cell lines, 
including the National Cancer Institute (NCI) panel of cancer cell lines249 and the widely 
used BC cell lines, closely resemble their primary tumours and CSCs—a property that has fir 
mly secured their continued relevance in oncology, even though contentions encouraging the 
use of primary cancer cells are undisputable.250-258  Notwithstanding, several BC cell lines, 
including the MCF-7 mammary cancer cell line used in this study, have been adequately 
validated to exhibit similar extensive genomic, transcriptional, and biological heterogeneity 
expressed by their corresponding primary tumours and are frequently used to distinguish 
various molecular BC diagnostic markers and as experimental model systems to study the 
effects of potential BC therapeutic modalities.257,259-262  The MCF-7 (Michigan Cancer 
Foundation—human cell line 7 derived from a pleural effusion of a primary breast 
carcinoma) was originally isolated in 1970 from a 69-year-old Caucasian American 
woman.263,264  The main features of MCF-7 cells include their luminal epithelial nature, 
exemplification of invasive breast ductal carcinoma, ER+/PR+, marked proliferative response 
to oestrogen, ERBB2 gene amplification (with Her2/neu protein overexpression),265 and 
tumorigenic potential in mice following oestrogen supplementation.  This cell line also 
exhibits several characteristics of differentiated mammary epithelial cells, including the 
ability to metabolize oestradiol, a ligand for the cytoplasmic ER.  
1.5 Research Proposal 
 
1.5.1 Problem Statement 
The successful outcome of cancer chemotherapy is often eclipsed by the persistent high 
incidence and mortality rates associated with the disease worldwide.114,116,197,266,267  Moreover, 
the desired therapeutic attainment or efficacy of many antitumour agents currently in use and 
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even those undergoing clinical trials may be confined to the type of cancer, thus limiting their 
general prognostic value and application.268-271  The substantial levels of clinical attrition for 
oncology drugs further accentuate the need to optimize existing cancer treatment modalities 
and foster future anticancer drug discovery strategies.  Fundamental, therefore, in any 
consideration of the sensitivity of cancer cells or the predictive clinical response to a given 
chemotherapeutic regimen is an understanding of the molecular mechanisms that underpin 
the expression of the cancer phenotype.236,270,272-274   
The prevailing trend in cancer (including MBC) therapeutics entails the integration of 
genomic and proteomic approaches.171,172,176,233,275-278  Genomic instability and thus tumour 
cell heterogeneity confer on cancer cells a growth and survival phenotype, including 
resistance to different types of therapy.  The identification and exploitation of genes and 
molecular biomarkers that constitute this hallmark of cancer is now widely accepted as the 
paradigm for synthetic lethality which is displayed when concurrent mutations of two or 
more genes are lethal, while mutation of one gene alone is not.279  This is also the case for 
personal and targeted therapy of breast cancer.280  Disturbances in cell growth and 
proliferation are perhaps the best characterized components of neoplasia.  Carcinogenesis and 
oncogenesis are associated with complex genetic alterations and phenotypic changes that 
confer a selective growth advantage on cancer cells which may be coupled with aggressive 
invasive behaviour or a high metastatic potential.  Cell proliferation and cell-cycle 
progression are functionally dependent on the expression of a wide array of genes that 
control such molecular events.281,282  Gene-specific mutations in signalling networks are 
quintessential traits shared by many types of cancer cells.281-283   
Thus, the ability of tumour cells to evade the homeostatic controls which maintain the 
appropriate number of cells in normal tissues is consistently demonstrated by aberrations in 
signal transduction pathways.  Significant advances in our understanding of the signal 
transduction cascades mediating and regulating cell growth and differentiation in a broad 
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spectrum of oncological contexts are being translated into useful diagnostics and therapeutics 
for MBC.182,284,285  A huge literature attests to the causal link between altered cellular 
signalling and breast cancer, the implicated ligands and their receptors, intracellular 
signalling molecules, the transformed phenotype, and the prime candidates for targeted 
therapy.286,287  In particular, the interception of tyrosine kinase receptors, e.g., the epidermal 
growth factor receptor (EGFR), as a therapeutic approach to interfere with the molecular 
mechanisms that propel the growth of tumour cells and prolong their survival has attracted 
considerable interest.285,288-290   
Since breast cancer classification is based on gene expression patterns of heterogeneous 
subtypes that closely mimic various developmental phases of normal mammary epithelial 
cells (MECs), delineation of the molecular mechanisms of MEC development is anticipated 
to yield critical insights into initiation and progression of breast cancer.  As alluded to above, 
signalling cascades involving EGFR and its ligands play pivotal roles in normal and 
pathological mammary gland behaviour—ligands for EGFR are overexpressed in a 
significant proportion of breast cancers, and elevated expression of EGFR is associated with 
poor clinical outcome, thus raising hopes for effective targeting of EGFR.181,195,223,275,291   
EGFR monoclonal antibodies and small-molecule TKIs64-6667,179,285,290,292-296 tested extensively 
for their potential to significantly inhibit sites in these signal transduction cascades in breast 
cancer or other cancer clinical settings include trastuzumab (herceptin),297-301 cetuximab 
(erbitux), pertuzumab,223,299,302,303 gefitinib (iressa)292,304 and erlotinib (tarceva).305-307  In the 
present study, various classes of anticancer drugs and TKIs, either alone or in combination, 
have been evaluated for their cytotoxic effects on MCF-7 breast cancer cells and correlated 
with experimental models of drug synergy and efficacy.  Tables 1.3 and 1.4 summarize the 
characteristics of conventional antineoplastic agents and TKIs (in this study confined to 
doxorubicin and cisplatin, and 3 TKIs), respectively, used as single or combination drugs 
against MCF-7 mammary carcinoma cells in this study.  
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Table 1.3: Conventional antineoplastic agents used in single or combination exposures against MCF-7 mammary carcinoma cells in this study 
Antineoplastic Agent Chemical Structure  Mechanism of Anticancer Action References 
Doxorubicin, Hydrochloride (DXR 
or DOX), Adriamycin·HCl 
 
IUPAC/Chemical Name 
(8S,10S)-10-(2R,4S,5S,6S)-4-amino-
5-hydroxy-6-methyloxan-2-yl]oxy)-
6,8,11-trihydroxy-8-(2-
hydroxyacetyl)-1-methoxy-
5,7,8,9,10,12-hexahydrotetracene-
5,12-dione, monohydrochloride 
 
CAS Number 
25316-40-9 
 
Chemical Formula 
C27H29NO11HCl 
 
Molecular Weight 
580 g/mol 
 
(Source: http://www.drugbank.ca/drugs/DB00997; 
https://www.caymanchem.com/app/template/Product.vm/cata
log/15007/promo/emolecules)  
Doxorubicin (DOX or DXR) is an anthracycline antibiotic.  
Its intermediate precursor, daunorubicin, was first isolated 
from Streptomyces peucetius in 1969.  DOX is formed by a 
C-14 hydroxylation of daunorubicin.  Used as an anticancer 
drug because if its ability to inhibit growth and proliferation 
of tumours and to induce apoptosis.  DOX is considered to be 
the most effective agent in the treatment of breast cancer 
patients and has been used clinically for more than 30 years 
for the treatment of a variety of malignancies. However, the 
clinical use of DOX is limited by dose-related cardiotoxicity 
and cancer cell resistance to treatment.  Studies are underway 
to alleviate the cardiotoxicity without interfering with its 
killing efficacy.  DOX has been reported to inhibit DNA 
synthesis at concentrations as low as 0.1–5 μM in breast 
tumour cells.  This may be due to its intercalation into DNA, 
whereby DOX inserts between stacked base pairs.   
The double helix becomes distorted and unwinds, and the 
DNA molecule assumes a more ladder-like conformation. 
This is typical of aromatic molecules composed of 
heterocyclic rings such as other intercalating agents like 
ethidium bromide.  Intercalation with DNA results in 
inhibition of macromolecule synthesis, reactive oxygen 
species (ROS) production, DNA cross-linking, and affects 
the integrity of cell membranes.  Excess ROS activates the 
mitochondrial death pathway resulting in apoptosis.  
Although DOX-mediated ROS production leads to apoptosis, 
a more noteworthy feature of DOX-induced apoptosis is its 
ability to intercalate DNA and inhibit topoisomerase II, the 
enzyme that cleaves both strands of dsDNA, passes a region 
of DNA duplex between the cut ends, and then rejoins the 
ends. This enzyme is very important in DNA replication and 
thus a key target of DOX. 
207,209,213,308-320 
Continued/… 
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Table 1.3: Conventional antineoplastic used in single or combination exposures against MCF-7 mammary carcinoma cells in this study (continued) 
Antineoplastic Agent Chemical Structure  Mechanism of Anticancer Action References 
Doxorubicin, Hydrochloride 
 
Structure of a DNA oligonucleotide with two doxorubicin 
drugs (shown in pink) intercalated between the base pairs. 
(Source: http://chemweb.bham.ac.uk/~hannonmj/Mike%20 
page/3wayjonction.html) 
DOX has also been shown to increase the ratio of pro-
apoptotic to anti-apoptotic Bcl-2 family members.  These 
mechanisms cause DNA damage and intracellular 
accumulation of ROS, which could explain how DOX 
mediates apoptosis and cell cycle arrest.  DOX has been 
reported to cause cell cycle arrest and apoptosis in MCF-7 
cells.  A recent Phase II trial with breast cancer patients 
meeting eligibility criteria such as HER2-negative status, 
hormone refractory tumour, assessable targets, with 
preserved performance status, and who had not received prior 
chemotherapy for their metastatic disease, showed that 
patients who received intravenous pegylated liposomal DOX  
concurrently with gemcitabine developed treatment-related 
adverse events such as neutropaenia, thrombopaenia, hand-
foot syndrome, mild cardiac toxicity and stomatitis, which 
significantly affected their quality of life, thus suggesting that 
lower doses of DOX and gemcitabine should be preferred.   
Several studies on the treatment of breast cancer, however, 
have shown that combination of DXR with other classes of 
anticancer drugs, including cyclophosphamide, trastuzumab, 
bevacizumab, taxanes (paclitaxel, docetaxel), vinflunine, 
cisplatin and infusional fluoruracil is feasible with 
manageable toxicity.  Despite the fact that DOX is considered 
to be the most effective agent in the treatment of breast 
cancer patients, the development of resistance to this agent is 
a frequent occurrence and thus represents a major 
impediment to successful treatment outcome.  Current efforts 
are directed at the identification of novel biomarkers that 
would predict treatment response and offer tailored 
personalized therapies to patients. 
 
Continued/… 
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Table 1.3: Conventional antineoplastic used in single or combination exposures against MCF-7 mammary carcinoma cells in this study (continued) 
Antineoplastic Agent Chemical Structure  Mechanism of Anticancer Action References 
Cisplatin (CDDP or CPL), Cis-
Diammineplatinum (II) dichloride 
 
IUPAC/Chemical Name 
Dichloroplatinumdiamine 
 
CAS Number 
15663-27-1 
 
Chemical Formula 
Pt(NH3)2Cl2 
 
Molecular Weight 
300.06 g/mol 
 
 
(Source: http://www.drugbank.ca/drugs/DB00515)  
 
 
(Source: Wang and Lippard 321) 
Cis-Diammineplatinum (II) dichloride (CDDP or CPL) is a 
platinum-based antineoplastic drug which is widely used to 
treat various cancer types, including metastatic breast cancer.  
The major current concern is the development of CDDP 
resistance in some tumour types.  Therefore, many research 
endeavors seek to overcome resistance and decrease drug 
dose in combination regimens to limit toxicity and increase 
or maintain its therapeutic efficacy.  CDDP is capable of 
forming adducts within the DNA dinucleotide and cause 
intra-strand cross-links that interrupt DNA transcription and 
replication, resulting in cell cycle arrest and apoptosis. CPL 
also inhibits nucleotide excision repair (NER) by the 
mitochondria.  The NER mechanism removes DNA-CPL 
adducts, however, adducts also form in the mitochondrial 
DNA, therefore, inhibiting this process of adduct removal.  
CPL inhibits 50% of growth in MCF-7 cells at concentrations 
between 60-70 µM.   
CPL induces apoptosis in cancer cells through the death 
receptor pathway or through the intrinsic mitochondrial death 
pathway. The exact mechanism is extensively being studied, 
but the intrinsic pathway may be mediated through signaling 
of the JNK cascade, p53 and induction of inhibition of Bcl-2 
family of proteins (anti- or pro-apoptotic members).  Some of 
the observed side effects in breast cancer patients treated with 
CPL are ototoxicity, neurotoxicity and nephrotoxicity.  CPL–
gemcitabine combination treatment has shown promising 
results in phase II clinical trials for treating metastatic triple 
negative breast cancer, which is characterized by the absence 
of oestrogen (ER), progesterone (PR) and HER2/neu receptor 
expression.  Likewise, subcutaneous delivery of 
nanoconjugated DOX and CPL for locally advanced breast 
cancer demonstrates improved efficacy and decreased 
toxicity. 
211,321-328 
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Table 1.4: Tyrosine kinase inhibitors used in single or combination exposures against MCF-7 mammary carcinoma cells in this study 
Tyrosine Kinase Inhibitor  Chemical Structure  Mechanism of Anticancer Action References 
EGFR Inhibitor 1 
(EGFR Inhibitor I) 
 
IUPAC/Chemical Name 
Cyclopropanecarboxylic acid-(3-(6-
(3-trifluoromethyl-phenylamino)-
pyrimidin-4-ylamino)-phenyl)-amide 
 
CAS Number 
879127-07-8 
 
Chemical Formula 
C21H18F3N5O 
 
Molecular Weight 
413.4 g/mol 
 (Source: Zhang et al. http://pubs.acs.org/doi/abs/10.1021/ja0567485  
http://www.merckmillipore.com/)  
EGFR Inhibitor is a cell-permeable 4,6-dianilinopyrimidine 
compound that acts as a potent, ATP-competitive, and highly 
selective inhibitor of EGFR and some EGFR mutants 
(IC50=21 nM, 63 nM, and 4 nM for EGFRwt, EGFRL858R 
and EGFRL861Q, respectively) vs. erbB4/Her4 (IC50=7.64 
μM) and a panel of 55 other kinases.  Shown to completely 
block EGF-induced EGFR autophosphorylation in U-2OS 
cells at 10 μM. 
329 
Names assigned to EGFR inhibitors for the purpose of this study. 
For a list of newly developed EGFR inhibitors, cf. http://www.drugs.com/drug-class/egfr-inhibitors.html 
Continued/… 
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Table 1.4: Tyrosine kinase inhibitors used in single or combination exposures against MCF-7 mammary carcinoma cells in this study (continued) 
Tyrosine Kinase Inhibitor  Chemical Structure  Mechanism of Anticancer Action References 
EGFR Inhibitor 2 
(EGFR Inhibitor II, BIBX1382, 
BIBX1382BS, Falnidamol) 
 
IUPAC/Chemical Name 
N8-(3-Chloro-4-fluorophenyl)-N2-(1-
methylpiperidin-4-yl)-pyrimido[5,4-
d]pyrimidine-2,8-diamine, 2HCl 
 
CAS Number 
196612-93-8 
 
Chemical Formula 
C18H19ClFN7•2HCl•2H2O 
 
Molecular Weight 
496.8 g/mol 
(Source: http://www.scbt.com/datasheet-202497-bibx-1382.html; 
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6918
508#itabs-2d) 
Overexpression of the EGFRs and hEGFR 2 occurs frequently 
in human cancers and is associated with aggressive tumour 
behaviour and poor patient prognosis.  BIBX1382BS is a 
representative of the human epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitors. BIBX1382 is a cell-
permeable pyrimidopyrimidine compound that acts as a 
potent, reversible, ATP-competitive, and highly selective 
inhibitor of EGFR (ErbB-1, HER-1) both in cell-free 
enzymatic reactions (IC50=3 nM) and in culture (IC50=0.15, 
1.82, and 3.2 µM in EGF-, HGF-, and FCS-dependent 
thymidine incorporation, respectively, in KB cells).  It has 
1,000-fold greater selectivity over ErbB-2 (HER-2, neu; 
IC50=3.4 µM) and shows negligible activity towards IGF1R, 
β-InsRK, HGFR, c-src, and VEGFR-2 even at concentrations 
as high as 10 µM.  Its antitumor efficacy has also been 
demonstrated in a murine xenograft model.  BIBX1382 can be 
used to distinguish between the ErbB kinases in intact cells 
when used at appropriate concentrations. 
330-333 
Names assigned to EGFR inhibitors for the purpose of this study. 
For a list of newly developed EGFR inhibitors, cf. http://www.drugs.com/drug-class/egfr-inhibitors.html 
Continued/… 
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Table 1.4: Tyrosine kinase inhibitors used in single or combination exposures against MCF-7 mammary carcinoma cells in this study (continued) 
Tyrosine Kinase Inhibitor  Chemical Structure  Mechanism of Anticancer Action References 
EGFR Inhibitor 3 
(EGFR/ErbB-2/ErbB-4 Inhibitor) 
 
IUPAC/Chemical Name 
N-(4-((3-Chloro-4-
fluorophenyl)amino)pyrido[3,4-
d]pyrimidin-6-yl)2-butynamide 
 
CAS Number 
881001 
 
Chemical Formula 
C17H11ClFN5O 
 
Molecular Weight 
355.8 g/mol 
 
 
(Source: www.calbiochem.com; http://www.emdmillipore.com/life-
science-research/egfr-erbb-2-erbb-4-inhibitor/EMD_BIO-324840/ 
p_u3qb.s1Lz4oAAAEW0WEfVhTm; http://www.guideto-pharma 
cology.org/GRAC/LigandDisplayForward?ligandId=5965)  
 
EGFR/ErbB-2/ErbB-4 Inhibitor is a cell-permeable, ATP-
binding site-targeting alkynamidopyrimidine compound that 
acts as a potent and irreversible inhibitor of erbB activities 
(IC50=0.3, 1.1, and 0.5 nM for erbB-1, erbB-2, and erbB-4, 
respectively).  Inhibits EGF- and heregulin-induced erbB 
autophosphorylation in NIH3T3-erbB-1 and in MDAMB-453 
cells (IC50=2.5 and 24 nM, respectively). 
 
Names assigned to EGFR inhibitors for the purpose of this study, but also used interchangeably with their conventional names. 
For a list of newly developed EGFR inhibitors, cf. http://www.drugs.com/drug-class/egfr-inhibitors.html  
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 1.5.2 Research Hypothesis 
Combinations of conventional antineoplastic agents (DOX and CPL) and TKIs (EGFR 
Inhibitor I, EGFR Inhibitor II/BIBX1382 and EGFR/ErbB-2/ErbB-4 Inhibitor), act 
synergistically to yield greater anticancer efficacy than those predicted by their individual 
activities against MCF-7 breast cancer cells in vitro. 
 1.5.3 Research Objectives 
The objectives of the present study are to: 
 Evaluate combinations of conventional molecularly-targeted antineoplastic agents 
and TKIs for enhanced efficacy towards MCF-7 breast cancer cell killing in vitro. 
 Correlate the molecular features and plausible pharmacodynamic effects of the 
various drug combinations in the tumour-drug systems with the sensitivity and 
mechanisms of action/resistance in relation to drug synergy (additivity) or 
antagonism reference models. 
 Identify the most promising anticancer drug and TKI combinations, using MCF-7 
breast cancer cell culture assay systems. 
 Assess the morphological changes and expression levels of EGFR in MCF-7 breast 
carcinoma cells following treatment with TKIs. 
1.5.4 Significance of the Study
It is generally accepted that cancer initiation and progression occur through single or multiple 
gene alterations, including oncogene activation, loss of function of tumour suppressor genes, 
or modification/mutation of genes involved in the regulation of cell growth and proliferation.  
EGFR frequently amplified in a significant proportion of breast cancer patients, resulting in 
aggressive clinical tumour progression, a higher risk of developing metastases, and a lower 
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survival rate compared to patients with normal EGFR expression.  Thus, EGFR 
overexpression in cancer can be exploited to identify candidates for EGFR-directed therapy 
and for its prognostic value.  However, many EGFR-related signalling genes commonly 
associated with cancer coordinately regulate cancer cell chemosensitivity, resulting in poor 
clinical outcome. 
A significant challenge remains for basic, preclinical and clinical researchers to target the 
functional connections between EGFR signalling components and to integrate this 
knowledge and experience into successful clinical cancer chemotherapeutics.  The 
development of novel therapeutic TKIs directed against the EGFR/erbB family members has 
made a special impact in cancer chemotherapy as demonstrated by the remarkable 
improvement in clinical outcome by incorporation of these agents into various regimens.  
However, concerns have been raised whether a large fraction of patients with early-stage 
HER2-positive breast cancer may actually enjoy many years of life free of recurrence in the 
face of such personalized therapy.  A notable response to the complexity of cancer 
chemotherapy in this regard has been the resurgence of a well-established principle, viz., the 
advocacy and use of drug combinations to enhance tumour cell sensitivity and circumvent 
resistance.  In this study, an approach to drug combination and synergy analysis will be 
applied to specific tyrosine kinase inhibitors in view of their prominent status as current 
oncolytic agents of choice for metastatic breast cancer, and the contention surrounding their 
limited efficacy, adverse effects and mechanisms of resistance. 
1.6 Outline of Chapters 
Chapter 1: Introduction and Literature Review 
Chapter 2: Materials and Methods 
Chapter 3: Results and Discussion 
Chapter 4: Conclusions and Future Perspectives 
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1.7 Summary
This chapter provided an introduction and background to the study undertaken in this 
dissertation.  The research described herein deals with the effects of various combinations of 
different classes of anticancer drugs and tyrosine kinase inhibitors on the human MCF-7 
breast carcinoma cell line.  Due to the complexities and heterogeneity of breast cancers, 
Chapter 1 offered an overview of current knowledge of the functional anatomy and 
physiology of the female breast, its development, differentiation and neoplastic 
transformation.  This chapter also reflected on the non-malignant and pre-malignant 
pathological changes that occur in breast tissue and the importance of mammography 
screening and clinicopathological diagnositics in the early detection of precancerous lesions 
to promote novel individualized treatments in breast cancer patients.  A particular focus on 
the molecular pathogenesis and taxonomy of breast cancer forms an integral part of this 
chapter, along with up-to-date coverage of the epidemiology, incidence and mortality 
statistics that define the global breast cancer landscape.   
Since breast cancer is the most common cause of cancer deaths among females worldwide, a 
brief impression of the aetiological and risk factors associated with the disease was deemed 
appropriate for this chapter.  Recent genomic classifications of breast cancers that distinguish 
breast cancer intrinsic subtypes have been included in order to emphasize variances in 
incidence, survival and therapeutic responses in breast cancer patients.  The National 
Comprehensive Cancer Network and European Society for Medical Oncology list of single 
agents and frequent combination regimens recommended or preferred in the management of 
metastatic breast cancer is also provided.  Furthermore, this chapter also encapsulates the 
significance of molecular biomarkers in portraying the disparities in molecular and clinical 
characteristics of breast cancer.  Specifically, the central roles played by the epidermal 
growth factor receptor (EGFR/erbB) family members in pathogenic signalling of breast 
cancer is highlighted as attractive targets for mono- and combination therapies, the purpose 
of the research undertaken in this study.   
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Introduction 
This chapter focuses on the research methodology and the design that has been chosen for the 
study.  The research proposal, problem statement, hypothesis, objectives and significance of 
the study were described in Chapter 1.  This chapter summarizes the materials and methods 
used such as the drugs tested and chemicals required for the maintenance of MCF-7 breast 
carcinoma cell cultures.  Analyses of MCF-7 breast carcinoma cells exposed to doxorubicin, 
cisplatin and EGFR inhibitors (TKIs), alone and in combination, included growth and dose-
response curves (cytotoxicity assays), drug synergy analysis, morphological staining of 
apoptotic cells with haematoxylin and eosin and Annexin V-FITC, and quantitative Real-
Time PCR (qPCR) of EGFR gene expression.  The statistical methods used for data analysis 
are also described.  
2.2 Approval to Conduct the Study and Ethical Considerations 
The research described in this dissertation was approved by the University of the Western 
Cape Faculty Board Research and Ethics Committee and the Senate Research Committee 
(Registration/Ethical Clearance Numbers: Project Registration #: ScRIRC 2007/3/29; 
Funding Application #: ScRIRC 2007/3/44 and Senate Registration #: 07-3-37).  This study 
involved in vitro cell culture work.  The extensive use of continuous cancer cell lines, such as 
MCF-7 breast carcinoma cells, an authenticated cell line of known provenance 
(www.atcc.org), carries little risk to humans from routine cell culture.  However, risk of 
exposure to any form of infection was minimized by avoiding the use of "sharps" (such as 
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needles and blades) and any items or processes likely to create aerosols.  Aseptic technique 
and good cell culture practice and the recommended procedures for handling, use, storage, 
transportation and disposal of genetically modified organisms, including modified cell lines, 
have been adhered to in this study as provided in the Genetically Modified Organisms 
(Contained Use) Regulations Health and Safety Commission. ISBN 0717611868 Guide to 
Genetically Modified Organisms (Contained Use) Regulations, 1992. HSE Guide, L29, HSE 
Books, PO Box 1999, Sudbury, Suffolk CO10 6FS, 1992.  See also 
http://www.sigmaaldrich.com/Area_of_Interest/Life_Sciencesources/ECACC_Handbook/Cel
l_Culture_Techniques_2.html. 
A level 2 containment, the minimum requirement for manipulating human cancer cell lines as 
described in the Advisory Committee on Dangerous Pathogens (ACDP) guidelines Advisory 
Committee on Dangerous Pathogens, 4th edition.  Categorization of biological agents 
according to hazard and categories of containment, The Stationery Office Books, PO Box 
276, London SW8 5DT) was applied in this study.  Control of the disposal of laboratory 
waste to prevent exposure of staff and the environment to infectious hazards and to prevent 
contamination was executed according to recommended procedures (Health Services 
Advisory Committee. ISBN 0717604470 Safe Disposal of Clinical Waste. HSE Books, PO 
Box 1999, Sudbury, Suffolk CO10 6FS, 1992).   
2.3 Drugs and Chemicals 
Chemicals used in this study include EGFR-Inhibitor [Cyclopropanecarboxylic acid-(3-(6-(3-
trifluoromethyl-phenylamino)-pyrimidin-4-ylamino)-phenyl-amide, EGFR/ErbB-2/ErbB-4 
Inhibitor [N-(4-((3-Chloror-4-fluorophenyl)amino)pyrido [3,4-d] pyrmidin-6-yl) 2-
butynamide, EGFR Inhibitor II, BIBX1382 [N8-(3-Chloror-4-fluorophenyl)-N2-(1-
methylpiperidin-4-yl)-pyrimido [5,4-D] pyrimidine-2, 8-diamine, 2HCl, EGFR forward 
primer design, EGFR reverse primer design, trypsin-EDTA, Qiagen QuantiTect® reverse 
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transcription kit (Calbiochem and Qiagen via Whitehead Scientific), heat inactivated foetal 
bovine serum (Biochrome, The Scientific Group), phosphate buffered saline and Dulbecco’s 
modified Eagles medium F-12 glutamax (Gibco, Life Technologies), penicillin/streptomycin, 
staurosporine, Annexin V-FITC, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTT), dimethylsulfoxide, isopropanol, haematoxylin and 
eosin (Sigma–Aldrich), Tripure (Roche), chloroform (Merck Chemicals), GoTaq® Flexi 
DNA polymerase, 25 mM magnesium chloride solution, 5X Green GoTaq® Flexi Buffer, 5X 
Colorless GoTaq® Flexi Buffer, Go Taq® DNA Polymerase, PCR Nucleotide Mix, 
Nuclease-Free Water (Promega, Anatech).  All other chemicals were purchased either from 
Merck or Sigma–Aldrich and were of the highest purity and analytical grade. 
2.4 Maintenance of MCF-7 Breast Carcinoma Cell Cultures
All tissue culture operations were carried out in a model NU-5510E NuAire DHD autoflow 
automatic CO2 air-jacketed incubator (and an AireGard NU-201-430E horizontal laminar 
airflow table top workstation that provides a HEPA filtered clean work area (NuAire).  The 
human breast cancer cell line, MCF-7, was kindly provided by Professor Maryna De Kock, 
Department of Medical Biosciences, University of the Western Cape, South Africa.  The 
MCF-7 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) and 
supplemented with 10% heat-inactivated foetal bovine serum (HIFBS), 0.2% 
penicillin/streptomycin (100 U/ml penicillin and 100 µg/ml streptomycin) and grown as 
monolayer cultures at 37C in a humidified incubator (Relative Humidity/RH 80%) in an 
atmosphere of 5% CO2:95% air. 
Cryovials containing the MCF-7 mammary carcinoma cells were removed from -80°C 
storage and placed in a 37°C waterbath to thaw.  The caps were wiped with 70% ethanol and 
the contents of the vial transferred to a T-25 culture flask (surface area (SA) 2500 mm2) 
containing 5 ml of complete medium (GIBCO® Dulbecco’s Modified Eagles Medium/F-12 
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supplemented with 1% penicillin-streptomycin, and 10% HIFBS, all acquired from 
Invitrogen).  The flask was placed on a PrimoVert phase-contrast microscope to visualize the 
presence of suspended cells, and then placed in a 37°C incubator at 5% CO2.  The cells were 
allowed to attach for 24h, after which the flask was removed from the incubator and 
attachment confirmed by microscopy.  The flask was incubated until cells reached 
approximately 80-90% confluency and the medium was replaced periodically.   
When confluency had been reached, cells were trypsinized.  The medium was aspirated and 
the cells washed with 2 ml PBS.  After 1 min, the PBS was aspirated and 1ml 0.25% 
Trypsin-EDTA was added to the flask and placed in the incubator for 5-15 min in order for 
the cells to detach.  The flask was then removed from the incubator and placed in a laminar 
flow cabinet.  Thereafter, 2 ml complete medium was added to the flask to deactivate the 
trypsin.  The cells were gently mixed using an electronic pipette aid and detached cells 
aspirated and transferred to a 15 ml conical centrifuge tube, placed in a centrifuge and spun 
for 5 min at 2500 rpm to separate the cells from the medium-trypsin solution.  After 
centrifugation, the supernatant was discarded and the cell pellet resuspended in 5 ml 
complete medium.  The cells were mixed to ensure a homogeneous cell suspension, 1ml of 
which was transferred to T-75 culture flask (SA 7500 mm2) containing 12 ml complete 
medium to maintain stock cultures.   
2.5 Growth Curve Analysis of MCF-7 Breast Carcinoma Cells Exposed to TKIs
MCF-7 breast carcinoma cells were seeded into a 24-well plate (well SA 200 mm2) at a 
density of 105 cells per well and incubated under standard conditions as described above.  
After cell attachment (24h), cells were treated with EGFR-Inhibitor I at different 
concentrations (5 nM and 20 nM) vs untreated control (complete culture medium) and 
incubated for 96h at 37°C in a humidified atmosphere with 5% CO2:95% air.  After the 
incubation period, cells were harvested with 1ml trypsin-EDTA from wells every 24h for the 
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duration of the experiment.  Cells were counted with Neubauer Improved Bright-line 
haemocytometer and the results recorded.  The experiment was repeated 4 times and the 
results pooled. 
2.6 Growth Curve Analysis of MCF-7 Breast Carcinoma Cells Exposed to DOX, 
CPL and EGFR/ErbB2/ErbB4 Inhibitor 
Stock cultures of MCF-7 breast carcinoma cells were trypsinated and transferred to a 
centrifuge tube and spun at 2500 rpm for 4 minutes.  The supernatant was removed and the 
pellet resuspended in 5 ml complete medium.  Cells were seeded in 35-mm diameter petri-
dishes at 106 cells/ml.  An aliquot of 100 µl cells was added to each dish in four replicate 
plates.  Cells were exposed to 1 µM DOX, 10 µM CPL, and a control dish containing no 
drug.  Dishes were incubated for 24, 48 and 72h.  After the set time, dishes were trypsinated 
and cells counted using a Bio-Rad TC-10 cell counter at a ratio 1:1 of cell suspension and 0.4 
µM trypan blue.  In another set of experiments, a growth curve was generated for MCF-7 
breast carcinoma cells exposed to DOX (1.2 µM), CPL (15.8 µM) and 0.5 nM 
EGFR/ErbB2/ErbB4 Inhibitor relative to control.  Briefly, cells were seeded into 24-well 
plates at 5 x 104 cells/ml and cultured in the presence of the DOX, CPL and 
EGFR/ErbB2/ErB4 Inhibitor for 24, 48 and 72h, and cell counts obtained as described above.  
2.7 Dose-Response Curve Analysis of MCF-7 Breast Carcinoma Cells Exposed to 
TKIs Alone and in Various Combinations 
MCF-7 breast carcinoma cell viability was periodically checked by adding 15 μl of 0.4 µM 
trypan blue to 15 µl cell suspension in an Eppendorf tube and mixed.  Trypan blue is a dye 
that differentiates between viable and non-viable cells by only staining non-viable cells and 
being excluded from viable cells.  Viable cells were counted using either a Neubauer 
Improved Bright-line haemocytometer or an automated TC-10 (BioRad) cell counter.  Dose-
response curve analysis of MCF-7 breast carcinoma cells exposed to TKIs alone and in 
various combinations entailed culturing cells in octuplicate wells of 96-well plates, i.e., 
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control vs treatment with uniform cell densities (2×104 cells/well).  Plates were incubated at 
37°C in a humidified atmosphere with 5% CO2 for 24h to allow cells to attach.  Cells in 
respective wells were exposed to dimethylsulfoxide (DMSO; vehicle control) or TKIs 
(EGFR inhibitor I, EGFR Inhibitor II/BIBX1382 and EGFR/ErbB-2/ErB4 Inhibitor) alone at 
various concentrations ranging from 0.0001 μM to 100 μM and in combinations with 
equimolar concentrations of the other TKIs.  Control plates were standardized for DMSO 
(vehicle).  The plates were incubated for 72h.  After incubation, 20μl of 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) 
was added to each well and incubated at 37°C in a humidified 5% CO2 atmosphere for 4h.  
MTS is a component of the CellTiter® Proliferation Assay which is a colorimetric method 
that is used to measure the amount of viable cells based on the bioreduction of MTS into a 
formazan product.  After 4h, the plates were removed from the incubator and the absorbance 
recorded at 560 nm using a Promega GloMax™-Multimode model E7031 microplate reader. 
The quantity of formazan product as measured by the amount of 490 nm absorbance is 
directly proportional to the number of living cells in culture. 
2.8 Cell Viability and MTT Proliferation Assay
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) is reduced to 
formazan, following cleavage of the tetrazolium ring by succinate dehydrogenase within the 
mitochondria of metabolically active cells.334,335  The inability of formazan to diffuse through 
the cell membrane allows its accumulation within healthy living cells.  The insoluble 
formazan crystals that form within the cell can be dissolved in acidified isopropanol, 
dimethyl sulfoxide (DMSO) or sodium dodecyl sulfate (SDS).  MCF-7 mammary carcinoma 
cells were seeded at a density of 5 X 104 cell/ml into 96-well flat-bottom plates.  A 100-µl 
cell suspension was added to each well and cells were allowed to attach for 24h under normal 
incubation conditions.  After 24h, medium was removed and replaced with 200 µl complete 
medium containing increasing log10 concentrations of DOX, CPL and TKI, alone and in 
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combination (0.0001, 0.001 0.01, 0.1, 1, 10 and 100 µM) in six replicate wells for DOX and 
CPL and (0.0001, 0.001 0.01, 0.1, 1, 10 and 100 µM) for the EGFR/ErbB2/ErbB4 inhibitor.  
Plates were incubated for 24, 48 and 72h, respectively.  After the incubation period, 20 µl 
MTT solution (5 mg/ml MTT in PBS) was added to each well, the plate covered with 
aluminum foil and incubated for 2h.  Thereafter the supernatant was aspirated and 200 µl 
neat isopropanol added to each well and incubated at room temperature on a vortex shaker 
for 25 min, still enclosed in foil.  Plates were read at 560 nm using the Promega GloMaxTM 
multiscan or Titertek Multiskan model MCC/340 plate reader. 
2.9 MCF-7 Mammary Carcinoma Growth Curve Analysis
The cells were trypsinized and transferred to a centrifuge tube and spun at 2500 rpm for 5 
min. The supernatant was removed and the pellet resuspended in 5ml complete medium.  
Cells were seeded into 24-well plates at 5 x 104 cells/ml.  Cells were exposed to 1.25 µM 
DOX, 15.8 µM CPL 0.5 nM EGFR/ErbB-2/ErbB-4 inhibitor and a control row containing no 
drug.  Plates were incubated for 24, 48 and 72h.  After the set time, cells were trypsinized 
with 0.25% trypsin-EDTA and counted using the Bio-Rad TC-10 cell counter at a ratio 1:1 
cell suspension: 0.4 µM trypan blue. 
2.10 Analysis of Drug Combinations
The median-effective concentration (EC50, also used interchangeably with IC50), i.e., the 
concentration of TKI that can be expected to cause a defined effect on 50% of a given 
population of MCF-7 breast carcinoma cells under defined conditions (individually and in 
combination) were determined from regression analysis of sigmoidal dose-response curves, 
using the built-in 4- or 5-parameter logistic equations of GraphPad Prism (Version 6.04 for 
Windows, GraphPad Software, San Diego California USA, http://www.graphpad.com and 
http://www.graphpad.com/guides/prism/6/curve-fitting/).336  EC50 data are best-fit values 
obtained from non-linear regression analysis for each TKI or drug alone or in combination. 
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The potency ratio and associated 95% CI (confidence interval) were computed according to 
the method of Fieller337 by subtracting the log EC50 of drug in combination from the log EC50 
of drug alone and back-transformation (antilogarithm) of data.  GraphPad QuickCalcs, 
Graphpad Prism, SigmaPlot (version 12.5, http://www.sigmaplot.com/) and OriginLab Pro 
(version 9.1, http://www.OriginLab.com) were used for data and graphic analysis.  Multidrug 
effects were used to study the efficacy of different TKI combinations in MCF-7 cells.  Data 
were analyzed using both the Loewe additivity and Bliss independence drug interaction 
synergy models.338-344  Combination indices were derived from parameters of the median 
effect plots that were calculated according to the Chou and Talalay method345,346 using the 
computer programmes CombiTool (IMB Jena Biocomputing Group, http://www.imb-
jena.de/www_bioc/CombiTool/),343,347 CompuSyn (http://www.combosyn.com) and 
CalcuSyn (http://www.biosoft.com).  The Loewe dose additivity model is defined by the 
equation dx/Dx+dy/Dy=1, where Dx and Dy represent the concentrations of individual drugs 
required to exert the same effect as concentrations dx and dy used in combination.  Values 
less than 1.0 indicate synergistic interactions, values greater than 1.0 indicate antagonistic 
interactions, and values equal to 1.0 indicate additive interactions.  The Bliss independence 
model is defined by the equation: Exy=Ex+Ey –ExEy for 0<E<1 and where Exy is the additive 
effect of drugs x and y as predicted by their individual effects Ex and Ey.   
Likewise, the drug interaction index was calculated using CombiTool, according to 
established methods.342,345-348  Briefly, synergism, additivity and antagonism for drug 
combinations were computed on the basis of the multiple drug-effect equation, and 
quantitated by the combination index (CI), where CI=1, CI<1 and CI>1 indicate synergism, 
additivity effect and antagonism, respectively.  Based on the classic isobologram, the CI 
value is calculated as: 
1 2
1 2
(D) (D)CI (D ) (D )x x
   
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For example, in the combination of DOX+CPL, at the 75% inhibition level (Fa=0.75), (Dx)1 
and (Dx)2 are the concentrations of DOX and CPL, respectively, that induce a 75% inhibition 
of cell growth; (D)1 and (D)2 are the concentrations of DOX and CPL in combination that 
also inhibits cell growth by 75% (isoeffective as compared with the single drugs alone).  The 
statistical significance of these indices was determined by Monte Carlo simulations 
(Combostat).349  The dose-reduction index (DRI) is defined as the degree of dose reduction 
that is possible in combination for a given degree of effect as compared with the 
concentration of each drug alone:  
1 2
1 2
1 2
(D ) (D )(DRI) =  and (DRI)(D) (D)
x x  
2.11 Cell Morphological Analysis: Haematoxylin and Eosin Staining of Cells
A morphological assessment was done by means of observation, thus assessing for changes 
in the morphological development of the cells, which included cell shrinkage, chromatin 
condensation and apoptotic body formation.  Morphology was evaluated by haematoxylin 
and eosin (H&E) stain, and photos were taken using an inverted microscope PrimoVert with 
integrated camera and monitor.  Magnification was 200x for all slides.  MCF-7 breast 
carcinoma cells were seeded onto sterile coverslips (22x22 mm) and grown in 35-mm 
diameter petri dishes (surface area 962 mm2).  Cells were seeded at 3x105 cells per dish in 
2ml culture medium.  After 24h of incubation, cells were exposed to a range of different 
concentrations of 3 TKIs, i.e., EGFR Inhibitor I (8.8 µM, 17.6 µM, 35.18 µM, 70.36 µM and 
140.72 µM), EGFR Inhibitor II/BIBX1382 (2.1 µM, 4.2µM, 8.4 µM, 16.82 µM and 33.64 
µM) and EGFR/ErbB2/ErB4 Inhibitor (0.85 µM, 1.7 µM, 3.39 µM, 6.78 µM and 13.56 µM) 
over 24, 48 and 72 hour time intervals.   
Coverslips were removed from petri dishes by the use of a tweezer, and transferred into a 
staining dish.  Bouin’s fixative was added for 20min, which was followed by addition of 70% 
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ethanol for 15 min.  Coverslips were rinsed with tap water and placed into a dish containing 
haematoxylin for 20 min.  Coverslips were rinsed for 2 min with water and 70% ethanol 
successively for 2 min.  A 1% eosin solution was used to wash coverslip with for 2 min.  
This was followed by rinsing steps involving 70% ethanol, 96% ethanol, 100% ethanol and 
xylol for 5 min for each solution.  Coverslips were fixed onto poly-L-lysine coated slides 
using mounting medium, allowed to dry and evaluated with an inverted microscope. 
2.12 Annexin V-Cy3™ Apoptosis Detection Assay
MCF-7 breast carcinoma cells were seeded into 35-mm diameter petri dishes (surface area 
962mm2) at 3x105 cells per dish in 2 ml culture medium.  After 24h of incubation to allow 
cells to attach, cells were exposed to a range of different concentrations of 3 TKIs EGFR (8.8 
µM, 17.6 µM, 35.18 µM, 70.36 µM and 140.72 µM), EGFR Inhibitor II/BIBX1382 1382 
(2.1 µM, 4.2 µM, 8.4 µM, 16.82 µM and 33.64 µM) and EGFR/ErbB2/ErB4 Inhibitor (0.85 
µM, 1.7 µM, 3.39 µM, 6.78 µM and 13.56 µM) over 24, 48 and 72 hour time intervals in 
order to induce apoptosis.  Staurosporine (Sigma-Aldrich) 1 µg/ml was used as positive 
control for apoptosis.  After inducing apoptosis using the specified concentrations of TKIs, 
cells were washed in phosphate buffered saline (PBS).  Thereafter, cells were trypsinated and 
resuspended in PBS.  A 2-mm tip PAP pen (Sigma-Aldrich), a special marking pen that 
delivers a thin film-like green-tinged hydrophobic barrier when a circle is drawn around a 
specimen on a slide, was used to draw circles of 1 cm diameter on poly-prep-poly-L-lysine-
coated slides to restrict movement of cell suspension to the slide.  A droplet (50 µl) of cell 
suspension was placed inside the circle and cells were allowed to attach to the slide by 
incubating at room temperature. 
The cells were washed with binding buffer (10 mM Hepes/NaOH, pH 7.5, containing 150 
mM NaCl, 5 mM KCl, 1 mM CaCl2 and 1.8 mM CaCl2)350 and a double label staining 
solution (Sigma-Aldrich; Annexin V Cy3.18 and 6-carboxyfluorescein diacetate) added onto 
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each circle and covered with foil.  Cells were incubated at room temperature for 10min.  
Slides were washed with 1X binding buffer in order to remove excess unbound staining 
solution.  A cover slip was added onto the slide and results were viewed using a fluorescent 
microscope.  Cells starting the apoptotic process were stained with stains—Annexin Cy3.18 
(red) and 6-carboxyfluorescein diacetate (green).  Annexin-Cy3.18 (AnnCy3) binds to 
phosphatidylserine present in the outer leaflet of the plasma membrane of cells starting the 
apoptotic process.  The binding is observed as red fluorescence.  6-Carboxyfluorescein 
diacetate (6-CFDA) is used to measure viability.  When this non-fluorescent compound 
enters living cells, esterases present hydrolyze it, producing the fluorescent compound, 6-
carboxyfluorescein (6-CF).  This appears as green fluorescence (Sources: Sigma-Aldrich 
Annexin V-Cy3™ Apoptosis Detection Kit (http://www.sigmaaldrich.com/ 
content/dam/sigma-aldrich/docs/Sigma/Bulletin/apoacbul.pdf). 
2.13 Epidermal Growth Factor Receptor (EGFR) Gene Expression Analysis
 
2.13.1 RNA Extraction from Cultured MCF-7 Breast Carcinoma Cells 
MCF-7 cells breast carcinoma were cultured and treated for 48h with various concentrations 
of the 3 tyrosine kinase inhibitors selected for this study, viz., EGFR Inhibitor I (8.8 µM, 
17.6 µM and 35.18 µM), EGFR Inhibitor II/BIBX1382 (2.1 µM, 4.2 µM and 8.4 µM) and 
EGFR/ErbB2/ErB4 Inhibitor (0.85 µM, 1.7 µM, 3.39 µM).  RNA was extracted from treated 
and untreated control MCF-7 breast carcinoma cell cultures by adding 1ml of cold TriPure 
isolation reagent (Roche) to the cell pellet and homogenized.  The TriPure reagent contains 
phenol and guanidine thiocyanate which allow the simultaneous extracion of RNA, DNA and 
proteins from cells and tissues.351  The homogenates were transferred to a sterile 2-ml 
Eppendorf tube and left at room temperature for 5min.  A volume of 0.2 ml of chloroform 
was added to the Eppendorf tube for every millilitre of Tripure added, and the tube vortexed 
for 15 seconds.   
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The tubes were the left at room temperature for 15min. After this the tubes were centrifuged 
at 12000 rpm for 15 min which resulted in the solution separating into three phases.  The 
upper layer of aqueous solution was removed and 0.5ml was transferred into another sterile 
1.5-ml Eppendorf tube.  This was followed by adding 0.5 ml of isopropanol to the solution 
and mixing it. The RNA was precipitated overnight at -20C.  The RNA pellet was removed 
the following day centrifuged at 12000 rpm for 10 min at 4C.  The supernatant was removed 
and 1ml of 80% ethanol added to the RNA pellet and vortexed to dissolve the pellet, 
followed by centrifugation at 7500 rpm for 5 min at 4C.  The supernatant was aspirated and 
the pellet resuspended in 0.1 ml UltraPure™ diethylpyrocarbonate (DEPC)-treated water 
(Life Technologies).  The RNA was quantified with a Nanodrop ND-1000 spectrophotometer 
(Thermoscientific) which determines the ratio of absorbance at 260 nm and 280 nm to 
calculate the purity of DNA and RNA.  A ratio of ~1.8 is usually accepted as “pure” for 
DNA, whereas a ratio of ~2.0 is indicative of “pure” RNA.  If the ratio is significantly lower 
in either case, it may imply the presence of protein, phenol or other contaminants that absorb 
strongly at or near 280 nm.351 
2.13.2 Reverse Transcription of RNA—cDNA Synthesis of Total RNA 
The total RNA extracted was reverse transcribed into cDNA using the QuantiTect® Reverse 
Transcription Kit (Qiagen Group) according to manufacturer’s instructions. 
2.13.3 Polymerase Chain Reaction (PCR)
The PCR reaction was set-up to a final volume of 25 µl which included 0.5 µl dNTP mix, 1.5 
µl MgCl2, 1 µl for each EGFR-forward and EGFR-reverse primer, 5 µl of 5 X Green 
GoTaq® Flexi buffer, 0.3 µl GoTaq® DNA polymerase and 2 µl cDNA template.  The 
prepared samples were placed in a thermal cycler with the following conditions: Initial 
denaturation 93°C for 4 min, Denaturation 94°C for 0.5 min, Annealing 52°C for 0.5 min, 
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Extension 72°C for 0.5 min, Final Extension 72°C for 10 min and Soaking 4°C for an 
undetermined time.   
A 2% agarose gel was prepared and 1.5 µl of ethidium bromide, a fluorescent dye that binds 
to DNA, was added to the gel.  Samples were thawed on ice and loaded into the wells in the 
following order: Well 1: DNA ladder, Well 2: Positive control (untreated MCF-7 sample), 
Well 3: Negative Control (nuclease-free water), Well 4: EGFR Inhibitor I 8.8 µM, Well 5: 
EGFR Inhibitor I 17.6 µM, Well 6: EGFR Inhibitor I 35.18 µM; Well 7: EGFR Inhibitor 
II/BIBX1382 2.1 µM, Well 8: EGFR Inhibitor II/BIBX1382 4.2 µM, Well 9: EGFR Inhibitor 
II/BIBX1382 8.4 µM, Well 10: EGFR/ErbB-2/ErbB-4 Inhibitor 0.85 µM, Well 11: 
EGFR/ErbB-2/ErbB-4 Inhibitor 1.7 µM and Well 12: EGFR/ErbB-2/ErbB-4 Inhibitor 3.39 
µM.   
The gel was run at 75 V for 70 min and then viewed using a fluorescent scanner (Doc-ItLS® 
Image Acquisition Software, Version 5.5.5a; Doc-It Life Sciences Software, UVP™, Inc., 
San Gabriel, USA; UV Transluminator UVP™, Inc., San Gabriel, CA 91778, USA). 
2.13.4 Quantitative Real-Time PCR (qPCR)
Gene expression analysis of the target gene (EGFR) and reference gene (PBGD) was carried 
out as follows: each reaction consisted of 5 µl Power Sybr® Green PCR Mastermix (ABI), 1 
µl of each primer (forward and reverse) at a final concentration of 50 nM, 1 µl of cDNA 
template (equivalent to approx. 200 ng RNA) and nuclease-free water.  The reaction mixtures 
were pipetted into PCR tubes and placed into the ABI 7900HT Fast Real-Time PCR 
machine.  The qPCR reaction conditions were as follows: a pre-denaturation step at 95°C for 
10min followed by 40 cycles of denaturation for 15 seconds, annealing at 60°C for 60s and 
extension at 60°C for 60s.  This was followed by a melting curve analysis of products from 
amplification of EGFR. 
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2.14 Statistical Analysis 
Regression analysis of dose-response curves, IC50s and p values using One-Way ANOVA or 
Student’s t-test were calculated using GraphPad Prism (GraphPad Prism version 6.04 for 
Windows, GraphPad Software, San Diego California USA, www.graphpad.com).  Data 
obtained for the growth inhibitory effects of DOX, CPL and the EGFR/ErbB2/ErbB4 
inhibitor on MCF-7 mammary carcinoma cells were analyzed by One-Way ANOVA using 
SigmaPlot for Windows version 12.5 (http://www.sigmaplot.com).  All pairwise multiple 
comparisons were performed according to the Holm-Sidak method and the overall 
significance level was set at 0.005. Actual p- values are indicated in the text.  Best-fit IC50 
values and corresponding 95% confidence intervals were obtained from non-linear regression 
analysis of sigmoidal dose-response curves, using the three-parameter logistic equation of 
GraphPad Prism (GraphPad Prism version 6.04 for Windows, GraphPad Software, San Diego 
California USA, http://www.graphpad.com).  Combination indices (CIs) and dose-reduction 
indices (DRIs) of drug combinations were calculated using the CalcuSyn 
(http://www.biosoft.com) and ComboSyn software (http://www.combosyn.com).  All data 
were derived from 2-3 independent experiments. 
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CHAPTER 3 
RESULTS AND DISCUSSION 
3.1 Introduction 
In this chapter, the results of the research undertaken in this study are discussed.  Details of 
the research methodology used to obtain and analyze the data have been presented in Chapter 
2.  In this study, MCF-7 breast carcinoma cells were exposed to 2 classes of conventional 
anticancer agents (DOX and CPL) and 3 types of TKIs with varying and overlapping 
specificities (EGFR Inhibitor I, EGFR Inhibitor II/BIBX1382 and EGFR/ErbB2/ErB4 
Inhibitor).  Initially, growth curves for MCF-7 breast carcinoma cells were generated to 
establish their behaviour under normal culture conditions and their proliferation in response 
to DOX, CPL and the EGFR/ErbB2/ErB4 Inhibitor.  The latter TKI was chosen for its 
multiplex inhibitory repertoire.  MCF-7 breast carcinoma cells were also exposed to various 
single and combination regimens of DOX, CPL and the selected TKIs in order to determine 
drug potencies, combination drug interactions (additivity, synergy and antagonism) and dose-
reduction indices (DRIs).   
A carefully designed pilot study was conducted to ascertain the relative potencies of and 
degree of drug interactions between DOX and CPL, alone and in combination, in MCF-7 
breast carcinoma cells.  This was followed by a main study with a more inclusive design, i.e., 
involving not only DOX and CPL, but as well as their combination with the multispecific 
EGFR/ErbB2/ErB4 Inhibitor.  A morphological study on MCF-7 breast carcinoma cells was 
performed, using haematoxylin and eosin (H&E) staining, to assess changes in the 
morphological development of the cells, including cell shrinkage, chromatin condensation 
and apoptotic body formation, following treatment with the various TKIs.  This was followed 
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by Annexin V-Cy3 fluorescent staining of the cells exposed to the TKIs.  In addition, an 
analysis of the expression of the EGFR gene in MCF-7 breast carcinoma cells was 
accomplished by Real-Time qPCR and sample quality control of RNA extracted from 
untreated control and TKI-treated MCF-7 breast carcinoma cells.  The results are discussed 
in the sections that follow. 
3.2 Growth Curve Analysis of MCF-7 Breast Carcinoma Cells Exposed to TKIs 
The response of MCF-7 breast carcinoma cells to EGFR Inhibitor I at a fixed concentration 
of 0.5 µM is depicted in Figure 3.1.  The cells were seeded at a higher density than control 
and were exposed to EGFR Inhibitor I at the start of the experiment.  The cell number 
decreased at a steady rate after 48h of exposure up until the termination of the experiment at 
96h.  The concentration of 0.5 µM was effective in inhibiting the growth of cells in the 
exponential phase. 
  
Figure 3.1: Growth curve of MCF-7 cells with distinct lag, log, plateau and decline phases.  Cells were seeded 
at a higher initial density and exposed to constant concentration (0.5 µM) of EGFR Inhibitor I. Data are 
means±SEM (n=16). 
 
In addition, MCF-7 breast carcinoma cells were exposed to EGFR inhibitor I concentrations 
of 5 nM and 20 nM (Figure 3.2).  The MCF-7 control (i.e., cells not treated with inhibitor) 
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illustrated a typical growth curve in which all four phases (lag phase, log phase, plateau and 
decline phase) of growth were noted.  EGFR inhibitor I at 5 nM did not show any effective 
inhibition.  The inhibitory effect was inadequate and exponential growth of the cells could 
still be noticed between days 1-3 in culture.  However, cells were treated with EGFR 
inhibitor I at 20 nM showed an immediate inhibitory effect 24h after drug exposure.  
However, as the exposure period progressed, the cells appeared to grow, but at a very slow 
rate between days 2-4.  Thus, 20 nM was more effective than 5nM in exerting a greater 
growth inhibitory effect on the cells (p<0.05). 
  
Figure 3.2: The effects of EGFR inhibitor I on the growth of MCF-7 mammary carcinoma cells. Cells were 
treated with inhibitor at concentrations 5 nM and 20 nM. Data are means±SEM (n=16). 
 
3.3 Dose-Response Curve Analysis of MCF-7 Breast Carcinoma Cells Exposed to 
TKIs Alone and in Various Combinations 
The EC50 for EGFR inhibitor I when used on its own was the highest (35.18 nM) among the 
inhibitors used in this study (Figure 3.3).  The EC50 for EGFR Inhibitor II/BIBX1382 (8.41 
nM) was about four times lower when used alone, in comparison with the EC50 of EGFR 
inhibitor I.  The third TKI, EGFR/ErbB2/ErB4 Inhibitor, yielded an EC50 of 3.39 nM and was 
10-fold lower than the EC50 of EGFR inhibitor I, and 2-fold lower than the EGFR Inhibitor 
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II/BIBX1382 (Figure 3.3).  However, the differences in the EC50s of the 3 TKIs when used 
alone were not statistically significant because their 95% CIs overlapped considerably 
(compare legends for each exposure in Figure 3.3). 
  
Figure 3.3: Dose-response curves of MCF-7 mammary carcinoma cells exposed to three types of EGFR 
inhibitors individually. Equimolar log dose concentrations were used. Data are means±SEM (n=8). 
 
The 3 TKIs were also used in combination with each other.  The combination between EGFR 
Inhibitor I and EGFR Inhibitor II/BIBX1382 produced an EC50 of 0.078 nM (Figure 3.4) 
which was the lowest EC50 for all the inhibitor sets used in combination.  The combination 
between EGFR Inhibitor I and EGFR Inhibitor II/BIBX1382 also showed a higher potency 
ratio for EGFR Inhibitor I (450) than EGFR Inhibitor II/BIBX1382 (108) (Table 3.1).  It was 
interesting to find that there was a relation between a high EC50 and potency ratio.  The 
higher the EC50 for any inhibitor used on its own, the higher its potency ratio when used in 
combination with another inhibitor.  This relation is seen in the combination of EGFR 
Inhibitor I and EGFR/ErbB-2/ErB-4 Inhibitor with potency ratios of 90 and 9, respectively 
(Table 3.1).   
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Figure 3.4: Combination treatment of MCF-7 mammary carcinoma cells with three types of EGFR inhibitors 
at equimolar log dose concentrations. Data are means±SEM (n=8). 
 
Combination of EGFR Inhibitor II/BIBX1382 and EGFR/ErbB2/ErB4 Inhibitor produced the 
highest EC50 of 0.52 nM (Figure 3.4).  The potency ratios were 16 for EGFR Inhibitor 
II/BIBX1382 and 7 for EGFR/ErbB2/ErB4 Inhibitor in the combination.  MCF-7 breast 
carcinoma cells exposed to inhibitors individually displayed inhibition in growth with 
EGFR/ErbB-2/ErB-4 Inhibitor having a more potent effect (EC50 =3.39 nM) on the cells than 
the other inhibitors (Table 3.1).  Among the three inhibitors, EGFR Inhibitor I was the least 
effective on its own in inhibiting MCF-7 breast carcinoma cell growth with the highest EC50 
=35.18 nM (Table 3.1).   
The inhibitors that were used individually produced EC50s that differed significantly 
(p<0.0001) when compared amongst each other.  Inhibitors were used in various 
combinations, however, the EGFR Inhibitor I+EGFR Inhibitor II/BIBX1382 were the most 
potent (EC50=0.078 nM) than the other drug combinations (Table 3.1).   
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Table 3.1: Responses of MCF-7 breast carcinoma cells to EGFR tyrosine kinase inhibitors alone and in combination 
Treatment EC50 (nM)¶ 95% CI§¶ R2† Potency Ratio†† 
EGFR Inhibitor 1 (EGFR Inhibitor I) 35.18a 12.35-100.2 0.778 - - 
EGFR Inhibitor 2 (EGFR Inhibitor II/BIBX1382) 8.41a 4.85-14.59 0.916 - - 
EGFR Inhibitor 3 (EGFR/ErbB2/ErB4 Inhibitor)  3.39a 1.91-6.01 0.918 - - 
EGFR Inhibitor I+ EGFR Inhibitor II 0.078 0.056-0.107 0.961 EGFR Inhibitor I:450b EGFR Inhibitor 2:108b 
EGFR Inhibitor I+EGFR/ErbB2/ErB4 Inhibitor 0.39 0.23-0.65 0.925 EGFR Inhibitor I:90b EGFR/ErbB2/ErB4 Inhibitor: 9b 
EGFR Inhibitor II+EGFR/ErbB2/ErB4 Inhibitor 0.52 0.31-0.88 0.921 EGFR Inhibitor II:16c EGFR/ErbB2/ErB4 Inhibitor: 7b 
¶Best-fit estimates of the effective concentration of drug required to kill 50% of the cell population; §Confidence interval; †Goodness of fit of sigmoidal dose-
response regression analysis; ††Fold increase in activity of the drug in combination. Potency ratio and statistical results computed by the method of EC 
Fieller,337,352, using GraphPad Quickcalcs:http://www.graphpad.com/quickcalcs; ap<0.0001; bp<0.0001; cp=0.0067. 
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The EC50 of the drug combinations were significantly different (p<0.0001) to that of the drugs 
used individually.  Potency ratios were also calculated for all the TKI combinations with 
EGFR Inhibitor I showing the greatest potency (potency ratio 450) in the EGFR Inhibitor 
I+EGFR Inhibitor II/BIBX1382 combination. The potency ratios of the drug combinations 
were significantly different (p<0.0001), i.e., EGFR Inhibitor I was significantly different to 
EGFR Inhibitor 2 in the EGFR Inhibitor I+EGFR Inhibitor II/BIBX1382 combination, etc). 
3.4 Analysis of Synergism and Drug Interactions of EGFR/TKI Inhibitor 
Combinations 
All the TKIs that were used in combination with each other displayed synergy and conformed 
to both the Loewe additivity and Bliss independence models of synergy (Figures 3.5-A to 3.5-
C).  The synergistic action between the different inhibitors was confirmed by the generalized 
isobolar median-effect method, using the CombiTool computer programme.  Lower 
combination indices denoting greater synergy, was observed at lower effect levels (Fa).  This 
means that at lower drug concentrations, the combination indices were lower than at higher 
dose levels and, therefore, implied greater efficacy of TKI combinations than their respective 
individual effects on MCF-7 breast carcinoma cells. 
3.5 Growth Curve Analysis of MCF-7 Cells Exposed to DOX and CPL 
MCF-7 breast carcinoma cells were seeded a density of 106 cells/ml in 35-mm petri dishes 
containing 100 µl cells and complete medium for the control, and final concentrations in 
complete medium of 1 µM DOX and 10 µM CPL, respectively.  Cells were monitored for 
three days and counted after each consecutive day using the Bio-Rad TC10 cell counter.  
Figure 3.6 shows exponential growth of cells in the control group after the seeding day (day 
0) to day 2, and that a plateau has been reached at day 3.  The concentrations of DOX and 
CPL used in these experiments were based on estimates of their published IC50 values for 
MCF-7 breast carcinoma cells.325,353    
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Figure 3.5: Plots of the different combination indices at various effect (fraction affected) levels for the 
experimental designs and analyses of drug interactions.  Synergistic interactions of EGFR inhibitor 
combinations in MCF-7 cells, represented in the Loewe additivity model (A), the Bliss independence model 
(B) and the median effect analysis of the combination index or index of interaction (C).  The dashed line 
indicates the Loewe additivity hypothesis, i.e. interaction indices greater than 1 represent antagonism and 
those less than 1 synergism. 
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There was a significant growth inhibition in the DOX-treated cells relative to control 
(p<0.0001, R2=0.44).  This observation is in line with previous findings that one of the 
mechanisms of DOX is the induction of cell cycle arrest.314,353  There was a significant 
difference in growth inhibition between CPL-treated cells compared to the control.  What 
was also evident from the growth curve generated for CPL-treated cells is the significant 
decrease in cell number, unlike that for DOX-treated cells, over 3 days.  It is known that CPL 
intercalates DNA, which results in apoptosis,354 and has no significant effect on cells at 
concentrations less than 2 µM,355 but it is quite clear that there is a decrease in cell survival at 
a concentration of 10 µM. 
  
Figure 3.6: Growth of MCF-7 mammary carcinoma cells exposed to final concentrations of 1 µM DOX and 
10 µM CPL relative to control.  Both DOX and CPL significantly inhibited cell growth for the duration in 
culture (t-test p<0.0001). 
 
3.6 Determination of the Relative Potencies of and Degree of Drug Interactions 
Between DOX and CPL, Alone and in Combination, in MCF-7 Breast Carcinoma 
Cells – First Independent Set of Experiments (Pilot Study) 
Figure 3.7 and Table 3.2 display the IC50s obtained for each drug and its combination in 
cultures of MCF-7 breast carcinoma cells after 24, 48 and 72h exposure.  The MTT 
cytotoxicity was performed as described previously.335  Cells were incubated with the drugs 
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following a 24h attachment period.  Cells were allowed to grow in the presence of drug for 
24, 48 and 72h and absorbance readings (A560 nm) recorded with a Promega GloMax™ 
multimode microplate reader.  Figure 3.7 and Table 3.2 summarizes the differences in MCF-
7 cell responses to the drugs.  After 24h exposure, CPL and DOX treatments differed 
significantly (p<0.0001).  MCF-7 breast carcinoma cells were 13-fold, 22-fold and 10-fold 
more sensitive to CPL in the combination with DOX after 24, 48 and 72h, respectively, as 
reflected by the sensitization ratios (SRs, Table 3.2).  By comparison, MCF-7 breast 
carcinoma cells did not exhibit any appreciable increased sensitivity to DOX when it is 
combined with CPL (SRs 0.53, 1.36 and 0.95, respectively, after 24, 48 and 72h exposure to 
the combination).  The SR is the quotient of the IC50 of the drug alone (e.g., DOX) and its 
combination with the other drug (e.g., DOX+CPL).  The SR provides information on how 
effective (efficacy) the drugs are when used in combination treatment.   
It is quite clear that there is no significant decrease in responses of MCF-7 cells to DOX 
following exposure to the DOX-CPL combination, as borne out by the observation that the 
DOX and combination dose-response curves overlap.  This drug combination thus shows 
strong antagonism and is consistent with the notion that they compete for DNA inter-strand 
cross-linking.312,314  Both drugs intercalate DNA, causing cell cycle arrest and apoptosis, the 
former effect being evident in this study.  Therefore, DOX is by far the more efficacious drug 
as it clearly eclipses the effects CPL in the combination.   
Table 3.3 shows the dose reduction indices (DRIs) for DOX and CPL when used in 
combination.  The DRIs indicate that no significant reduction of DOX concentration will 
yield the same fractional response of MCF-7 breast carcinoma cells to the anthracycline 
when used in combination with CPL.  However, the CPL dose can be reduced over 6-fold to 
yield the same fractional response on MCF-7 breast carcinoma cells, i.e., 0.12 fraction 
affected.  The fraction affected refers to the fraction of the population of MCF-7 breast 
carcinoma cells that had been affected after treatment at a given concentration. 
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Figure 3.7: Dose response curves obtained by nonlinear regression analysis following exposure of MCF-7 
mammary carcinoma cells to DOX and CPL, either alone or in combination, for 24, 48 and 72h, respectively.  
Indicated are the 50% inhibitory concentrations (IC50s) and 95% Confidence Intervals (CI) for DOX, CPL and 
the combination of the two drugs in equimolar concentrations.  DOX, doxorubicin; CPL, cisplatin. 
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Table 3.2: Responses of MCF-7 breast carcinoma cells exposed to DOX or CPL alone and in 
combination for the times indicated 
Drug Time (h) IC50 (µM) 95% CI (µM) Sensitization Ratio† 
DOX 24 0.2 0.16-0.25 0.53 
48 0.15 0.13-0.18 1.36 
72 0.19 0.15-0.25 0.95 
CPL 24 5.1 3.7-7.1 13.42 
48 2.4 1.5-4 21.82 
72 2.1 1.5-2.9 10.50 
Combination 24 0.38 0.26-0.54  
48 0.11 0.07-0.17 
72 0.2 0.16-0.28 
†SR is the ratio of the IC50 of drug alone over IC50 of drug combination; DOX, doxorubicin; CPL, cisplatin; 
IC50, the concentration of drug that will exert a 50% response, i.e., reduce the A560 in the cells treated with drug 
by 50% relative to control. 
 
There is a decrease in the DRI for CPL at greater fractions affected, thus indicating that the 
drugs did not work synergistically when used in combination.  The rationale behind dose 
reduction in the clinical setting is to decrease the level of toxicity towards the host while 
retaining therapeutic efficacy.  Therefore, the DRI is an important clinical consideration in 
cancer chemotherapy.  The first mechanism of action employed by both DOX and CPL is 
intercalation with genomic DNA.  Hence, the competing mechanisms decrease the in vitro 
efficacy of drugs when used in combination, but in this system (Table 3.1 and Figure 3.7), 
DOX is clearly the better antineoplastic agent whose efficacy is unaltered by the presence of 
CPL.  Further evidence regarding the level of antagonism between DOX and CPL is given in 
Figure 3.8, a polygonogram derived from practical application of drugs used in combination, 
as described previously.345,346  Explanation and sample illustration of polygonograms are 
provided in Table 3.4 and Figure 3.9).  A thick broken line was produced, therefore, there is 
strong antagonism between DOX and CPL in the combination treatment (Table 3.4).   
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Table 3.3: Dose-reduction indices of DOX and CPL after exposure of MCF-7 breast 
carcinoma cells to a combination of the drugs for 72h (pilot run) 
Fraction Affected 
Drug Alone Dose Reduction Index (DRI)† 
DOX (µM) CPL (µM) DOX CPL 
0.12 0.0066 0.0635 0.664 6.348 
0.15 0.0111 0.0986 0.111 0.986 
0.46 0.3150 1.7624 0.315 1.762 
0.70 2.3420 9.9188 0.234 0.992 
0.75 4.0464 15.8853 0.040 0.159 
†DRI, The dose-reduction index denotes the folds of dose reduction allowed for each drug in the combination 
when compared with each drug alone, at a given effect level.356-361 
 
  
Figure 3.8: Polygonogram showing the interaction between DOX and CPL when used in combination. Thick 
broken line indicates very strong antagonism. 
 
The proposed mechanisms of action of DOX and CPL are the same, i.e., intercalation of 
DNA, resulting in cell cycle arrest and apoptosis (see also Table 1.3).312,314  Targeting 
apoptosis is a molecular tenet for cancer chemotherapeutic drug development and discovery. 
362,363  DOX induces apoptosis by intercalation with the DNA double helix, ROS production, 
inhibition of topoisomerase II and macromolecule synthesis.314  CPL binds genomic DNA 
forming adducts, mainly intra-strand crosslinks, interrupts DNA transcription and replication, 
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and induces cell death by damaging the DNA.326,355,364  These competing mechanisms may 
explain why there is such a strong level of antagonism between DOX and CPL when used in 
combination.  This study opens up many areas that require further investigation, e.g., why 
DOX has such a significantly lower IC50 compared to CPL following exposure of MCF-7 
breast carcinoma cells to the drugs for 24, 48 and 72h (Table 3.2 and Figure 3.7). 
Combining drugs is an important tenet to enhance efficacy of treatment and reduce dose and 
cytotoxic side effects seen at high concentrations of drugs when used alone.356,361  DOX and 
CPL combination treatment produced strong levels of antagonism which is consistent with 
the notion that even antagonism may produce a clinical beneficial DRI that correlates with 
reduced host toxicity and therapeutic efficacy.356,361  DOX and CPL are also cytotoxic to 
normal cells when used in chemotherapy, i.e., DOX is often cardiotoxic and CPL has 
neurotoxic side effects.  Understanding and targeting these mechanisms of cytotoxicity 
would be a major breakthrough in cancer drug development. 
Table 3.4: Description and symbols of synergism or antagonism in drug combination studies 
analyzed with the combination index method 
Based on the conceptualizations of Chou et al.356,361  Reproduced with permission from The American Society 
for Pharmacology and Experimental Therapeutics (ASPET, http://www.aspet.org/; see Annexure 4) Original 
source (Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and 
antagonism in drug combination studies. Pharmacological Reviews 2006;58(3):621-681; 
doi:10.1124/pr.58.3.10) 
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Figure 3.9: Sample illustration of polygonograms. a, heptagonal polygonogram for seven anti-HIV agents 
using two-drug combinations in vitro (AZT, D4T, DDC, and DDI—all nucleoside reverse transcriptase 
inhibitors; NEV, a non-nucleoside reverse transcriptase inhibitor; INF, interferon-α-2a; and ABT-538, a 
protease inhibitor). Details of experimental results leading to this polygonogram are given in section VI.C.3.  
There are 120 possible combinations for seven drugs. More details are given in section VI.C.3., Fig. 12, and 
Tables 20 through 23. The CompuSyn printout (90 pages) for two to five-drug combinations is given in 
Supplemental Data (http://pharmrev.aspetjournals.org/cgi/content/full/pr.58.3.10/DC1).  Synergism is 
represented by the solid red-tone line, and antagonism is represented by the broken blue-tone line. The 
thickness of the line represents the strength of synergism or antagonism.  A recommended semiquantitative 
description of the degrees of synergism and antagonism is shown. b, polygonograms for five antitumor agents 
with different mechanisms of action. Crude experimental data and the summary of analytical results are given 
in Tables 10 and 11 (Data from Chou et al., 1994).365 Further analysis for the complete CompuSyn report for 
printout is given in Supplemental Data Annexure IV.  See also Chou, 1994.366  Reproduced with permission 
from The American Society for Pharmacology and Experimental Therapeutics (ASPET, http://www.aspet.org/; 
see Annexure 4) Original source (Chou T-C. Theoretical basis, experimental design, and computerized 
simulation of synergism and antagonism in drug combination studies. Pharmacological Reviews 
2006;58(3):621-681; doi:10.1124/pr.58.3.10) 
 
3.7 Growth Curve Analysis of MCF-7 Cells Exposed to DOX, CPL and the 
EGFR/ErbB2/ErbB4 Inhibitor 
MCF-7 breast carcinoma cells were suspended at a density of 5 x 105 cells/ml and 100 µl of 
cell suspension added to each well of a 24-well plate.  Complete medium containing cells 
served as control, and final concentrations of 1.2 µM DOX, 15.8 µM CPL and 0.5 nM 
EGFR/ErbB2/ErB4 Inhibitor containing media were added to the 24-well plates.  Cells were 
monitored for three days (72h) and counted consecutively every 24h using the Bio-Rad TC-
10 cell counter.  The concentrations of DOX and CPL used in these experiments were based 
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on previously reported IC50 values for MCF-7 breast carcinoma cells.325,353  The 
concentration of the EGFR/ErbB2/ErBb4 inhibitor used in the experiment derived from data 
presented in Table 3.1 and the rationale to use the lowest possible concentration of TKI that 
yielded generalized efficacy.  Furthermore, due to cost considerations and budgetary 
constraints, the multiplex EGFR/ErbB2/ErB4 Inhibitor was selected for all combination 
studies with DOX and CPL.  Figure 3.10 displays the effects on MCF-7 breast carcinoma cell 
growth following exposure to the drugs DOX, CPL and the EGFR/ErbB2/ErB4 Inhibitor at 
the specified concentrations. 
  
Figure 3.10: Growth inhibitory effects of DOX, CPL and EGFR/ErbB2/ErbB4 inhibitor on MCF-7 mammary 
carcinoma cells at 24, 48 and 72 hour intervals (n=16).  Data were analyzed by One-way ANOVA using 
SigmaPlot for Windows version 12.5 (www.sigmaplot.com).  All pairwise multiple comparisons were 
performed according to the Holm-Sidak method and the overall significance level was set at 0.005.  Actual p- 
values are indicated in the text. 
 
After 24h exposure, there was a significant inhibition of growth in the DOX- and CPL-
treated cells relative to control (p<0.001 in both cases), but there was no significant growth 
inhibition in cells treated with EGFR/ErbB2/ErB4 Inhibitor (p=0.203).  After 48h exposure, 
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all 3 drugs significantly decreased (p<0.001) MCF-7 breast carcinoma cell growth relative to 
control.  After 72h exposure to the drugs, there was a negligible decrease in cell growth 
induced by DOX, CPL and the EGFR/ErbB2/ErBb4 Inhibitor (p<0.063, p<0.082 and 
p<0.182, respectively), compared to control, suggesting that the MCF-7 mammary carcinoma 
cells became resistant to the cytotoxic effects of these compounds between 48 and 72h.  
These results provided a platform for studying the effects of these drugs in combination as 
delineated in the next section. 
3.8 Potencies of DOX, CPL and the EGFR/ErbB2/ErbB4 Inhibitor in MCF-7 Breast 
Carcinoma Cells  
Following treatment of MCF-7 breast carcinoma cells with DOX, CPL and 
EGFR/ErbB2/ErB4 Inhibitor, either alone or in combination for 24, 48 and 72h, the 
respective IC50 values were obtained from nonlinear regression analysis of the sigmoidal 
dose-response curves generated from absorbance data of MTT cytotoxicity essays (Figures 
3.11 to 3.13).   
3.8.1 Potencies of DOX and CPL, Alone and in Combination, in MCF-7 Breast 
Carcinoma Cells - Second Independent Set of Experiments (Main Study) 
The dose-response curves depicted in Figure 3.11 illustrate that the MCF-7 mammary 
carcinoma cell line was more sensitive to CPL than DOX after 24h (IC50 values of 0.094 µM 
and 1.104 µM, respectively), where R2=0.90 and 0.87, respectively, but as the time interval 
of drug exposure progressed, the MCF-7 mammary carcinoma cell line proved to be more 
sensitive to DOX than CPL both at 48h (IC50 values of 0.03 µM and 1.86 µM, respectively) 
where R2=0.95 and 0.81, respectively, and the 72h interval, (IC50 values of 0.041 µM and 
6.965 µM, respectively) where R2=0.94 and 0.65, respectively.  Analysis of the responses of 
MCF-7 breast carcinoma cells to DOX and CPL in combination at 24, 48 and 72h, IC50 
values of 0.117 µM, 0.053 µM and 0.082 µM, respectively, were obtained, where R2=0.94, 
0.83 and 0.95, respectively.  It was noticeable that at 24h there was an increase in 
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concentration required for CPL and a decrease in concentration required for DOX (IC50 
values of 0.094 µM and 1,104 µM, respectively) to attain the combination concentration 
value of 0.117 µM.  At 48h, IC50 values of 1.86 µM and 0.03 µM, respectively) and 72h (IC50 
values of 6.965 µM and 0.041 µM, respectively), an increase in concentration required for 
DOX and a decrease in concentration required for CPL was required to gain the combined 
concentration value of 0.082 µM.  The responses show that at 24h, CPL proves to be the 
more effective drug, but at 48 and 72h, DOX was the more effective drug, suggesting that 
MCF-7 breast carcinoma cells developed resistance to CPL.   
Although both DOX and CPL act by intercalating cellular DNA, causing cell cycle arrest and 
apoptosis, the mechanisms by which DOX is known to induce apoptosis by the intercalation 
with the DNA double helix, ROS production and inhibition of topoisomerase II and 
macromolecule synthesis,314 seems more effective at inducing cell death in the MCF-7 
mammary carcinoma cell line after 24h than the mechanism by which CPL triggers cell 
killing.  The mechanism by which DOX induces apoptosis involves binding to genomic 
DNA, forming adducts, mainly intrastrand crosslinks, which interrupts DNA transcription 
and replication, and induction of cell death by damaging the DNA,364, which proved to be 
more effective at 24h, but less effective compared to DOX at 48 and 72h. 
3.8.2 Potencies of DOX and EGFR/ErbB2/ErB4 Inhibitor, Alone and in 
Combination, in MCF-7 Breast Carcinoma Cells 
Figure 3.12 summarizes the effects of DOX and the EGFR/ErbB2/ErB4 Inhibitor alone, and 
in combination on the MCF-7 mammary carcinoma cell line.  After 24h, the cells appeared to 
be much more sensitive to DOX than the EGFR/ErbB2/ErbB4 Inhibitor—IC50 values 1.104 
µM (R2=0.87) and 14.87 µM (R2=0.90), respectively.  After drug exposure for 48h (IC50 
values 0.03 µM and 6.27 µM, respectively) where R2=0.95 and 0.81, respectively, and 72h 
(IC50 values 0.04 µM and 14.87 µM, respectively) where R2=0.94 and 0.90, respectively, 
DOX alone still proved to be more efficacious than the EGFR/ErbB2/ErbB4 Inhibitor alone.   
 
 
 
 
76 
 
 
 
 
 
 
Figure 3.11: Dose response curves of DOX and CPL alone and in combination after 24, 48 and 72h drug exposure. IC50 values, 95% CI values and R² values are indicated. IC50 values, 50% 
growth inhibitory concentration; 95% CI values, 95% confidence intervals and R² values; regression line correlation coefficient. 
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Figure 3.12: Dose response curves of DOX and the EGFR/ ErbB2/ErBb4 inhibitor alone and in combination at 24, 48 and 72h following drug exposure. IC50 values, CI values and R² values 
are indicated. IC50 values, 95% CI values and R² values are indicated. IC50 values, 50% growth inhibitory concentration; 95% CI values, 95% confidence intervals and R² values; regression 
line correlation coefficient. 
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Analyzing the drugs in combination at 24h, the IC50 value was 0.04 µM (R2=0.92) which is a 
reduction in the IC50 values of DOX and the ErbB2/ErbB4 Inhibitor alone.  After 48h 
exposure the combination IC50 value was 0.005 µM (R2=0.90), demonstrating drug additivity 
or weak synergism.  Exposure of MCF-7 breast carcinoma cells to the DOX-
EGFR/ErbB2/ErB4 Inhibitor combination for 72h, yielded an IC50 of 0.17 µM.  The IC50 of 
the EGFR/ErbB2/ErbB4 Inhibitor approximated that of the 24h dose-response relation, 
whereas the IC50 for DOX remained relatively constant.   
3.8.3 Potencies of CPL and EGFR/ErbB2/ErB4 Inhibitor, Alone and in Combination, 
in MCF-7 Breast Carcinoma Cells 
Figure 3.13 represents the effects of CPL and the EGFR/ErbB2/ErbB4 Inhibitor alone and in 
combination on MCF-7 breast carcinoma cells.  After 24h drug exposure, the cells were more 
sensitive to CPL alone, than the EGFR/ErbB2/ErbB4 inhibitor alone—IC50 values 0.094 µM 
and 14.87 µM, respectively) with R2=0.90 and 0.90, respectively, and when compared in 
combination, an IC50 value of 0.661 µM where R2=0.89 was obtained.  When exposed to the 
drugs alone at 48h, the IC50 value for the EGFR/ErbB2/ErbB4 Inhibitor decreased by more 
than 50% compared to its IC50 value at 24h (IC50 values 14.87 µM and 6.27 µM, 
respectively) where R2=0.90 and 0.81, respectively, with a combination IC50 value of 0.661 
µM (R2=0.89).   
Exposure of cells to CPL alone at 48h still proved to be more effective than the 
EGFR/ErbB2/ErbB4 Inhibitor as its IC50 value was still significantly lower (IC50 values at 
48h were 1.86 µM (R2=0.81) and 6.27 µM (R2=0.81), respectively.  The IC50 values for drugs 
alone increased after 72h—IC50 of 8 µM (R2=0.94) and 7.17 µM (R2=0.72), respectively.  In 
combination, the IC50 value was 0.912 µM (R2=0.94), suggesting that the 
CPL+EGFR/ErbB2/ErB4 Inhibitor combination was more efficacious in killing MCF-7 
breast carcinoma cells than either compound alone.  Such enhanced toxicity may be applied 
usefully in experimental models of in vitro anticancer drug cytotoxicity in various panels of 
tumour cell lines and in vivo animal systems. 
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Figure 3.13: Dose response curves of CPL and the EGFR/ ErbB2/ErBb4 inhibitor alone and in combination at 24, 48 and 72h following drug exposure. IC50 values, CI values and R² values 
are indicated. IC50 values, 95% CI values and R² values are indicated. IC50 values, 50% growth inhibitory concentration; 95% CI values, 95% confidence intervals and R² values; regression 
line correlation coefficient. 
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3.9 Drug Combination Analysis of the Effects of DOX, CPL and the 
EGFR/ErbB2/ErB4 Inhibitor on MCF-7 Breast Carcinoma Cells 
The effects of exposure of MCF-7 breast carcinoma cells to DOX, CPL and 
EGFR/ErbB2/ErB4 Inhibitor in combination for 24, 48 and 72h, were analyzed according to 
both the Bliss independence and the Loewe additivity criteria and the interaction index as 
described previously and detailed in Chapter 2.  The results are summarized in Figure 3.14.  
The combination index (CI) theorem of Chou and Talalay offers quantitative definitions for 
additive effects (CI=1), synergism (C<1) and antagonism (CI>1) in drug 
combinations.345,356,358,361 
3.9.1 Drug Combination Analysis of the Effects of DOX and CPL on MCF-7 
Breast Carcinoma Cells 
Analysis of the combined effect of DOX and CPL after 24h revealed antagonism (CI>1) 
between Fa 0.2-1.0, and additivity between Fa 0.3-1.0 (Figure 3.14-A).  The Fa is defined as a 
percentage of cell death ranging from 0 to 1 at a given log dose exposure.  Analyzing the 48h 
interval, there is an extremely high level of antagonism between the two drugs, but decreases 
and synergism occurs as the Fa approaches 0.6 to 1.  The 72h exposure of MCF-7 breast 
carcinoma cells to the DOX and CPL combination mimics the 48h time point.  A strong level 
of antagonism between DOX and CPL is expected when they are used in combination, as 
both drugs intercalate DNA to induce apoptosis.  However, it is clear that DOX is by far the 
more efficacious drug as it clearly eclipses the effects CPL in the combination (see Figure 
3.11). 
3.9.2 Drug Combination Analysis of the Effects of DOX and the 
EGFR/ErbB2/ErB4 Inhibitor on MCF-7 Breast Carcinoma Cells 
Figure 3.14-B indicates antagonism between DOX and the EGFR/ErbB2/ErbB4 Inhibitor for 
Fa levels 0-0.2 after 24h, and synergism between Fa levels 0.4-1.0.  For both the 48 and 72h, a 
high level of antagonism is observed between the drugs (Fa levels 0 t 0.6), followed by 
additivity and synergism for Fa 0.6-1.0. 
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Figure 3.14: The log combination index (log CI) versus fraction of cells affected (Fa) by DOX and CPL (A), the EGFR/ErbB2/ErBb4 inhibitor and DOX (B), and the EGFR/ErbB2/ErbB4 
inhibitor and CPL (C), in combination at 24, 48 and 72 hour intervals, showing antagonism or synergism.  Antagonism between the 2 drugs in the combination occurs if CI > 1, additivity if 
CI=0 and synergism if CI < 1. 
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3.9.3 Drug Combination Analysis of the Effects of CPL and the 
EGFR/ErbB2/ErB4 Inhibitor on MCF-7 Breast Carcinoma Cells 
Figure 3.14-C displays the degree of antagonism and synergism between CPL and the 
EGFR/ErbB2/ErbB4 Inhibitor at different exposure times.  After 24h exposure of the MCF-7 
mammary carcinoma cell line to the combination, antagonism between the two drugs was 
evident for all Fa levels.  However, after 48h, the degree of antagonism diminished (Fa 0-0.3), 
followed by a rise in synergism between Fa 0.4-1.0.  After 72h exposure of MCF-7 breast 
carcinoma cells to the combination, a predominant degree of synergism between the two 
drugs occurred at all Fa levels.  The use of multiple drugs with different mechanisms or 
modes of action may also direct the effects against single cellular targets of breast cancer and 
treat it more effectively.  The possible favourable outcomes for synergism include increasing 
the efficacy of the therapeutic effect, decreasing the dosage, but increasing or maintaining the 
same efficacy to avoid toxicity, minimizing or slowing down the development of drug 
resistance, and providing selective synergism or efficacy against target versus host toxicity.   
3.10 Dose-Reduction Indices of DOX, CPL and the EGFR/ErbB2/ErB4 Inhibitor 
Combinations in MCF-7 Breast Carcinoma Cells 
The DRI is important in clinical situations, in which dose reduction leads to reduced toxicity 
toward the host while the therapeutic efficacy is retained, and although DRI>1 is beneficial, 
it does not necessarily indicate synergism or an additive effect - even a slight antagonism 
may also lead to DRI>1.  The greater the DRI value, the greater dose reduction for a given 
therapeutic effect, but this does not automatically imply synergism.345,356,358,361 
3.10.1 Dose-Reduction Indices of the DOX and CPL Combination in MCF-7 
Breast Carcinoma Cells 
Table 3.5 displays the dose reduction indices (DRIs) for DOX and CPL used in the 24, 48 
and 72h combination exposure of MCF-7 breast carcinoma cells.  After 24h exposure to 
DOX+CPL combination, DRIs indicated that at Fa 0.5 (i.e., 50% cell killing) the dose of CPL 
can be halved (DRI=0.508) whereas that of DOX can be reduced 767-fold (DRI=766.82) to 
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achieve 50% cytotoxicity that would have been attained by single exposures of MCF-7 breast 
carcinoma cells to 3.49 µM CPL or 30 µM DOX.  At Fa 0.75 (75% cell killing), the dose of 
CPL can be reduced 0.7-fold and that of DOX about 4.55x 105-fold.    However, after 48 and 
72h, the dose of DOX can be decreased 1.63 x 104- and 141-fold, respectively to achieve an 
Fa of 0.75.  By contrast, after 48 and 72h, the dose of CPL can be decreased 182- and 1041-
fold.  Clearly, DOX is more efficacious than CPL in the combination after 24, 48 and 72h 
exposure. 
3.10.2 Dose-Reduction Indices of the DOX and EGFR/ErbB2/ErbB4 Inhibitor 
Combination in MCF-7 Breast Carcinoma Cells 
Table 3.6 displays the DRIs for DOX and the EGRF/ErbB2/ErbB4 Inhibitor in combination. 
After 24h exposure of MCF-7 breast carcinoma cells to the Dox+EGFR/ErbB2/ErB4 
Inhibitor combination, the DRI for DOX was 2785 and the DRI for EGFR/ErbB2/ErB4 
Inhibitor was 13.42 at Fa 0.75, and the higher DRI for DOX trend continued for Fa 0.75 and 
Fa 0.95 after 48 and 72h.  The combination of DOX and the EGRF/ErbB2/ErbB4 inhibitor 
displayed increased DRI values for both drugs which could prove valuable in clinical trials.  
The drugs used in combination can retain efficacy at lower doses which can reduce cytotoxic 
effects to the host, when compared to the drugs used alone.  
3.10.3 Dose-Reduction Indices of the CPL and EGFR/ErbB2/ErbB4 Inhibitor 
Combination in MCF-7 Breast Carcinoma Cells 
Table 3.7 summarizes the DRIs for CPL and the EGFR/ErbB2/ErB4 Inhibitor after exposure 
of MCF-7 breast carcinoma cells to the combination for 24, 48 and 72h.  Judged by the DRIs, 
it is evident that the combination of CPL+EGFR/ErbB2/ErB4 Inhibitor is not as effective as 
that of DOX+EGFR/ErbB2/ErB4 Inhibitor (compare Tables 3.6 and 3.7).  Nevertheless, 
combining CPL with EGFR/ErbB2/ErB4 Inhibitor yielded DRI>1 for both drugs at Fa 0.5 
onward after 48 and 72h, but not 24h.  This combination may thus be beneficial in 
experimental anticancer drug designs and testing.  
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Table 3.5: Dose-reduction indices of DOX and CPL after exposure of MCF-7 mammary 
carcinoma cells to a combination of the drugs for 24, 48 and 72h 
Fraction Affected 
(Fa) 
Drug alone (µM) Dose Reduction Index (DRI)* 
24h 
Cisplatin  Doxorubicin  Cisplatin Doxorubicin 
0.05 0.0882 0.0013 0.209 2.83x10-5 
0.25 0.8855 0.7125 0.365 1.292 
0.5 3.4942 30.2995 0.508 766.823 
0.75 13.7887 1288.5458 0.708 4.55x 105 
0.95 138.4147 7.02 x 105 1.235 2.08 x1010 
Fraction Affected 
(Fa) 
48h 
Cisplatin  Doxorubicin  Cisplatin Doxorubicin 
0.05 0.0882 0.0013 0.022 1.99 x 10-18 
0.25 0.8855 0.7125 1.353 2.01x10-8 
0.5 3.4942 30.2995 15.678 0.018 
0.75 13.7887 1288.546 181.695 1.63 x 104 
0.95 138.4147 7.02 x 105 1.11 x 104 1.65 x 1014 
Fraction Affected 
(Fa) 
72h 
Cisplatin  Doxorubicin  Cisplatin Doxorubicin 
0.05 0.0882 0.0013 4.82 x 105 8.78 x 10-20 
0.25 0.8855 0.7125 2.92 x 104 4.21 x 10-10 
0.5 3.4942 30.2995 5517.015 0 
0.75 13.7887 1288.5458 1040.668 140.886 
0.95 138.4147 7.02 x 105 63.129 6.76 x 1011 
*DRI, The dose-reduction index denotes the folds of dose reduction allowed for each drug in the 
combination when compared with each drug alone, at a given Fa level.356-358,361 
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Table 3.6: Dose-reduction indices of DOX and the EGFR/ErbB2/ErbB4 inhibitor after exposure 
of MCF-7 mammary carcinoma cells to the drugs in combination at 24, 48 and 72h 
Fraction 
Affected 
(Fa) 
Drug alone (µM) Dose Reduction Index (DRI)* 
24h 
Doxorubicin EGFR/ErbB2/ErbB4 
Inhibitor 
Doxorubicin EGFR/ErbB2/Er
bB4 Inhibitor 
0.05 0.0882 0.0013 9.46x10-5 0 
0.25 0.8855 0.7125 4.55 0.258 
0.5 3.4942 30.2995 2785.175 13.42 
0.75 13.7887 1288.5458 1.70 x 106 697.157 
0.95 138.4147 7.02 x 105 8.20 x 1010 5.32 x 105 
Fraction 
Affected 
(Fa) 
48h 
Doxorubicin EGFR/ErbB2/ErbB4 
Inhibitor 
Doxorubicin EGFR/ErbB2/Er
bB4 Inhibitor 
0.05 0.0882 0.0013 3.27 x 10-17 9.82 
0.25 0.8855 0.7125 1.50 x 10-7 13.00 
0.5 3.4942 30.2995 0.085 15.33 
0.75 13.7887 1288.5458 4.76 x 104 18.10 
0.95 138.4147 7.02 x 105 2.19 x 1014 23.90 
Fraction 
Affected 
(Fa) 
72h 
Doxorubicin EGFR/ErbB2/ErbB4 
Inhibitor 
Doxorubicin EGFR/ErbB2/Er
bB4 Inhibitor 
0.05 0.0882 0.0013 2.94 x 10-18 4.41 x 104 
0.25 0.8855 0.7125 6.21x10-9 1946.503 
0.5 3.4942 30.2995 0.002 303.705 
0.75 13.7887 1288.5458 783.757 47.386 
0.95 138.4147 7.02 x 105 1.66 x 1012 2.09 
*DRI, The dose-reduction index denotes the folds of dose reduction allowed for each drug in the 
combination when compared with each drug alone, at a given Fa level.356-358,361 
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Table 3.7: Dose-reduction indices of CPL and the EGFR/ErbB2/ErbB4 inhibitor after exposure 
of MCF-7 mammary carcinoma cells to the drugs in combination at 24, 48 and 72h 
Fraction 
Affected 
(Fa) 
Drug alone (µM) Dose Reduction Index (DRI)* 
24h 
Cisplatin EGFR/ErbB2/ErbB4 
Inhibitor 
Cisplatin EGFR/ErbB2/ErbB4 
Inhibitor 
0.05 0.0882 0.0013 0.024 1.16 x 10-5 
0.25 0.8855 0.7125 0.022 0.004 
0.5 3.4942 30.2995 0.021 0.155 
0.75 13.7887 1288.5458 0.02 5.344 
0.95 138.4147 7.02 x 105 0.019 2055.218 
Fraction 
Affected 
(Fa) 
48h 
Cisplatin EGFR/ErbB2/ErbB4 
Inhibitor 
Cisplatin EGFR/ErbB2/ErbB4 
Inhibitor 
0.05 0.0882 0.0013 0.014 0.366 
0.25 0.8855 0.7125 0.995 1.277 
0.5 3.4942 30.2995 12.84 2.686 
0.75 13.7887 1288.5458 165.718 5.649 
0.95 138.4147 7.02 x 105 1.22 x 104 19.701 
Fraction 
Affected 
(Fa) 
72h 
Cisplatin EGFR/ErbB2/ErbB4 
Inhibitor 
Cisplatin EGFR/ErbB2/ErbB4 
Inhibitor 
0.05 0.0882 0.0013 1170.166 3.203 
0.25 0.8855 0.7125 528.292 2.385 
0.5 3.4942 30.2995 329.088 2 
0.75 13.7887 1288.5458 204.999 1.678 
0.95 138.4147 7.02 x 105 92.55 1.249 
*DRI, The dose-reduction index denotes the folds of dose reduction allowed for each drug in the 
combination when compared with each drug alone, at a given Fa level.356-358,361 
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3.11 Haematoxylin and Eosin (H&E) Staining of MCF-7 Breast Carcinoma Cells 
Exposed to EGFR/TKI Inhibitors 
Haematoxylin and eosin (H&E) staining was performed to evaluate the effects of the 3 TKIs 
on the morphology of MCF-7 breast cancer cells.  The effects of the inhibitors are illustrated 
as follows: EGFR Inhibitor I (Figures 3.15-A to 3.15-G), EGFR Inhibitor II/BIBX1382 
(Figures 3.16-A to 3.16-F) and EGFR/ErbB2/ErbB4 Inhibitor (Figures 3.17-A to 3.17-G).  
Concise elucidations of the effects of the TKIs are provided in subsections 3.81 to 3.83 
below. 
3.11.1 MCF-7 Breast Carcinoma Cell Morphology Based on Haematoxylin and Eosin 
Staining of Cultures Exposed to EGFR Inhibitor I 
MCF-7 breast carcinoma cells were exposed to EGFR Inhibitor in two-fold concentration 
increments, i.e., 8.8 µM, 17.6 µM, 35.18 µM, 70.36 µM and 140.72 µM over 48h.  EGFR 
inhibitor I had a more pronounced effect on MCF-7 cell morphology compared to the other 
two TKIs.  Cells started detaching from adjacent cells at lower concentrations, with 
characteristic features of cytoplasmic shrinkage and cell condensation indicative of apoptosis 
following almost immediately as the concentration of the inhibitor increased (compare 
Figures 3.15-A to 3.15-G). 
3.11.2 MCF-7 Breast Carcinoma Cell Morphology Based on Haematoxylin and Eosin 
Staining of Cultures Exposed to EGFR Inhibitor II/BIBX1382 
MCF-7 breast carcinoma cells were exposed to 2-fold increments of EGFR Inhibitor 
II/BIBX1382 concentrations, viz., 2.1 µM, 4.2 µM, 8.4 µM, 16.82 µM and 33.64 µM over 
48h.  Upon exposure to EGFR Inhibitor II/BIBX1382, MCF-7 breast carcinoma cells 
exhibited normal cell division at lower concentrations 2.1µM to 16.82 µM and significant 
morphological changes at highest concentration of 33.64 µM.  At this concentration cells 
demonstrated cytoplasmic shrinkage and chromatin condensation indicative of apoptosis 
(compare Figures 3.16-A to 3.16-F). 
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3.11.3 MCF-7 Breast Carcinoma Cell Morphology Based on Haematoxylin and Eosin 
Staining of Cultures Exposed to EGFR/ErbB2/ErbB4 Inhibitor 
MCF-7 breast carcinoma cells were exposed to EGFR/ErbB-2/ErbB-4 Inhibitor at increasing 
doses, i.e., 0.85 µM, 1.7 µM, 3.39 µM, 6.78 µM and 13.56 µM over 48h.  Since the 
EGFR/ErbB-2/ErbB-4 Inhibitor is a combination or multiplex TKI—it has inhibitory 
specificity against various members of the EGFR/ErbB family of tyrosine kinase receptors—
and, as such, was used in lower concentrations compared to the other TKIs used in this study.  
However, at the indicated concentrations, MCF-7 breast carcinoma cells showed no 
significant morphological alterations compared to the untreated control.  Thus, MCF-7 breast 
carcinoma cells populations were still proliferating and there was no reliable evidence of 
apoptosis (compare Figures 3.17-A to 3.17-G). 
3.12 Annexin V-Cy3 Fluorescent Staining of MCF-7 Breast Carcinoma Cells Exposed 
to EGFR/TKI Inhibitors 
MCF-7 breast carcinoma cells were exposed to all 3 TKIs at different concentrations for 48h 
as detailed in subsections 3.9.1 to 3.9.3.  After exposure, Annexin V-Cy3, a fluorescent stain, 
was added to the cells in order to detect cells undergoing apoptosis.  During apoptosis, 
cellular changes result in loss of cell membrane phospholipid asymmetry with 
phosphatidylserine being exposed on the outer layer of the plasma membrane.  Annexin V-
Cy3 binds the phosphatidylserine in cells undergoing early stages of apoptosis or necrosis, 
and these cellular processes are observed as red fluorescence with a fluorescent microscope.  
By contrast, 6-CFDA is used as an indicator of cell viability.  6-CFDA is a non-fluorescent 
substrate of esterases in living cells which, upon entry into cells, is hydrolyzed to a 
fluorescent compound, 6-carboxyfluorescein (6-CF) that yields green fluorescence.  The 
results of the Annexin V-Cy3 fluorescent staining of MCF-7 breast carcinoma cells are 
illustrated as follows:  EGFR Inhibitor I (Figures 3.18-A to 3.18-G), EGFR Inhibitor 
II/BIBX1382 (Figures 3.19-A to 3.19-G) and EGFR/ErbB2/ErbB4 Inhibitor (Figures 3.20-A 
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to 3.20-G).  Succinct clarifications of the effects of the TKIs are provided in subsections 
3.12.1 to 3.12.3. 
 
Figure 3.15-A: Haematoxylin & eosin staining morphology of MCF-7 cells used as EGFR Inhibitor I 
untreated control after 48h.  Cells exhibit intact cell membranes and unperturbed connections between them.  
The blue arrow indicates cell division (metaphase).  Parallel to the untreated control, cells were exposed to 
incremental concentrations of EGFR Inhibitor I (8.8 µM, 17.6 µM, 35.18 µM, 70.36 µM and 140.72 µM) over 
48h.  EGFR Inhibitor I had a more pronounced effect on MCF-7 cell morphology compared to the other two 
tyrosine kinase inhibitors (TKI) (EGFR Inhibitor II/BIBX1382 and EGFR/ErbB2/ErbB4 Inhibitor).  Cells 
started to detach from neighbouring cells at lower concentrations of TKI, with characteristic features of 
cytoplasmic shrinkage and cell condensation, indicative of apoptosis, which was apparent almost immediately 
as the concentrations of the inhibitor were increased (See Figures 3.15-A to 3.15-F). (Magnification X200) 
 
Figure 3.15-B: Haematoxylin & eosin staining morphology of MCF-7 cells used as EGFR Inhibitor I 
staurosporine positive control.  The effects of 1 µM staurosporine over 48h on MCF-7 cells as a positive 
indicator for apoptosis.  Green arrows indicate apoptotic cells with shrunken cytoplasm and condensed 
chromatin. (Magnification X200) 
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Figure 3.15-C: Haematoxylin & eosin staining morphology of MCF-7 cells treated with 8.8 µM EGFR 
Inhibitor I for 48h.  Green arrows indicate apoptotic features such as condensed chromatin and cytoplasm 
shrinkage. (Magnification X200) 
 
Figure 3.15-D: Haematoxylin & eosin staining morphology of MCF-7 cells treated with 17.86 µM EGFR 
Inhibitor I for 48h.  Green arrows indicate apoptotic features such as condensed chromatin and shrunken 
cytoplasm. (Magnification X200) 
 
Figure 3.15-E: Haematoxylin & eosin staining morphology of MCF-7 cells treated with 35.18 µM EGFR 
Inhibitor I for 48h.  Green arrows indicate apoptotic features such as condensed chromatin and shrunken 
cytoplasm. (Magnification X200) 
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Figure 3.15-F: Haematoxylin & eosin staining morphology of 
MCF-7 cells treated with 70.36 µM EGFR Inhibitor I for 48h. 
Very few viable cells.  Green arrows indicate condensed 
chromatin and shrunken cytoplasm of apoptotic cells. 
(Magnification X200) 
Figure 3.15-G: Haematoxylin & eosin staining morphology of 
MCF-7 cells treated with 140.72 µM µM EGFR Inhibitor I for 
48h.  Complete cellular death is evident at this concentration.  
Green arrows indicate condensed chromatin and shrunken 
cytoplasm of apoptotic cells. (Magnification X200) 
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Figure 3.16-A: Haematoxylin & eosin staining morphology of MCF-7 cells used as EGFR Inhibitor 
II/BIBX1382 untreated control after 48h.  Cells exhibit intact cell membranes and unperturbed connections 
between them.  The blue arrow indicates cell division (metaphase).  Parallel to the untreated control, cells 
were exposed to incremental concentrations of EGFR Inhibitor II/BIBX1382 (2.1 µM, 4.2 µM, 8.4 µM, 16.82 
µM and 33.64 µM) over 48h.  MCF-7 cells exposed to EGFR Inhibitor II/BIBX1382 showed normal cell 
division at the lower concentrations, i.e., 2.1 µM to 16.82 µM and significant morphological changes at the 
highest concentration of 33.64 µM.  At this concentration, cells showed cytoplasmic shrinkage and chromatin 
condensation indicative of apoptosis (See Figures 3.16-A to 3.16-G). (Magnification X200) 
 
Figure 3.16-B: Haematoxylin & eosin staining morphology of MCF-7 cells used as EGFR Inhibitor 
II/BIBX1382 staurosporine positive control.  The effects of 1 µM staurosporine on MCF-7 cells as a positive 
indicator for apoptosis.  Green arrows indicate apoptotic cells with shrunken cytoplasm and condensed 
chromatin. (Magnification X200) 
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Figure 3.16-C: Haematoxylin & eosin staining morphology of MCF-7 cells treated with 2.1 µM EGFR 
Inhibitor II/BIBX1382.  Blue arrows indicate cell division (anaphase and metaphase). (Magnification X200) 
 
Figure 3.16-D: Haematoxylin & eosin staining morphology of MCF-7 cells treated with 4.2 µM EGFR 
Inhibitor II/BIBX1382.  Blue arrows indicate normal cellular division (metaphase). (Magnification X200) 
 
Figure 3.16-E: Haematoxylin & eosin staining morphology of MCF-7 cells treated with 8.4 µM EGFR 
Inhibitor II/BIBX1382. Blue arrows indicate irregular-shaped dividing cells. (Magnification X200) 
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Figure 3.16-F: Haematoxylin & eosin staining morphology of 
MCF-7 cells treated with 16.82 µM EGFR Inhibitor 
II/BIBX1382.  The blue arrow indicates a dividing cell in 
metaphase.  The green arrow shows a cell with condensed 
chromatin and shrunken cytoplasm. (Magnification X200) 
Figure 3.16-G: Haematoxylin & eosin staining morphology of 
MCF-7 cells treated with 33.64 µM EGFR Inhibitor 
II/BIBX1382.  Green arrows indicate complete apoptosis with all 
cells presenting with condensed chromatin and cytoplasmic 
shrinkage. (Magnification X200) 
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Figure 3.17-A: Haematoxylin & eosin staining morphology of MCF-7 cells used as EGFR/ErbB2/ErbB4 
Inhibitor untreated control after 48h.  Parallel to the untreated control, cells were exposed to incremental 
concentrations of EGFR/ErbB2/ErbB4 (0.85 µM, 1.7 µM, 3.39 µM, 6.78 µM and 13.56 µM) over 48h.  
EGFR/ErbB2/ErbB4 is a combination or multi-targeted inhibitor and was used in lower concentrations 
compared to EGFR Inhibitor I and EGFR Inhibitor II/BIBX1382.  There was no significant difference in the 
effect of the EGFR/ErbB2/ErbB4 Inhibitor on MCF-7 cell morphology compared to the untreated control.  
Cell populations were still proliferating as indicated by the blue arrows and there were no real traces of 
apoptosis (See Figures 3.17-A to 3.17-G). (Magnification X200) 
 
Figure 3.17-B: Haematoxylin & eosin staining morphology of MCF-7 cells used as EGFR/ErbB2/ErbB4 
Inhibitor staurosporine positive control.  The effects of 1 µM staurosporine on MCF-7 cells as a positive 
indicator for apoptosis.  Green arrows indicate apoptotic cells with shrunken cytoplasm and condensed 
chromatin. (Magnification X200) 
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Figure 3.17-C: Haematoxylin & eosin staining morphology of MCF-7 cells treated with 0.85 µM 
EGFR/ErbB2/ErbB4 Inhibitor.  Cells are still attached to neighbouring cells.  Blue arrows indicate cell 
division (anaphase and metaphase). (Magnification X200) 
 
Figure 3.17-D: Haematoxylin & eosin staining morphology of MCF-7 cells treated with 1.7 µM 
EGFR/ErbB2/ErbB4 Inhibitor.  Cells are still attached to neighbouring cells.  Blue arrows indicate normal 
mitosis (metaphase). (Magnification X200) 
 
Figure 3.17-E: Haematoxylin & eosin staining morphology of MCF-7 cells treated with 3.39 µM 
EGFR/ErbB2/ErbB4 Inhibitor.  Blue arrows indicate normal mitosis (anaphase and metaphase). 
(Magnification X200) 
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Figure 3.17-F: Haematoxylin & eosin staining morphology of MCF-7 cells treated with 6.78 µM 
EGFR/ErbB2/ErbB4 Inhibitor.  Blue arrows indicate cells undergoing mitosis (normal anaphase and 
metaphase). (Magnification X200) 
 
Figure 3.17-G: Haematoxylin & eosin staining morphology of MCF-7 cells treated with 13.56 µM 
EGFR/ErbB2/ErbB4 Inhibitor.  Blue arrows indicate cells undergoing mitosis (normal anaphase and 
metaphase). (Magnification X200) 
 
3.12.1 Analysis of EGFR Inhibitor I-Induced Apoptosis in MCF-7 Breast Carcinoma 
Cells by Annexin V-Cy3 Fluorescent Staining 
MCF-7 breast carcinoma cells were exposed to EGFR Inhibitor I in escalating 
concentrations, i.e., 8.8 µM, 17.6 µM, 35.18 µM, 70.36 µM and 140.72 µM over 48h.  Cells 
showed substantial early stages of apoptosis occurring at concentrations of 35.18 µM, 70.36 
µM and 140.72 µM relative to control (compare Figures 3.18-A to 3.18-G).  
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Figure 3.18-A: EGFR Inhibitor I—Untreated apoptosis negative control MCF-7 breast cancer cells stained 
with Annexin V-Cy3 fluorescent dye.  Green fluorescence indicates viable cells. 
 
Figure 3.18-B: EGFR Inhibitor I—Staurosporine-treated apoptosis positive control MCF-7 breast cancer cells 
stained with Annexin V-Cy3 fluorescent dye.  Green fluorescence indicates viable cells.  Staurosporine (1 µM, 
48h)-induced apoptosis in MCF-7 cells is evident in cells that stained red (red fluorescence, white arrow) and 
green (yellow arrow). 
 
Figure 3.18-C: Annexin V-Cy3 fluorescent staining of MCF-7 breast cancer cells treated with 8.8 µM EGFR 
Inhibitor I for 48h.  The yellow arrow indicates viable cells. 
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Figure 3.18-D: Annexin V-Cy3 fluorescent staining of MCF-7 breast cancer cells treated with 17.6 µM EGFR 
Inhibitor I for 48h.  The yellow arrow indicates a viable cells and the white arrow points to an apoptotic cell. 
 
Figure 3.18-E: Annexin V-Cy3 fluorescent staining of MCF-7 breast cancer cells treated with 35.18 µM EGFR 
Inhibitor I for 48h.  Viable (yellow arrow) and apoptotic (white arrow) cells are visible. 
 
Figure 3.18-F: Annexin V-Cy3 fluorescent staining of MCF-7 breast cancer cells treated with 70.36 µM EGFR 
Inhibitor I for 48h.  Viable (yellow arrow) and apoptotic (white arrow) cells are visible. 
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Figure 3.18-G: Annexin V-Cy3 fluorescent staining of MCF-7 breast cancer cells treated with 140.72 µM EGFR 
Inhibitor I for 48h.  A larger proportion of cells are undergoing apoptosis (white arrows). 
 
3.12.2 Analysis of EGFR Inhibitor II/BIBX1382-Induced Apoptosis in MCF-7 Breast 
Carcinoma Cells by Annexin V-Cy3 Fluorescent Staining 
MCF-7 breast carcinoma cells were exposed to EGFR Inhibitor II/BIBX1382 at 
concentrations of 2.1 µM, 4.2 µM, 8.4 µM, 16.82 µM and 33.64 µM over 48h. In the 
presence of this inhibitor, a high level of viable cells across most concentrations were noted 
while cell death or apoptosis only occurred at the highest concentration of 33.64 µM (see 
Figures 3.19-A to 3.19-G). 
3.12.3 Analysis of EGFR/ErbB2/ErbB4 Inhibitor-Induced Apoptosis in MCF-7 Breast 
Carcinoma Cells by Annexin V-Cy3 Fluorescent Staining 
MCF-7 breast carcinoma cells were exposed to EGFR/ErbB-2/ErbB-4 Inhibitor at doses of 
0.85 µM, 1.7 µM, 3.39 µM, 6.78 µM and 13.56 µM over 48h.  This combination inhibitor 
showed no significant populations of cells undergoing apoptosis.  Small traces of individual 
cells entering apoptosis were seen at 1.7 µM and 3.39 µM concentrations (refer to Figures 
3.20-A to 3.20-G).  
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Figure 3.19-A: EGFR Inhibitor II/ BIBX1382—Untreated apoptosis negative control MCF-7 breast cancer 
cells stained with Annexin V-Cy3 fluorescent dye.  Green fluorescence indicates viable cells. 
 
Figure 3.19-B: EGFR Inhibitor II/ BIBX1382—Staurosporine-treated apoptosis positive control MCF-7 
breast cancer cells stained with Annexin V-Cy3 fluorescent dye.  Green fluorescence indicates viable cells.  
Staurosporine (1 µM, 48h)-induced apoptosis in MCF-7 cells is evident in cells that stained red (red 
fluorescence, white arrow) and green (yellow arrow). 
 
Figure 3.19-C: Annexin V-Cy3 fluorescent staining of MCF-7 breast cancer cells treated with 2.1 µM EGFR 
Inhibitor II/ BIBX1382 for 48h.  Green fluorescence (yellow arrows) indicates viable cells. 
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Figure 3.19-D: Annexin V-Cy3 fluorescent staining of MCF-7 breast cancer cells treated with 4.2 µM EGFR 
Inhibitor II/ BIBX1382 for 48h.  The yellow arrows indicate viable cells.  Aggregated cells most likely indicate 
very early onset of apoptotic aggregosome formation. 
 
Figure 3.19-E: Annexin V-Cy3 fluorescent staining of MCF-7 breast cancer cells treated with 8.4 µM EGFR 
Inhibitor II/ BIBX1382 for 48h.  Viable (yellow arrow) and apoptotic (white arrow) cells are visible.  The central 
yellow areas within cells suggest chromatin/nuclear condensation, an early sign of apoptosis. 
 
Figure 3.19-F: Annexin V-Cy3 fluorescent staining of MCF-7 breast cancer cells treated with 16.82 µM EGFR 
Inhibitor II/ BIBX1382 for 48h.  Viable (yellow arrow) cells are visible, but also clumps of cells displaying 
chromatin/nuclear condensation. 
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Figure 3.19-G: Annexin V-Cy3 fluorescent staining of MCF-7 breast cancer cells treated with 33.64 µM EGFR 
Inhibitor II/ BIBX1382 for 48h.  Large-scale cellular fragmentation and morphological alterations become 
evident. 
 
Figure 3.20-A: EGFR/ErbB2/ErbB4 Inhibitor—Untreated apoptosis negative control MCF-7 breast cancer 
cells stained with Annexin V-Cy3 fluorescent dye.  Green fluorescence indicates viable cells. 
 
Figure 3.20-B: EGFR/ErbB2/ErbB4 Inhibitor—Staurosporine-treated apoptosis positive control MCF-7 
breast cancer cells stained with Annexin V-Cy3 fluorescent dye.  Green fluorescence indicates viable cells.  
Staurosporine (1 µM, 48h)-induced apoptosis in MCF-7 cells is evident in cells that stained red (red 
fluorescence, white arrow) and green (yellow arrow). 
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Figure 3.20-C: Annexin V-Cy3 fluorescent staining of MCF-7 breast cancer cells treated with 0.85 µM 
EGFR/ErbB2/ErbB4 Inhibitor for 48h.  Green fluorescence (yellow arrows) indicates viable cells. 
 
Figure 3.20-D: Annexin V-Cy3 fluorescent staining of MCF-7 breast cancer cells treated with 1.7 µM 
EGFR/ErbB2/ErbB4 Inhibitor for 48h.  A large proportion of cells are still viable (yellow arrow) at this 
concentration, with very few apoptotic cells (white arrow). 
 
Figure 3.20-E: Annexin V-Cy3 fluorescent staining of MCF-7 breast cancer cells treated with 3.39 µM 
EGFR/ErbB2/ErbB4 Inhibitor for 48h.  Viable (yellow arrow) and apoptotic (white arrow) cells are visible.  The 
central yellow areas within cells suggest chromatin/nuclear condensation, an early sign of apoptosis. 
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Figure 3.20-F: Annexin V-Cy3 fluorescent staining of MCF-7 breast cancer cells treated with 6.78 µM 
EGFR/ErbB2/ErbB4 Inhibitor for 48h.  Viable cells are present (yellow arrows). 
 
Figure 3.20-G: Annexin V-Cy3 fluorescent staining of MCF-7 breast cancer cells treated with 13.56 µM 
EGFR/ErbB2/ErbB4 Inhibitor for 48h.  Large-scale cellular fragmentation and morphological alterations 
become evident. 
 
3.13 Epidermal Growth Factor Receptor Gene Expression Analysis in MCF-7 
Breast Carcinoma Cells 
 
3.13.1 The Expression Profile of EGFR in 4 Breast Cancer Cell Lines 
EGFR expression was assessed in four cell lines, including normal mammary cell type MCF-
12A (Figure 3.21-A).  A relatively low expression of the EGFR gene can be seen in the 
MCF-7 mammary carcinoma cell line in this protocol, however, agarose gel electrophoresis 
of different annealing temperature gradients revealed an EGFR product of about 250 bp 
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(Figure 3.21-B).  MCF-7 mammary carcinoma cells were subsequently treated with different 
concentrations of EGFR inhibitors (TKIs): EGFR Inhibitor I, EGFR Inhibitor II/BIBX1382 
and EGFR/ErbB2/ErbB4 Inhibitor (Figures 3.21-C and 3.21-D). 
 
 
Figure 3.21-A: The expression profile of EGFR in 4 breast cancer cell lines.  Lane 1: 100 bp Marker; Lane 2: 
MCF-7; Lane 3: T47D; Lane 4: MDA-MB-231. 
 
Figure 3.21-B: Agarose gel electrophoresis of different annealing temperature gradients.  Red arrow indicates 
non-specific binding; blue arrow shows the migration position of the EGFR gene. 
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3.13.2 Optimization of PCR of Epidermal Growth Factor Receptor in MCF-7 
Breast Carcinoma Cells 
Conventional PCR was conducted on TKI-treated MCF-7 mammary carcinoma cells.  
Amplification of the EGFR gene demonstrated non-specific product binding.  Optimization of 
PCR reactions was conducted in an attempt to rectify the non-specific binding.  Figure 3.21-B 
demonstrates differential annealing temperatures achieved by the use of a gradient cycler.  
The differences in annealing temperatures were not effective in eliminating the formation of 
non-specific product binding.  Further optimization involved regulation of EGFR primer 
concentration (Figure 3.21-C).  A primer concentration of 0.5 µl was incorporated in the PCR 
mix, but this neither resulted in a significant difference nor elimination of primer dimers.  
Further optimization was required, i.e., a decrease to 0.25 µl in primer concentration which 
yielded nearly complete elimination of primer dimer formation (Figure 3.21-D). 
  
Figure 3.21-C: Agarose gel electrophoresis using 0.5µl primer concentrations, showing non-specific product 
binding.  Abbreviations used: EGFR, EGFR Inhibitor I; BIBX, EGFR Inhibitor II/ BIBX1382; ErbB-4, 
EGFR/ErbB2/ErbB4 Inhibitor. 
 
3.13.3 Real-Time qPCR of EGFR in MCF-7 Breast Carcinoma Cells 
Following PCR which identified the presence and general expression of EGFR, a 
quantification of the EGFR gene was considered necessary.  Quantification of target gene 
expression requires a gene with unchanged expression in tissues to normalize the expression 
of the target gene.   
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Figure 3.21-D: Agarose gel electrophoresis using 0.25µl primer concentrations, showing non-specific product 
binding.  Abbreviations used: EGFR, EGFR Inhibitor I; BIBX, EGFR Inhibitor II/BIBX1382; ErbB-4, 
EGFR/ErbB2/ErbB4 Inhibitor. 
 
This gene is referred to as a “housekeeping” or a reference gene.  Normal Minimum 
Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines 
recommend that at least of 5 references genes be used.367,368  Literature on quantitative Real-
Time PCR also highlights the importance of using appropriate reference genes as expression 
of a specific reference gene might be altered during certain experimental conditions.369-372  
The reference gene used in this study encodes porphobilinogen deaminase (PBGD). 
3.13.4 Sample Quality Control of RNA Isolated from Untreated Control and 
TKI-Treated MCF-7 Breast Carcinoma Cells 
Thirty samples of MCF-7 mammary carcinoma cells, including TKI-treated and untreated 
control samples, were subjected to quality control evaluations.  After the process of RNA 
extraction as mentioned above, concentrations of the RNA and 260/280 nm absorbance ratios 
were evaluated using a Nanodrop ND-1000 spectrophotometer (Thermoscientific).  High 
RNA quality with 260/280 absorbance readings of between 1.9 and 2.2 are recommended for 
qPCR.371  Table 3.8 summarizes the concentrations and 260/280 absorbance ratios obtained 
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from Nanodrop ND-1000 spectrophotometry of RNA samples isolated from MCF-7 breast 
carcinoma cells treated with TKIs and untreated controls.  The RNA integrity and quality 
was assessed by electrophoreses on a 1% agarose gel (Figure 3.22-A). 
  
Figure 3.22-A: Agarose gel electrophoresis of RNA samples subjected to qPCR analysis.  Sample IDs as per 
Table 3.8.  L1kb and L100bp are DNA ladders (Supplier Promega). 
 
3.13.5 PCR Efficiency 
Following cDNA synthesis as mentioned above, an aliquot of cDNA was pooled from all 30 
samples and 2-fold serial dilutions made.  The dilutions which were used as template, 
together with reference and target gene primers (50 nM) were assayed.  A standard curve was 
generated for each primer and the slopes of the curve were used to generate the correlation 
coefficient (R2) and PCR efficiency (Table 3.9).  Each standard curve was performed in 
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triplicate.  The PCR efficiencies for both the reference (PBGD) and target (EGFR) gene 
primers were acceptable. 
3.13.6 qPCR Primer Specificity
Primer set specificity for PBGD and EGFR was assessed by generation of respective melting 
curve (Figures 3.22-B and 3.22-C).  Both primer sets showed excessive amounts of primer 
dimers.  This was not improved by lower concentrations of primers used in this study. 
3.13.7 Analysis of the Expression of the Target Gene (EGFR) Relative to the 
Reference Gene (PBGD) by qBasePlus 
The expression of target gene (EGFR) relative to a single reference gene (PBGD) was 
determined by using the qBasePlus software (BioGazelle).  Each experimental sample was 
assayed in triplicate to standardize technical variation.  Figure 3.22-D shows a decrease in 
gene expression levels at high EGFR Inhibitor I, EGFR Inhibitor II/BIBX1382 and 
EGFR/ErbB2/ErbB4 Inhibitor concentrations.  An unpaired t-test (two-sided significance) 
was used to compare the relative expression of EGFR between samples treated with EGFR 
Inhibitor I, EGFR Inhibitor II/BIBX1382 and EGFR/ErbB2/ErbB4 Inhibitor (Table 3.10).  
The test revealed that the expression of EGFR in samples treated with 8.4 µM EGFR 
Inhibitor II/BIBX1382 and 35.18 µM EGFR Inhibitor I were significantly lower than in the 
control sample (p<0.05, unpaired t-test, two sided).  It also demonstrates no significance in p-
values amongst different concentrations of TKIs. 
3.13.8 Appraisal of EGFR Expression Analysis in MCF-7 Breast Carcinoma Cells
In this study, conventional PCR was used to detect and illustrate the presence of EGFR gene 
in the samples, while RT-qPCR was used to determine the mRNA expression levels of this 
gene in MCF-7 breast carcinoma cells. 
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Table 3.8: Concentrations of RNA and 260/280 absorbance ratios of MCF-7 breast carcinoma cells treated 
and not treated with EGFR inhibitors (TKIs) obtained from Nanodrop ND-1000 spectrophotometry 
Tube 
# 
Sample ID: µM Date Time Concentration 
(ng/µl) 
Absorbance 
Ratio (nm) 
260/280 
4 EGFR Inhibitor II/BIBX1382: 2.1  2013/11/04 10:10 AM 352.99 1.81 
20 EGFR Inhibitor II/BIBX1382: 2.1  2013/11/04 10:22 AM 130.19 1.74 
29 EGFR Inhibitor II/BIBX1382: 2.1  2013/11/04 10:27 AM 128.87 1.76 
3 EGFR Inhibitor II/BIBX1382: 4.2  2013/11/04 10:10 AM 233.47 1.53 
19 EGFR Inhibitor II/BIBX1382: 4.2  2013/11/04 10:22 AM 265.69 1.88 
28 EGFR Inhibitor II/BIBX1382: 4.2  2013/11/04 10:27 AM 248.49 1.49 
11 EGFR Inhibitor II/BIBX1382: 8.4  2013/11/04 10:18 AM 251.03 1.51 
12 EGFR Inhibitor II/BIBX1382: 8.4  2013/11/04 10:18 AM 208.53 1.86 
13 EGFR Inhibitor II/BIBX1382: 8.4  2013/11/04 10:18 AM 205.14 1.84 
5 EGFR Inhibitor I: 17.6  2013/11/04 10:11 AM 105.71 1.74 
21 EGFR Inhibitor I: 17.6  2013/11/04 10:23 AM 123.05 1.46 
30 EGFR Inhibitor I: 17.6  2013/11/04 10:28 AM 291.14 1.3 
10 EGFR Inhibitor I: 35.18  2013/11/04 10:17 AM 236.91 1.35 
16 EGFR Inhibitor I: 35.18  2013/11/04 10:20 AM 118.66 1.79 
25 EGFR Inhibitor I: 35.18  2013/11/04 10:25 AM 240.06 1.37 
9 EGFR Inhibitor I: 8.8  2013/11/04 10:16 AM 112.52 1.87 
15 EGFR Inhibitor I: 8.8  2013/11/04 10:20 AM 453.82 1.9 
24 EGFR Inhibitor I: 8.8  2013/11/04 10:25 AM 433.46 1.85 
6 EGFR/ErbB2/ErbB4 Inhibitor: 0.85  2013/11/04 10:12 AM 447.47 1.82 
14 EGFR/ErbB2/ErbB4 Inhibitor: 0.85  2013/11/04 10:19 AM 252.58 1.42 
22 EGFR/ErbB2/ErbB4 Inhibitor: 0.85  2013/11/04 10:23 AM 115.8 1.84 
18 EGFR/ErbB2/ErbB4 Inhibitor: 1.7  2013/11/04 10:21 AM 294.81 1.44 
27 EGFR/ErbB2/ErbB4 Inhibitor: 1.7  2013/11/04 10:26 AM 299.21 1.92 
2 EGFR/ErbB2/ErbB4 Inhibitor: 1.7  2013/11/04 10:09 AM 240.34 1.65 
7 EGFR/ErbB2/ErbB4 Inhibitor: 3.39  2013/11/04 10:13 AM 257.8 1.68 
8 EGFR/ErbB2/ErbB4 Inhibitor: 3.39  2013/11/04 10:16 AM 325.97 1.83 
23 EGFR/ErbB2/ErbB4 Inhibitor: 3.39  2013/11/04 10:24 AM 264.69 1.69 
1 MCF-7 Control 2013/11/04 10:07 AM 311.64 1.86 
17 MCF-7 Control 2013/11/04 10:21 AM 605.59 1.97 
26 MCF-7 Control 2013/11/04 10:26 AM 370.06 1.88 
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Table 3.9: qPCR amplification efficiency for target genes 
Gene Slope R2 value PCR Efficiency (%) 
EGFR -3.0359883 0.933473 113.81 
PBGD -3.1209326 0.9834424 109.176 
 
  
Figure 3.22-B: Melt curve analysis of products from amplification of the EGFR gene.  The target shows 
primer dimer formation as indicated by the non-specific peak between 70 and 80°C and blue arrow.  A 
duplicate EGFR species was also amplified as indicated by the shoulder on the melt curve of the amplicon (red 
arrow), which could be another EGFR transcript or a gDNA contaminant. 
 
A variety of methods are currently used to quantify mRNA expression, cDNA arrays, reverse 
transcription polymerase chain reaction (RT-PCR), Northern blotting, in situ hybridization 
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and RNAse protection assay.  Of all these methods, RT-PCR is the most flexible and most 
sensitive.  Applications of RT-PCR include gene detection, gene expression, genotyping and 
high resolution melting (HRM).369,373   
  
Figure 3.22-C: Melt curve analysis of products from amplification of the PBGD gene.  The target shows 
primer dimer formation as indicated by the non-specific peak between 70 and 80⁰C and blue arrow. 
 
The aim of this study was to identify the presence of EGFR in MCF-7 breast carcinoma 
samples as well as to evaluate EGFR gene expression levels in TKI-treated and untreated 
cells.  The extracted RNA samples were below the advisable reference level, but RNA 
integrity and quality was confirmed with electrophoresis.  Furthermore, our amplification 
efficiency ratio was within normal ranges following SYBR Green fluorescence and 
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generations of standard curves.  Melting curve analysis demonstrated primer dimer formation 
in both target (EGFR) and reference (PBGD) genes.   
  
Figure 3.22-D: Average expression of the EGFR gene in experimental groups treated with different 
concentrations of three EGFR inhibitors (TKIs).  Abbreviations used: EGFR, EGFR Inhibitor I; BIBX, EGFR 
Inhibitor II/BIBX1382; ErbB4, EGFR/ErbB2/ErbB4 Inhibitor. 
 
Primer dimer formations were insensitive to decreased concentration of primer used and 
therefore possible reasons for this non-specific product binding could be the purity of the 
designed primers which requires re-evaluation.  The melting curve relies solely on primer 
specificity considering the sequence independence of fluorescent dye SYBR Green I which 
binds to any double stranded DNA.  Binding of non-specific product could be remedied by 
generation of melting curve for our target product.  This is achieved by slightly increasing the 
temperature above melting temperature of the EGFR product and measuring fluorescence. 
This characteristic peak at the melting temperature will clearly eliminate non-specific 
product binding which peaks at lower temperatures.373  EGFR gene expression levels were 
significantly decreased at intermediate concentrations of some TKIs.  The intermediate 
concentrations of EGFR Inhibitor II/BIBX1382 (4.2 µM), EGFR Inhibitor I (17.6 µM) and 
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EGFR/ErbB2/ErbB4 Inhibitor (1.79 µM) appeared to have had a dramatic effect on 
inhibiting normal expression levels of the target gene, EGFR, with no significant difference 
amongst the higher concentrations of the inhibitors.  With this in mind, the use of these 
intermediate dosages would be recommended in further possible in vivo treatment 
experiments as the 2-fold higher concentration could potentially have a cytotoxic effect. 
Table 3.10: P-values for unpaired t-tests comparing treatment regimens between samples 
Treatment Comparison p-value 
Control vs EGFR Inhibitor II/BIBX1382 2.1 µM 0.057¶ 
Control vs EGFR Inhibitor II/BIBX1382 4.2 µM 0.116 
Control vs EGFR Inhibitor II/BIBX1382 8.4 µM 0.035 
Control vs EGFR Inhibitor I 8.8 µM 0.355 
Control vs EGFR Inhibitor I 17.6 µM 0.063¶ 
Control vs EGFR Inhibitor I 35.18 µM 0.039 
Control vs EGFR/ErbB2/ErbB4 Inhibitor 0.85 µM 0.106 
Control vs EGFR/ErbB2/ErbB4 Inhibitor 1.79 µM 0.078 
Control vs EGFR/ErbB2/ErbB4 Inhibitor 3.39 µM 0.157 
EGFR Inhibitor II/BIBX1382 4.2 µM vs EGFR Inhibitor I 8.8 µM 0.136 
EGFR Inhibitor II/BIBX1382 4.2 µM vs EGFR Inhibitor I 17.6 µM 0.972 
EGFR Inhibitor II/BIBX1382 8.4 µM vs EGFR Inhibitor I 35.18 µM 0.465 
EGFR Inhibitor I 8.8 µM vs EGFR/ErbB2/ErbB4 Inhibitor 1.79 µM 0.086 
EGFR Inhibitor I 17.6 µM vs EGFR/ErbB2/ErbB4 Inhibitor 1.79 µM 0.982 
EGFR Inhibitor I 35.18 µM vs EGFR/ErbB2/ErbB4 Inhibitor 3.39 µM 0.915 
EGFR Inhibitor II/BIBX1382 4.2 µM vs EGFR/ErbB2/ErbB4 Inhibitor 1.79 µM 0.988 
EGFR Inhibitor II/BIBX1382 8.4 µM vs EGFR/ErbB2/ErbB4 Inhibitor 3.39 µM 0.563 
p<0.05 indicates significant differences.  ¶Possibly marginally significant. 
 
The following deviations should be noted.  The extracted total RNA concentration was lower 
than anticipated. RNA extraction method needs to be revised.  Both primer pairs showed 
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primer dimer formations during qPCR.  Primers need to be purified more thoroughly.  Only 
one reference gene was sued in this study.  MIQE guidelines recommend the use of at least 3 
appropriate reference genes.367,368  In conclusion, all three TKIs used in this study responded 
in the manner we anticipated.  Although these inhibitors decrease gene expression levels.  
Future studies could involve the use of these inhibitors in combination with potentially 
complete inhibition of EGFR as this receptor tyrosine kinase have been associated with 
uncontrolled proliferation and survival in several cancers. 
3.14 Summary 
In this chapter, the findings of the research undertaken in this study have been discussed.  
MCF-7 breast carcinoma cells were exposed to the standard anticancer drugs, DOX and CPL, 
and three types of EGFR inhibitors (also called TKIs) with variable specificities, viz., EGFR 
Inhibitor I, EGFR Inhibitor II/BIBX1382 and EGFR/ErbB2/ErB4 Inhibitor.  MCF-7 breast 
carcinoma cells were treated with these drugs as single agents and combination regimens for 
24, 48 and 72h to establish their efficacies in the context drug synergism and antagonism 
according to the Loewe additivity and Bliss independence models as well as the median-
effect theorem of Chou and Talalay, as described in Chapter 2.  Growth curves of MCF-7 
breast carcinoma cells in the presence and absence of these agents were also generated and 
changes such as cell shrinkage, chromatin condensation and apoptotic body formation 
induced by the various combinations were monitored morphologically using H&E.  In 
addition, apoptosis triggered by these compounds was evaluated with Annexin V-Cy3 
fluorescent staining of cells.  Furthermore, the expression of the EGFR gene in MCF-7 breast 
carcinoma cells was validated by Real-Time qPCR and comparison of the target gene 
(EGFR) relative to the reference gene (PBGD) using the qBasePlus software.  In the next 
chapter, the study will be discussed in the context of combinatorial targeted drug 
perturbations of cancer cells, with special emphasis on the use of TKIs as a therapeutic 
rationale for and proof-of-concept in the management of breast cancer patients. 
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CHAPTER 4 
CONCLUSIONS AND FUTURE PERSPECTIVES 
4.1 Introduction 
Breast cancer is a disease with the highest prevalence among women and also the leading 
cause of female deaths worldwide.114,120,121  Breast cancer is certainly the most serious 
pathological lesion that occurs in breast tissue and constitutes a heterogeneous group of 
diseases with distinctive molecular and histological subtypes, metastatic behaviours and 
therapeutic responses in patients.11,12,22,23,27,374,375  The human epidermal growth factor 
receptor (EGFR/ErbB) family of receptor tyrosine kinases (RTKs) comprising HER1 
(EGFR/ErbB1), HER2 (ErbB2/neu), HER3 (ErbB3) and HER4 (ErbB4) play pivotal roles in 
normal ligand-mediated signal transduction processes such as cell proliferation, 
differentiation migration, programmed cell death (apoptosis), survival and responses to 
chemotherapeutics.285,376,377  However, overexpression, amplification, and gain-of-function 
mutations of oncogenic forms of the ErbB RTKs have been associated with the initiation, 
progression and maintenance of several cancer phenotypes, including breast and lung 
cancers.178,285,378-381 
The EGFR (ErbB1) is a prototype RTK.  To date, no bona fide ligand has unequivocally been 
identified for ErbB2/neu, but this RTK is competent to participate or contribute to both 
ligand-dependent and ligand-independent dimerization that mediate cellular responses.  
Despite being capable of ligand-dependent dimerization, the ErbB3 has a deficiency of a 
functional kinase domain and thus requires heterodimerization for effective signal 
transduction.382,383  The ErbB4 shares structural homology with ErbB1 and also undergoes 
homo- and heterodimerization upon ligand-binding.  Interestingly, EGFR signalling 
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correlates with the transcriptional coactivation of several oncogenes, including cyclin D1, 
iNOS, COX-2 and c-myc.316,378,380,384-386   
EGFR is expressed in non-malignant cell types in the tumour microenvironment (TME) and 
upregulates angiogenic and angiocrine factors such as vascular endothelial growth factor 
(VEGF), interleukin-8 (IL-8), and basic fibroblast growth factor (bFGF).  Hence, EGFR 
overexpression and gene amplification promote the preservation of the TME.387  This notion 
has been reinforced by reports of the existence of a kinase-independent prosurvival function 
of EGFR in that inhibitors often promote decreased cell proliferation, but not necessarily cell 
death.377  Moreover, certain tumour cells have retained their dependency on (oncogene-
addiction) to EGFR signalling, thus making this receptor a prime target for context-specific 
and personalized cancer therapies.  Equally important, ligands for the ErbB family of RTKs 
are overexpressed in a large proportion of breast cancers, and upregulation of EGFR is 
associated with poor clinical prognosis and disease recurrence.285,388   
Two classes of anti-EGFR agents—monoclonal antibodies and low-molecular-weight 
tyrosine kinase inhibitors (TKIs)—have proven antitumor efficacy in breast cancer 
patients.389  Small-molecule TKIs (e.g., erlotinib and gefitinib) perturb EGFR signalling by 
acting as reversible or irreversible competitive inhibitors of adenosine-5′-triphosphate (ATP) 
for the intracellular tyrosine kinase binding domain of the receptor, thus counteracting 
autophosphorylation as well as activation of multiple EGFR-coupled downstream signalling 
pathways, including RAS, phosphatidylinositol 3-kinase (PI3K), PKC, Src and signal 
transducer and activator of transcription 3 (STAT3).285  Quite a few of the EGFR TKIs 
currently in clinical use can concurrently inhibit multiple members of the ErbB family, e.g., 
lapatinib reversibly blocks both ErbB1 and ErbB2/neu.179   
By contrast, monoclonal antibodies (e.g., trastuzumab, cetuximab, panitumumab) directed 
against EGFR competitively bind the extracellular ligand-binding region of the receptor 
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obstructing ligand binding, receptor dimerization and endogenous ligand activation of EGFR 
in a highly specific manner.294,380,390  Nonetheless, intrinsic and acquired resistance to TKIs 
present major challenges to successful outcome of breast cancer chemotherapy.390-392   
The abovementioned clinical and basic science experiences pertaining to the therapeutic 
targeting of EGFR with small molecule TKIs and monoclonal antibodies have profound 
implications for the conceptualization and development of novel approaches to breast cancer 
therapies.  Current efforts in this therapeutic sphere are being directed at identifying 
molecular markers that can predict patients who are more likely to respond to anti-EGFR 
therapy, and developing combinatorial approaches with EGFR inhibitors and conventional 
antineoplasic agents to enhance clinical efficacy of targeted therapies for breast cancer 
patients.393   
The study reported in this dissertation forms part of such global endeavours and focused on 
the analysis of in vitro drug synergies and additive effects elicited by investigational 
combinations of doxorubicin, cisplatin and TKIs—EGFR Inhibitor I, EGFR Inhibitor 
II/BIBX1382 and EGFR/ErbB2/ErB4 Inhibitor—in a cell culture system comprising MCF-7 
breast carcinoma cells.  It is hoped that this study will contribute to a better understanding of 
the proof-of-concept of TKIs in mono- and combination chemotherapies for breast cancer. 
4.2 Research Hypothesis and Objectives of the Study 
The research hypothesis and objectives of this study have been stated in Chapter 1 (sections 
1.5.2 and 1.5.3).  The hypothesis that combinations of DOX and CPL, and TKIs (EGFR 
Inhibitor I, EGFR Inhibitor II/BIBX1382 and EGFR/ErbB2/ErbB4 Inhibitor), act 
synergistically to yield greater anticancer efficacies than those predicted by their individual 
activities against MCF-7 breast cancer cells in vitro is accepted.  Even though some 
combinations have not yielded synergistic effects only, but also antagonism, the hypothesis is 
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still true as borne out by the fact that even antagonistic drug interactions can be advantageous 
from a dose-reduction index (DRI) standpoint.345,356,358,361  All the research objectives have 
also been met.   
4.3 Generalized Context and Significance of this Study
Combinations of TKIs as well as associations between anti-EGFR drugs have been among 
the promising molecular targets for cancer therapy, but appropriate sequences of 
combinations still need to be established.  This study investigated the effects of TKIs on the 
growth and proliferation of MCF-7 breast carcinoma cells in culture.  MCF-7 cells were 
exposed to different concentrations of TKIs alone and in combination with each other.  
Inhibition of cell growth by TKIs used individually occurred in a dose- and time-dependent 
manner.  When EGFR Inhibitor I, EGFR Inhibitor II/BIBX1382 and the multi-specific 
EGFR/ErbB-2/ErB-4 Inhibitor were used in combination with each other at equimolar log 
dose concentrations, the combined effects on cell growth was significantly different to 
inhibitors used individually as reflected in a decreased EC50 (IC50) during combination 
treatment.  Generally, for the combinations with DOX, CPL and the TKIs, synergistic as well 
as antagonistic effects were observed at isoeffective concentrations (see Chapter 2, section 
2.10 for explanation) with resultant decreases in DRIs implying greater efficacies with the 
respective combinations.  
This study demonstrated a significant growth inhibition of MCF-7 cells upon exposure to 
TKI combinations.  The drug combination indices suggested that when TKIs are used in 
combination, their efficacy is enhanced through synergistic interactions at higher Fa (cell-kill) 
levels, consistent with both the Loewe additivity and Bliss independence models.338-342  
Studies relating to combination therapy and synergistic interactions between two or more 
drugs are well documented.  Synergistic interactions between drugs provide an approach to 
cancer chemotherapy in which the combined effects of two or more drugs are greater than 
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their single effects, thus increasing their efficacy at lower doses (concentrations) with lesser 
toxicity.  Drug synergism is an important research tool that can be exploited to develop more 
potent anticancer drug combinations that will eventually lead to better prognosis of malignant 
diseases and decreased cancer mortality rates.  Synergistic interactions have been reported in 
previous studies in cell lines that express medium to high levels of EGFR that were treated 
with a combination of cetuximab (a monoclonal antibody) and gefitinib (a TKI) and also in 
breast cancer cell lines that overexpress HER2 that were treated with combinations of 
chemotherapeutic drugs and trastuzumab.394,395   
After the success reported for gefitinib in the treatment of non-small-cell lung cancer 
(NSCLC), increased focus has shifted towards research and development of newer TKIs.380  
Activity against cancerous cells by TKI treatment, have been documented extensively.389,395  
Some TKIs that are undergoing intense clinical evaluation include lapatinib, a bispecific 
(dual) TKI capable of blocking both EGFR (ErbB1) and HER2 (ErbB2/neu).298,396-398  
Another reversible dual inhibitor similar to lapatinib, GW2974, has also been demonstrated 
to be efficacious (synergistic inhibitory effect) in combination with lapatinib and HA14-1 or 
GX15-070 (inhibitors of the anti-apoptotic protein, Bcl-2) against MCF-7 breast carcinoma 
cells and a HER2/neu-transfected MCF-7 cell line (MCF/18), and a tamoxifen-resistant 
MCF-7 cell line (MTR-3).186  Erlotinib is a first-line therapy for patients with EGFR-mutant 
NSCLC and pancreatic cancer, while cetuximab is effective in colon and head and neck 
cancers with wild-type KRAS.  Lapatinib and trastuzumab have been approved for treating 
HER2-overexpressing breast cancers.399  Combinations of TKIs, TKI-antitumour drugs and 
TKI-antitumour drugs/EGFR antibodies represent a persuasive clinical strategy to overcome 
drug resistance.284,400 
The present study is consistent with such previous assertions that concurrent blocking of the 
ErbB family of RTKs and other drug targets (e.g., topoisomerase II targeted by DOX and 
induction of apoptosis by CPL in a manner analogous to blocking the anti-apoptotic Bcl-2) in 
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cancer cells may be of particular benefit to breast cancer patients.  Elucidation of the 
mechanisms involved in the combined cytotoxicity of DOX, CPL and TKIs and optimizing 
their synergistic concentrations (multi-targeted cancer therapy) to enhance efficacy would be 
a major breakthrough in cancer drug discovery and development—targeting specific 
populations of cancer cells and reducing TKI-induced toxicity to normal cells and vital 
organs.401,402 
4.4 Limitations of the Study
This study is limited to MCF-7 breast carcinoma cells.  Every effort was made to study all 
possible combinations with DOX, CPL and the TKIs, but due to funding constraints, only the 
EGFR/ErbB2/ErB4 Inhibitor could be used in conjunction with these conventional anticancer 
drugs in dose-response assays.  This study did not measure the effects of the TKIs on 
endogenous RTK activity in MCF-7 breast carcinoma cells.  Such assays are critical to 
establish whether MCF-7 breast carcinoma cells can maintain their RTK competence or 
switch on alternative prosurvival biochemical mechanisms or signalling cross-talks 
independent of EGFR kinase activity.  Constitutive activation or inactivation of mediators 
due to various mutations or deletions can transduce active signalling autonomous from EGFR 
RTK.285  Signalling from alternative RTKs such as MET, IGF-1R, FGFR and EphA2 can 
maintain the key cell survival and/or proliferation signals in the RAS/RAF/MEK and 
PI3K/AKT pathways.403 
4.5 Future Research Perspectives on Targeted Therapy with TKIs 
As with many cancer chemotherapeutic agents, a major limitation of EGFR-targeted therapy 
is the development of tumour cell resistance.  A frequent mechanism of resistance to 
EGFR/HER2 inhibitors is the upregulation or activation of alternative RTKs.285  Various 
types of breast cancers display intrinsic resistance to the ErbB1 TKI—gefitinib—and, more 
commonly to ErbB1 TKIs.188  In NSCLC cell lines and primary cultures derived from patient 
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lung tumours with EGFR mutations, epithelial-mesenchymal transition (EMT) and the 
receptor tyrosine kinase, Axl, have been correlated with increased metastatic potential and 
resistance to inhibitors of EGFR and PI3K/Akt.  Hence, Axl may prove to be a novel EMT 
biomarker and prospective target for EGFR-mutant NSCLC and other epithelial neoplasms 
like ovarian and breast tumours.  Towards this end, the Axl inhibitor, SGI-7079, alone and in 
combination with erlotinib shows promise in increasing drug sensitivity and reversing 
erlotinib resistance in patients with Axl-expressing NSCLC with an EMT signature.403   
Cross-talk between EGFR/HER2 signalling with other pathways such as Wnt/ß-catenin, 
Notch and TNFα/IKK/NF-κB signalling pathway can also influence tumour cell sensitivity to 
EGFR/HER2 inhibitors.285  A truncated mutant of EGFR (EGFRvIII) is associated with 
oncogenesis in experimental tumour models and poor clinical prognosis of high-grade 
glioblastomas.  Tumours that express EGFRvIII generally do not respond favourably to 
approved small-molecule EGFR inhibitors and this may also be a plausible mechanism of 
drug resistance in several other cancers.404  Accordingly, the abstraction of molecular criteria, 
using genomics and proteomics, for predicting patient sensitivity to ErbB-TKIs becomes 
highly relevant for their appropriate use and for future studies.405   
Clearly, context-specific or proof-of-concept experimental designs are mandatory to establish 
optimal TKI and other anticancer drug combinations, doses, and schedules to predict the 
likelihood of advantageous patient responses and, at the same time, avert adverse events.  
From a molecular systems biology perspective, efforts abound to devise network models that 
would predict quantitative outcomes of combinatorial anticancer drug-pair treatments or 
targeting multiple genetic alterations (i.e., exploiting the paradigm for synthetic 
lethality).280,406  Recently, such a computational trial design, viz., the combinatorial 
perturbation and multiple input–multiple output (MIMO) model, tested inhibitors (IGF1 
receptor inhibitory antibody, ZD1839, LY294002, rapamycin, rottlerin and PD0325901), 
singly and in a combination matrix, in relation to the perturbation of the EGFR-MEK-ERK 
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and PI3K-AKT canonical pathways in MCF-7 breast carcinoma cells.  Such predictive 
models for perturbation responses in cancer cells may be invaluable in extracting information 
about pathways of molecular interactions in tumour cells and their collateral responses to 
combinatorial perturbations, e.g., the multi-level downstream signalling events that maintain 
the hallmarks of the malignant phenotype (sustaining proliferation, oncogenesis, 
angiogenesis, metastasis, drug resistance, evasion of apoptosis)281 associated with the EGFR 
family in breast cancer cells.177,180,406 
Another important avenue to pursue in breast cancer chemotherapeutics is the inhibition of 
metabolism which may prove a cancer’s Achilles’ heel.  Indeed, cell proliferation and 
oncogenesis are coupled to metabolic reprogramming and growth factor signalling cascades 
that influence metabolism through Ras and PI3K.  Remarkably, both PI3K/Akt and MAPK 
increase glycolysis, and are coupled to EGFR signalling and, similarly, c-myc is also the 
main oncogene implicated in glutamine addiction of cancer cells.279  Overexpression of 
EGFR and amplification of c-myc are features of basal-like breast cancer.34  Moreover, in 
human cancer cells, the persistence of a kinase-independent EGFR is to prevent autophagic 
cell death by maintaining intracellular glucose level through interaction and stabilization of 
the sodium/glucose cotransporter 1.377   
In the context of the above, the prosurvival and proproliferation repertoires of EGFR are 
achieved by at least two independent pathways—activation of the EGFR by its ligands to 
sustain cell proliferation, which may be perturbed by TKIs, and upregulation of glycolysis, 
which may explain the lack of cytotoxicity of inhibitors of EGFR tyrosine kinase activity and 
thus impact negatively on cancer treatment with TKIs.407  Finally, clarification of the 
interactions between TKIs and adenine triphosphate (ATP)-binding cassette (ABC) 
transporter proteins, such as ABCB1/P-glycoprotein (P-gp) and ABCG2/breast cancer 
resistance protein (BCRP) may generate important strategies in the application of molecular-
targeted chemotherapies of breast cancers. 
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ANNEXURE 1 
Permission to Reproduce Material: Molecular Oncology, Elsevier B.V. 
 
Figure 1.6 was reproduced with permission from Aleix Prat and Charles M. Perou.27 
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ANNEXURE 2 
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Figure 1.8 was reproduced with permission from Ciardiello and Tortora,179 Copyright Massachusetts Medical Society 
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ANNEXURE 3 
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Figures 1.9 and 1.10 were reproduced with permission from Karamouzis et al.180 
 
 
 
 
128 
ANNEXURE 4 
Permission to Reproduce Material: Pharmacological Reviews, The 
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The content on the explanation and sample illustration of polygonograms provided in Table 3.4 and Figure 
3.9 were reproduced with permission from The American Society for Pharmacology and Experimental 
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